INVENTOR SEARCH

```
=> fil capl; d que nos l25
FILE 'CAPLUS' ENTERED AT 13:06:28 ON 12 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 12 Sep 2007  VOL 147 ISS 12
FILE LAST UPDATED: 11 Sep 2007  (20070911/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE


=> d que nos l48
L4              STR
L8          7166 SEA FILE=REGISTRY SSS FUL L4
L19          979 SEA FILE=CAPLUS ABB=ON  BALZARINI J?/AU
L20          481 SEA FILE=CAPLUS ABB=ON  PREOBRAZHENSKAYA M?/AU
L21         2099 SEA FILE=CAPLUS ABB=ON  DECLERCQ E?/AU OR DE CLERCQ E?/AU
L32             STR
L33             STR
L34             STR
L39             3 SEA FILE=REGISTRY SUB=L8 SSS FUL (L32 OR L33 OR L34)
L47             4 SEA FILE=CAPLUS ABB=ON  L39
L48             4 SEA FILE=CAPLUS ABB=ON  (L19 OR L20 OR L21) AND L47


=> d ibib abs hitstr l48 1-4

L48  ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2006:876847  CAPLUS
DOCUMENT NUMBER:          145:465216
TITLE:                    Inhibition of feline (FIPV) and human (SARS)
                          coronavirus by semisynthetic derivatives of
                          glycopeptide antibiotics
AUTHOR(S):                Balzarini, Jan; Keyaerts, Els; Vijgen, Leen;
                          Egberink, Herman; De Clercq, Erik; Van
                          Ranst, Marc; Printsevskaya, Svetlana S.; Olsufyeva,
                          Eugenia N.; Solovieva, Svetlana E.;
                          Preobrazhenskaya, Maria N.
CORPORATE SOURCE:         Rega Institute for Medical Research, K.U. Leuven,
                          Louvain, B-3000, Belg.
SOURCE:                   Antiviral Research (2006), 72(1), 20-33
                          CODEN: ARSRDR; ISSN: 0166-3542
```

PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Various semisynthetic derivs. of glycopeptide antibiotics including vancomycin, eremomycin, teicoplanin, ristocetin A and DA-40926 have been evaluated for their inhibitory activity against feline infectious peritonitis virus (FIPV) and human (SARS-CoV, Frankfurt-1 strain) coronavirus in cell culture in comparison with their activity against human immunodeficiency virus (HIV). Several glycopeptide derivs. modified with hydrophobic substituents showed selective antiviral activity. For the most active compds., the 50% effective concns. (EC50) were in the lower micromolar range. In general, removal of the carbohydrate parts of the mols. did not affect the antiviral activity of the compds. Some compds. showed inhibitory activity against both, whereas other compds. proved inhibitory to either, FIPV or SARS-CoV. There was no close correlation between the EC50 values of the glycopeptide derivs. for FIPV or SARS-CoV.

IT 562105-30-0 562105-47-9 855674-07-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibition of FIPV and human SARS coronavirus by semisynthetic derivs. of glycopeptide antibiotics)

RN 562105-30-0 CAPLUS

CN Ristomycin A aglycone, 38-[[(6-aminohexyl)amino]carbonyl]-22,31-dichloro-41-[[[3-(decyldimethylammonio)propyl]amino]methyl]-38-de(methoxycarbonyl)-7-demethyl-19-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 562105-47-9 CAPLUS
CN Glycine, (2R)-2-[3-[4-[(2R)-2-carboxy-2-[[(phenylmethoxy)carbonyl]amino]ethyl]-2-chlorophenoxy]-4,5-dihydroxyphenyl]-N-[(1,1-dimethylethoxy)carbonyl]glycylglycyl-(.beta.R)-3-chloro-.beta.-hydroxy-L-tyrosyl-, 4-methyl ester, cyclic (15.fwdarw.34)-ether, cyclic 22,42-[4,6,6'-trihydroxy-5-[(tricyclo[3.3.1.13,7]dec-2-ylamino)methyl][1,1'-biphenyl]-3',2-diyl] deriv., [2(2R),4(2S)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 855674-07-6 CAPLUS
CN Vancomycin, 44-O-de[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl-.alpha.-L-lyxo-hexopyranosyl)-.beta.-D-glucopyranosyl]-26-decarboxy-26-[[(tricyclo[3.3.1.13,7]dec-1-ylmethyl)amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L48 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:383224 CAPLUS
DOCUMENT NUMBER: 143:70993
TITLE: Structure-Activity Relationship Studies of a Series of Antiviral and Antibacterial Aglycon Derivatives of the Glycopeptide Antibiotics Vancomycin, Eremomycin, and Dechloroeremomycin
AUTHOR(S): Printsevskaya, Svetlana S.; Solovieva, Svetlana E.; Olsufyeva, Eugenia N.; Mirchink, Elena P.; Isakova, Elena B.; De Clercq, Erik; Balzarini, Jan; Preobrazhenskaya, Maria N.
CORPORATE SOURCE: Gause Institute of New Antibiotic, Russian Academy of Medical Sciences, Moscow, 119021, Russia
SOURCE: Journal of Medicinal Chemistry (2005), 48(11), 3885-3890
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 143:70993

AB N-(Adamantyl-1)methyl, N-(adamantyl-2), and N-(.omega.-aminodecyl) amides of vancomycin, eremomycin, and dechloroeremomycin aglycons and their des-(N-Me-D-Leu) derivs. were synthesized and their antibacterial and anti-HIV activities were investigated. Carboxamides with an intact peptide core demonstrated activity against glycopeptide-susceptible and -resistant bacteria (1-32 .mu.M). N-(Adamantyl-1)methylcarboxamide of

eremomycin aglycons had good antiretroviral activity (1.6 .mu.M against HIV-1). Compds. with destroyed peptide core [des-(N-Me-D-Leu)-aglycon amides] were inactive against both glycopeptide-sensitive and -resistant bacteria. (Adamantyl-1)methylamide of des-(N-Me-D-Leu)-eremomycin aglycon had good antiretroviral activity (EC50 of 5.5 .mu.M for HIV-1 and 3.5 .mu.M for HIV-2). (Adamantyl-1)methylamides of eremomycin aglycon and its des-(N-Me-D-Leu)-deriv. are the most promising and selective antiretroviral agents. Their ability to induce bacterial resistance to glycopeptide antibiotics during prolonged administration may be expected to be very low or absent. This might make the use of these derivs. feasible in the prolonged therapy or prophylaxis of HIV infections.

IT 855674-07-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(structure-activity relationship of antiviral and antibacterial aglycon derivs. of glycopeptide antibiotics vancomycin, eremomycin, and dechloroeremomycin)

RN 855674-07-6 CAPLUS

CN Vancomycin, 44-O-de[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl-.alpha.-L-lyxo-hexopyranosyl)-.beta.-D-glucopyranosyl]-26-decarboxy-26-[[(tricyclo[3.3.1.13,7]dec-1-ylmethyl)amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L48 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:203690 CAPLUS

DOCUMENT NUMBER: 140:247018
TITLE: Glycopeptide antibiotic derivatives, their preparation and their use as antiviral agents
INVENTOR(S): Balzarini, Jan; Preobrazhenskaya, Maria; De Clercq, Erik
PATENT ASSIGNEE(S): K.U. Leuven Research and Development, Belg.
SOURCE: PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004019970	A2	20040311	WO 2003-BE144	20030901
WO 2004019970	A3	20040722		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2497159	A1	20040311	CA 2003-2497159	20030901
AU 2003260198	A1	20040319	AU 2003-260198	20030901
EP 1534316	A2	20050601	EP 2003-790574	20030901
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006503015	T	20060126	JP 2004-531311	20030901
CN 1741810	A	20060301	CN 2003-824842	20030901
US 2005250677	A1	20051110	US 2005-525784	20050228
IN 2005KN00528	A	20060224	IN 2005-KN528	20050330
IN 2007KN01836	A	20070810	IN 2007-KN1836	20070523

PRIORITY APPLN. INFO.:

GB 2002-20235	A	20020830
GB 2002-20233	A	20020831
GB 2003-10890	A	20030425
GB 2003-9521	A	20030425
WO 2003-BE144	W	20030901
IN 2005-KN528	A3	20050330

OTHER SOURCE(S): MARPAT 140:247018

AB Glycopeptide antibiotic derivs., processes for their prepn., their use as a medicine, their use to treat or prevent viral infections and their use to manuf. a medicine to treat or prevent viral infections are provided. The invention discloses the use of glycopeptide antibiotics and their semisynthetic derivs. to treat or prevent viral infections and their use to manuf. a medicine to treat or prevent viral infections of subjects, more in particular infections with viruses belonging to Retroviridae, Herpesviridae, Flaviviridae and the Coronaviridae, like HIV (human immunodeficiency virus), HCV (hepatitis C virus), BVDV (bovine viral diarrhea virus), SARS (severe acute respiratory syndrome)-causing virus, FCV (feline coronavirus), HSV (herpes simplex virus), VZV (varicella zoster virus) and CMV (cytomegalovirus).

IT 562105-30-0P 562105-47-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(glycopeptide antibiotic derivs., prepn. and use as antiviral agents)

RN 562105-30-0 CAPLUS

CN Ristomycin A aglycone, 38-[[(6-aminohexyl)amino]carbonyl]-22,31-dichloro-41-[[[3-(decyldimethylammonio)propyl]amino]methyl]-38-de(methoxycarbonyl)-7-demethyl-19-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 562105-47-9 CAPLUS

CN Glycine, (2R)-2-[3-[4-[(2R)-2-carboxy-2-[[(phenylmethoxy)carbonyl]amino]ethyl]-2-chlorophenoxy]-4,5-dihydroxyphenyl]-N-[(1,1-dimethylethoxy)carbonyl]glycylglycyl-(.beta.R)-3-chloro-.beta.-hydroxy-L-tyrosyl-, 4-methyl ester, cyclic (15.fwdarw.34)-ether, cyclic 22,42-[4,6,6'-trihydroxy-5-[(tricyclo[3.3.1.13,7]dec-2-ylamino)methyl][1,1'-biphenyl]-3',2-diyl] deriv., [2(2R),4(2S)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L48 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:397187 CAPLUS

DOCUMENT NUMBER: 139:111130

TITLE: Antiretroviral Activity of Semisynthetic Derivatives of Glycopeptide Antibiotics

AUTHOR(S): Balzarini, Jan; Pannecouque, Christophe; De Clercq, Erik; Pavlov, Andrey Y.; Printsevskaya, Svetlana S.; Miroshnikova, Olga V.; Reznikova, Marina I.; Preobrazhenskaya, Maria N.

CORPORATE SOURCE: Rega Institute for Medical Research, Katholieke Universiteit Leuven, Louvain, B-3000, Belg.

SOURCE: Journal of Medicinal Chemistry (2003), 46(13), 2755-2764
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A variety of semisynthetic derivs. of natural antibacterial glycopeptide antibiotics such as vancomycin, eremomycin, ristocetin A, teicoplanin A2-2, DA-40926, their aglycons, and also the products of their partial degrdn. with a destroyed or modified peptide core show marked anti-retroviral activity in cell culture. In particular, aglycon antibiotic derivs. contg. various substituents of a preferably hydrophobic nature displayed activity against human immunodeficiency virus type 1 (HIV-1), HIV-2, and Moloney murine sarcoma virus at a 50% inhibitory concn. in the lower micromolar (1-5 .mu.M) concn. range while not being cytostatic against human lymphocytic cells at 250 .mu.M or higher. The mode of anti-HIV action of the antibiotic aglycon derivs. could be ascribed to inhibition of the viral entry process.

IT 562105-47-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(antiretroviral activity of semisynthetic derivs. of glycopeptide antibiotics)
RN 562105-47-9 CAPLUS
CN Glycine, (2R)-2-[3-[4-[(2R)-2-carboxy-2-[[(phenylmethoxy)carbonyl]amino]ethyl]-2-chlorophenoxy]-4,5-dihydroxyphenyl]-N-[(1,1-dimethylethoxy)carbonyl]glycylglycyl-(.beta.R)-3-chloro-.beta.-hydroxy-L-tyrosyl-, 4-methyl ester, cyclic (15.fwdarw.34)-ether, cyclic 22,42-[4,6,6'-trihydroxy-5-[(tricyclo[3.3.1.13,7]dec-2-ylamino)methyl][1,1'-biphenyl]-3',2-diyl] deriv., [2(2R),4(2S)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT 562105-30-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antiretroviral activity of semisynthetic derivs. of glycopeptide antibiotics)
RN 562105-30-0 CAPLUS
CN Ristomycin A aglycone, 38-[[(6-aminohexyl)amino]carbonyl]-22,31-dichloro-41-[[[3-(decyldimethylammonio)propyl]amino]methyl]-38-de(methoxycarbonyl)-7-demethyl-19-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 2-A



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

BROAD STRUCTURE + AIDS/HIV
=>
=> => fil reg; d stat que l8; fil capl; d que nos l18; s l18 not l45
FILE 'REGISTRY' ENTERED AT 13:09:22 ON 12 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 SEP 2007 HIGHEST RN 946658-01-1
DICTIONARY FILE UPDATES: 11 SEP 2007 HIGHEST RN 946658-01-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

L4 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

Uploading L4.str



chain nodes :
31 32 40 45 46 47
ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 33 36 37 38 39 41 42 43 44
ring/chain nodes :
34 35
chain bonds :
10-46 19-31 21-32 25-47 38-40 41-45
ring/chain bonds :
11-34 15-34 18-35 24-26 28-36
ring bonds :
1-2 1-6 2-3 2-44 3-4 4-5 5-6 5-33 7-8 7-12 7-39 8-9 9-10 9-33 10-11
11-12 13-14 13-18 14-15 15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23
23-24 25-26 25-30 26-27 27-28 28-29 29-30 36-37 36-41 37-38 38-39 41-42
42-43 43-44
exact/norm bonds :
2-44 5-33 7-39 9-33 10-46 11-34 15-34 18-35 19-31 21-32 24-26 25-47 28-
36 36-37 36-41 37-38 38-39 38-40 41-42 41-45 42-43 43-44
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-
15 15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23 23-24 25-26 25-30
26-27 27-28 28-29 29-30

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:Atom 30:Atom 31:CLASS 32:CLASS 33:Atom 34:CLASS 35:CLASS 36:Atom 37:Atom
38:Atom 39:Atom 40:CLASS 41:Atom 42:Atom 43:Atom 44:Atom 45:CLASS 46:CLASS
47:CLASS

L8 7166 SEA FILE=REGISTRY SSS FUL L4

100.0% PROCESSED 7940 ITERATIONS 7166 ANSWERS
SEARCH TIME: 00.00.01

FILE 'CAPLUS' ENTERED AT 13:09:22 ON 12 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 12 Sep 2007 VOL 147 ISS 12
FILE LAST UPDATED: 11 Sep 2007 (20070911/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

```
L4              STR
L8          7166 SEA FILE=REGISTRY SSS FUL L4
L9          8578 SEA FILE=CAPLUS ABB=ON  L8
L11        40388 SEA FILE=CAPLUS ABB=ON  HUMAN IMMUNODEFICIENCY VIRUS+NT/CT
L13        20238 SEA FILE=CAPLUS ABB=ON  ANTI-AIDS AGENTS/CT
L14        21658 SEA FILE=CAPLUS ABB=ON  "AIDS (DISEASE)"+OLD/CT
L16         5597 SEA FILE=CAPLUS ABB=ON  L9 AND (PY<2003 OR AY<2003 OR PRY<2003)

L18           29 SEA FILE=CAPLUS ABB=ON  L16 AND (L11 OR L13 OR L14)



L46           28 L18 NOT L45

=> d ibib abs hitind hitstr 146 1-28

L46  ANSWER 1 OF 28  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2006:1256641  CAPLUS  Full-text
DOCUMENT NUMBER:          146:50262
TITLE:                    Antibiotic kit and compositions
INVENTOR(S):              Friedman, Doron; Besonov, Alex; Tamarkin, Dov; Eini,
                          Meir
PATENT ASSIGNEE(S):       Foamix Ltd., Israel
SOURCE:                   U.S. Pat. Appl. Publ., 31pp., Cont.-in-part of U.S.
                          Ser. No. 532,618.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   17
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     US 2006269485         A1    20061130    US 2006-448490           20060607 <--
     WO 2004037225         A2    20040506    WO 2003-IB5527           20031024 <--
     WO 2004037225         A3    20041229
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 2005069566         A1    20050331    US 2004-911367           20040804
     US 2006140984         A1    20060629    US 2005-532618           20051222 <--
     WO 2007099396         A2    20070907    WO 2006-IB3975           20060607
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
             KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
```

MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD,
SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

US 2002-429546P	P	20021129 <--
US 2003-492385P	P	20030804
WO 2003-IB5527	W	20031024
US 2004-911367	A2	20040804
US 2005-688244P	P	20050607
US 2005-532618	A2	20051222
IL 2002-152486	A	20021025 <--

AB The present invention relates to a therapeutic kit to provide an effective dosage of an antibiotic including an aerosol packaging assembly. The assembly includes a container accommodating a pressurized product; and an outlet capable of releasing the pressurized product as a foam, wherein the pressurized product comprises a foamable composition of an antibiotic; at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, an organic polar solvent, an emollient and mixts. at 2-50%, a surfactant, 0.01-5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent, water; and liquefied or compressed gas propellant at 3-25% by weight of the total composition

INCL 424045000

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1, 62

IT AIDS (disease)
Acne
Actinoplanes
Allergy inhibitors
Allium sativum
Anesthetics
Anti-inflammatory agents
Antibacterial agents
Antibiotics
Antioxidants
Antitumor agents
Antiviral agents
Arctium
Aspergillus flavus
Bacillus (bacterium genus)
Barosma
Beeswax
Buffers
Burn
Camellia sinensis
Containers
Cordyceps sinensis
Dermatitis
Ear, disease
Echinacea
Elytrigia repens
Escherichia coli
Faenia interjecta
Foams
Fungicides
Gelation agents

Human
Human papillomavirus
Humulus
Hydrophile-lipophile balance value
Hypericum perforatum
Immunomodulators
Immunosuppressants
Lavandula
Maytenus aquifolium
Maytenus evonymoides
Maytenus ilicifolia
Micromonospora
Mycosis
Neoplasm
Nonsteroidal anti-inflammatory drugs
Nose, disease
Osteoarthritis
Oxidizing agents
Parasiticides
Perilla
Permeation enhancers
Phaeoramularia
Photodynamic therapy
Plantago
Polar solvents
Propellants (sprays and foams)
Pseudomonas
Putterlickia pyracantha
Putterlickia retrospinosa
Putterlickia verrucosa
Radical scavengers
Respiratory system, disease
Rumex crispus
Skin, disease
Skin-lightening cosmetics
Streptomyces
Streptomyces arenae
Streptomyces refuineus
Surfactants
Sweat
Syphilis
Terfezia claveryi
Thistle
Thyme
Trifolium pratense
Tuberculostatics
Ulcer
Vagina, disease
Wart
Wound
Wound healing promoters
Zalerion arboricola
(antibiotic kit and compns.)

IT 50-21-5, Lactic acid, biological studies 50-59-9, Cefaloridine 50-70-4, Sorbitol, biological studies 50-76-0, Dactinomycin 50-81-7, Vitamin C, biological studies 50-81-7D, Vitamin C, derivs. 53-79-2, Puromycin 56-75-7, Chloramphenicol 56-81-5, Glycerol, biological studies 56-95-1, Chlorhexidine acetate 57-10-3, Hexadecanoic acid, biological studies 57-11-4, Stearic acid, biological studies 57-55-6, Propylene glycol, biological studies 57-62-5, Chlortetracycline

57-67-0, Sulfaguanidine 57-68-1, Sulfamethazine 57-92-1, Streptomycin 57-92-1D, Streptomycin, derivs. 59-01-8, Kanamycin 59-40-5, Sulfaquinoxaline 60-54-8, Tetracycline 61-32-5, Meticillin 61-33-6, biological studies 61-57-4, Niridazole 61-72-3, Cloxacillin 63-74-1, Sulfanilamide 66-79-5, Oxacillin 66-81-9, Cycloheximide 68-26-8, Vitamin A 68-26-8D, Vitamin A, derivs. 68-35-9, Sulfadiazine 68-41-7, Cycloserine 69-52-3, Ampicillin sodium 69-53-4, Ampicillin 69-65-8, Mannitol 72-14-0, Sulfathiazole 79-14-1, Glycolic acid, biological studies 79-57-2, Oxytetracycline 80-08-0, Dapsone 80-32-0, Sulfachlorpyridazine 80-35-3, Sulfamethoxypyridazine 80-74-0, Sulfisoxazole acetyl 83-88-5, Riboflavin, biological studies 85-73-4, Phthalylsulfathiazole 87-11-6, Thiolutin 94-36-0, Benzoyl peroxide, biological studies 98-88-4, Benzoyl chloride 106-14-9, 12-Hydroxy stearic acid 107-41-5, Hexylene glycol 108-46-3, Resorcinol, biological studies 108-95-2, Phenol, biological studies 110-17-8, Fumaric acid, biological studies 111-16-0, Pimelic acid 111-20-6, Sebacic acid, biological studies 111-90-0, Transcutol 112-85-6, Behenic acid 112-92-5, Stearyl alcohol 114-07-8, Erythromycin 114-86-3, Phenformin 115-68-4, Sulfadicramide 115-77-5, Pentaerythritol, biological studies 116-43-8, Succinylsulfathiazole 119-04-0, Framycetin 122-11-2, Sulfadimethoxine 123-99-9, Azelaic acid, biological studies 124-04-9, Adipic acid, biological studies 125-46-2, Usnic acid 125-65-5, Pleuromutilin 126-07-8, Griseofulvin 127-33-3, Demeclocycline 127-65-1 127-69-5, Sulfisoxazole 127-71-9, Sulfabenzamide 127-79-7, Sulfamerazine 128-46-1, Dihydrostreptomycin 138-39-6, Mafenide 144-80-9, Sulfacetamide 144-82-1, Sulfamethizole 144-83-2, Sulfapyridine 147-52-4, Nafcillin 147-55-7, Phenethicillin 152-47-6, Sulfalene 153-61-7, Cefalotin 154-21-2, Lincomycin 303-81-1, Novobiocin 389-08-2, Nalidixic acid 443-48-1, Metronidazole 468-28-0, Lupulone 479-98-1, Aucubin 488-04-0, Holomycin 497-72-3, Methymycin 503-83-3, Tetramic acid 505-48-6, Suberic acid 505-52-2, 1,13-Tridecanedioic acid 506-30-9, Arachidic acid 506-48-9, Octacosanoic acid 510-18-9, Acetomycin 512-64-1, Echinomycin 515-49-1, Sulfathiourea 515-64-0, Sulfisomidine 520-74-1, Agropyrene 526-08-9, Sulfaphenazol 530-43-8, Chloramphenicol palmitate 532-31-0, Silver benzoate 534-16-7, Silver carbonate 539-35-5, Mycobacidin 539-86-6, Allicin 547-44-4, Sulfacarbamide 551-27-9, Propicillin 551-92-8, Dimetridazole 563-63-3, Silver acetate 564-25-0, Doxycycline 593-50-0, 1-Triacontanol 599-88-2, Sulfaperine 606-58-6, Vengicide 629-96-9, Arachidyl alcohol 637-32-1, Proguanil hydrochloride 643-22-1 , Erythromycin stearate 661-19-8, Behenyl alcohol 693-23-2, 1,12-Dodecanedioic acid 723-46-6, Sulfamethoxazole 729-99-7, Sulfamoxole 738-70-5, Trimethoprim 738-72-7, Protomycin 751-97-3, Rolitetracycline 801-52-5, Porfiromycin 821-38-5, 1,14-Tetradecanedioic acid 914-00-1, Methacycline 982-57-0, Chloramphenicol succinate sodium 983-85-7, Penamecillin 987-02-0, Demethyltetracycline 992-21-2, Lymecycline 1018-71-9, Pyrrolnitrin 1066-17-7, Colistin 1088-92-2, Nifurtoinol 1115-70-4, Metformin hydrochloride 1161-88-2, Sulfatolamide 1181-54-0, Clomocycline 1190-53-0, Buformin hydrochloride 1220-83-3, Sulfamonomethoxine 1264-62-6, Erythromycin ethyl succinate 1314-13-2, Zinc oxide, biological studies 1314-23-4, Zirconium oxide, biological studies 1332-37-2, Iron oxide, biological studies 1391-41-9, Endomycin 1391-62-4, Fluvomycin 1392-21-8, Kitasamycin 1392-21-8D, Leucomycin, derivs. 1392-60-5, Mycosubtilin 1393-12-0, Rimocidin 1393-38-0, Subtilin 1393-48-2, Thiostrepton 1393-68-6, Bottromycin 1393-87-9, Fusafungin 1394-02-1, Hachimycin 1395-21-7, Bacillomycin 1397-84-8, Alazopeptin 1400-61-9, Nystatin 1401-63-4, Thioaurin 1401-69-0, Tylosin 1402-38-6, Actinomycin 1402-82-0, Amfomycin 1402-83-1, Angolamycin 1402-88-6, Ascosin 1403-17-4, Candicidin 1403-61-8, Fradicin 1403-66-3, Gentamicin

1403-71-0, Hamycin 1403-95-8, Mediocidin 1403-95-8D, Mediocidin, Me derivs. 1404-04-2, Neomycin 1404-08-6, Neutramycin 1404-26-8, Polymyxin B 1404-55-3, Ristocetin 1404-63-3, Sistomycosin 1404-74-6, Streptovaricin 1404-88-2, Tyrothricin 1404-90-6, Vancomycin 1404-90-6D, Vancomycin, demethyl derivs. 1405-33-0, Angustmycin 1405-41-0, Gentamycin sulfate 1405-87-4, Bacitracin 1405-97-6, Gramicidin 1406-11-7, Polymyxin 1406-16-2, Vitamin D 1406-16-2D, Vitamin D, derivs. 1406-18-4, Vitamin E 1414-39-7, Albomycin 1414-45-5, Nisin 1438-30-8, Netropsin 1695-77-8, Spectinomycin 1724-02-3D, Pentenedioic acid, derivs. 1852-04-6, Undecanedioic acid 1926-49-4, Clometocillin 2001-95-8, Valinomycin 2013-58-3, Meclocycline 2022-85-7, Flucytosine 2079-00-7, Blasticidin S 2086-83-1, Berberine 2096-42-6, Gougerotin 2134-29-4, Reuterin 2447-57-6, Sulfadoxine 2520-21-0, Celesticetin 2750-76-7, Rifamide 2751-09-9, Troleandomycin 2885-39-4, Acetoxycycloheximide 3116-76-5, Dicloxacillin 3366-95-8, Secnidazole 3485-14-1, Ciclacillin 3508-01-8, Silver palmitate 3511-16-8, Hetacillin 3521-62-8, Erythromycin estolate 3545-49-1 3563-14-2, Sulfasuccinamide 3689-76-7, Chlormidazole 3697-42-5, Chlorhexidine hydrochloride 3847-29-8, Erythromycin lactobionate 3922-90-5, Oleandomycin 3930-19-6, Streptonigrin 4107-73-7, Sulfatriazine 4117-65-1, Aspartocin 4135-11-9, Polymyxin B1 4564-87-8, Carbomycin 4572-56-9, Bromotetracycline 4682-50-2, Trichodermin 4696-76-8, Bekanamycin 4697-36-3, Carbenicillin 4800-94-6, Carbenicillin disodium 4803-27-4, Anthramycin 5250-39-5, Flucloxacillin 5306-85-4, Dimethyl isosorbide 5490-27-7, Dihydrostreptomycin sulfate 5636-92-0, Picloxydine 6377-18-0, Chartreusin 6379-56-2, Hygromycin 6489-97-0, Metampicillin 6506-37-2, Nimorazole
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antibiotic kit and compns.)

IT 72558-82-8, Ceftazidime 72559-06-9, Rifabutin 72615-20-4, Bactobolin 73090-70-7, Epiroprim 73151-29-8, Fenticonazole nitrate 73196-97-1, Dactimicin 73231-34-2, Florfenicol 73341-71-6, Oudemansin 73384-59-5, Ceftriaxone 73816-42-9, Meclocycline sulfosalicylate 73904-91-3, Microcin 74011-58-8, Enoxacin 74014-51-0, Rokitamycin 74298-63-8, Chlormidazole hydrochloride 74352-51-5 74352-52-6 74352-53-7 74352-54-8 74469-00-4, Amoxicillin-potassium clavulanate mixture 74497-04-4, Oxolonomycin 74512-12-2, Omoconazole 74758-63-7, Alanylclavam 74913-06-7, Chromomycin 75060-25-2, 3-Trehalosamine 75081-92-4, Epihygromycin 75433-48-6, Herbicolin 75635-18-6, Seldomycin 75635-19-7, Sorbistin 76157-50-1, Chlorocarcin 76260-86-1 76363-52-5, Cytophagin 76448-31-2, Propenidazole 76470-66-1, Loracarbef 76610-84-9, Cefbuperazone 76631-42-0, Nocardicin 76774-97-5, Istamycin 76828-82-5, Dnacin 77174-66-4 77175-51-0, Croconazole 77312-55-1 77312-57-3 77378-01-9 77398-03-9, 3-O-Demethylistamycin B 77550-86-8, Northienamycin 77642-19-4, Stubomycin 77904-47-3, Juvenimicin 78040-85-4, Coumermycin 78110-38-0, Aztreonam 78308-34-6, Neoviridogrisein 78565-33-0, Tridecaptin 78874-50-7 78874-51-8 78874-52-9 78874-53-0 78874-54-1 78922-09-5, Baumycin 79350-37-1, Cefixime 79392-34-0, Saframycin 79404-91-4, Cilofungin 79548-73-5, Pirlimycin 79620-36-3, Candiplanecin 79660-72-3, Fleroxacin 80209-40-1, Fragilomycin 80210-62-4, Cefpodoxime 80214-83-1, Roxithromycin 80394-72-5, Oxanosine 80449-89-4, Kristenin 80621-81-4, Rifaximin 80890-47-7, Concanamycin 81103-11-9, Clarithromycin 81202-83-7 81661-90-7, 5-O-Mycaminosyltylactone 81774-69-8, Polynitroxin 81831-80-3, Trioxacarcin 82419-36-1, Ofloxacin 82547-58-8, Cefteram 82547-81-7, Cefteram pivoxil 82664-20-8, Flurithromycin 82854-37-3, Echinacoside 83198-27-0, Saphenamycin 83905-01-5, Azithromycin 84305-41-9, Cefminox 84420-34-8, Paromomycin 84625-61-6, Itraconazole 84957-29-9, Cefpirome

84957-30-2, Cefquinome 85721-33-1, Ciprofloxacin 86003-55-6, Nikkomycin 86258-26-6, 3-Demethoxyistamycin B 86273-18-9, Lenampicillin 86386-73-4, Fluconazole 86408-37-9, Isohematinic acid 86596-26-1, Trestatin 86630-31-1, Saccharocin 86630-31-1D, Saccharocin, derivs. 87099-85-2, Spicamycin 87239-81-4, Cefpodoxime proxetil 87385-18-0, Ditrisarubicin C 87638-04-8, Carumonam 87726-17-8, Panipenem 87913-35-7, Awamycin 87915-59-1, Lankacidin 88026-21-5, Leptomycin 88040-23-7, Cefepime 88205-90-7, Oxirapentyn 88465-80-9, Arugomycin 88507-21-5, Staphylocidin 89139-42-4, Teicoplanin aglycone 89156-94-5, Akrobomycin 89699-33-2, Fosfonochlorin 89786-04-9, Tazobactam 90092-49-2, Clazamycin 91832-40-5, Cefdinir 92090-94-3, Kazusamycin 92665-29-7, Cefprozil 93106-60-6, Enrofloxacin 93107-08-5, Ciprofloxacin hydrochloride 93908-02-2, Rebeccamycin 94116-22-0, Guanidylfungin A 94593-72-3, Serirubicin 94935-63-4, Ampicillinsulbactam 95041-97-7, Acmimycin 95660-15-4, Chloropolysporin 96036-03-2, Meropenem 97519-39-6, Ceftibuten 98079-51-7, Lomefloxacin 98079-52-8, Lomefloxacin hydrochloride 99592-32-2, Sertaconazole 99592-39-9, Sertaconazole nitrate 99665-00-6, Flomoxef 100044-27-7, Bagacidin 100440-25-3, Terpentecin 100490-36-6, Tosufloxacin 100940-65-6, Sandramycin 100986-85-4, Levofloxacin 101363-10-4, Rufloxacin 101530-10-3, Lanoconazole 101670-43-3, Humidin 102418-10-0, Selenomycin 102646-78-6, Libanomycin A 102732-36-5, Hydropricin 102732-37-6, Oxypricin 102903-07-1, Antrimycin 102961-92-2, Corallopyronin 103060-53-3, Daptomycin 103358-10-7 103972-98-1 104145-95-1, Cefditoren 104486-81-9, Mupirocin calcium 104987-11-3, Tacrolimus 104987-12-4, Ascomycin 106486-76-4, Carzinophilin 106560-14-9, Faropenem 108050-54-0, Tilmicosin 108065-99-2, Globopeptin 108319-06-8, Temafloxacin 108351-50-4, Glidobactin 110231-33-9, Fumifungin 110871-86-8, Sparfloxacin 111092-67-2, Nanaomycin 111643-99-3, Tejeramycin 111839-55-5, Nargenicin 112008-27-2, Swalpamycin 112354-01-5, Xylocandin 112398-08-0, Danofloxacin 112811-59-3, Gatifloxacin 113041-69-3, Magainin 113285-19-1, Etamycin 113359-04-9, Cefozopran 113441-12-6, Primycin 113617-63-3, Orbifloxacin 114797-28-3, Esperamicin 117184-53-9, Aranorosin 117192-99-1, Boholmycin 117467-28-4, Cefditoren pivoxil 117541-57-8, Rhizocticin 118374-47-3, Lysobactin 118498-90-1, Unphenelfamycin 119006-77-8, Flutrimazole 119914-60-2, Grepafloxacin 120410-24-4, Biapenem 120500-15-4, Leinamycin 121634-34-2 121634-35-3 122301-98-8, Vermisporin 122841-10-5, Cefoselis 123997-21-7, Apidaecin 124759-75-7, Dynemicin 124759-75-7D, Dynemicin, derivs. 124858-35-1, Nadifloxacin 125213-21-0, Culpin 126602-89-9, Quinupristin-dalfopristin 127045-41-4, Pazufloxacin 127999-44-4, Tolytoxin 128104-18-7, Mersacidin 128808-89-9, Orthosomycin 129428-69-9, Megalomicin 130726-68-0, Neticonazole 132605-69-7, Butalactin 135889-00-8, Cefcapene 136398-54-4, Alisamycin 137234-62-9, Voriconazole 138626-63-8, Deoxymulundocandin 139638-79-2, Sperabillin 140932-79-2, Balhimycin 141363-91-9, Lanomycin 143383-65-7, Premafloxacin 145269-73-4, Neopeptifluorin 145269-84-7, Peptifluorin 146961-76-4, Alatrofloxacin 147059-72-1, Trovafloxacin 147816-23-7, Cefcapene pivoxil hydrochloride 148717-90-2, Squalamine 151096-09-2, Moxifloxacin 151499-39-7, Bafilomycin 151581-81-6, Pradimicin 153832-46-3, Ertapenem 160674-34-0, Bacillaene 162808-62-0, Caspofungin 175463-14-6, Gemifloxacin 178234-32-7, Acetylkitasamycin 178330-12-6, Ascosteroside 178694-47-8, Focusin 191114-48-4, Telithromycin 199169-60-3, Corynecandin 344362-08-9, Amycomycin 436813-45-5, Coniosetin 682351-48-0, Benanomycin 808103-38-0, Cepacidine 916322-17-3 916322-18-4 916322-19-5 916322-20-8 916322-23-1 916322-25-3 916322-28-6 916328-91-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antibiotic kit and compns.)

IT 1404-90-6, Vancomycin 1404-90-6D, Vancomycin, demethyl derivs. 89139-42-4, Teicoplanin aglycone 140932-79-2, Balhimycin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antibiotic kit and compns.)

RN 1404-90-6 CAPLUS

CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Bu-i

PAGE 2-A



RN 1404-90-6 CAPLUS
CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Bu-i

PAGE 2-A



RN 89139-42-4 CAPLUS
CN Ristomycin A aglycone, 22,31-dichloro-7-demethyl-64-O-demethyl-19-deoxy- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 3-A



PAGE 4-A



RN 140932-79-2 CAPLUS

CN Vancomycin, 22-O-(3-amino-2,3,6-trideoxy-3-C-methyl-α-L-threo-hexopyranos-4-ulos-1-yl)-2'-O-de(3-amino-2,3,6-trideoxy-3-C-methyl-α-L-lyxo-hexopyranosyl)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L46 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:485575 CAPLUS Full-text
DOCUMENT NUMBER: 143:32218
TITLE: Sustained-release biodegradable microcapsules for delivery of anti-infective agents in the treatment and prevention of infections
INVENTOR(S): Setterstrom, Jean A.; Tice, Thomas R.; Jacob, Elliot; Reid, Robert H.; Van Hamont, John; Boedecker, Edgar C.; Jeyanthi, Ramassubbu; Friden, Phil; Roberts, F. Donald; McQueen, Charles E.; Bhattacharjee, Apurba; Cross, Alan; Sadoff, Jerald; Zollinger, Wendell

PATENT ASSIGNEE(S): The United States of America as Represented by the Secretary of the Army, USA
SOURCE: U.S., 167 pp., Cont.-in-part of U.S. Ser. No. 920,326.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 17
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6902743	B1	20050607	US 1998-55505	19980406 <--
US 6410056	B1	20020625	US 1995-446148	19950522 <--
US 5762965	A	19980609	US 1996-598874	19960209 <--
US 6217911	B1	20010417	US 1996-675895	19960705 <--
US 5705197	A	19980106	US 1996-698896	19960816 <--
NZ 335409	A	20001222	NZ 1996-335409	19961118 <--
US 6447796	B1	20020910	US 1997-920326	19970821 <--
US 7033608	B1	20060425	US 1999-337945	19990622 <--
PRIORITY APPLN. INFO.:			US 1995-446148 A2	19950522 <--
			US 1995-446149 B1	19950522 <--
			US 1996-590973 B2	19960124 <--
			US 1996-598874 A2	19960209 <--
			US 1996-675895 A2	19960705 <--
			US 1996-698896 A2	19960816 <--
			US 1997-788734 A2	19970123 <--
			US 1997-896197 B2	19970717 <--
			US 1997-920326 A2	19970821 <--
			US 1984-590308 B2	19840316 <--
			US 1990-493597 B2	19900315 <--
			US 1990-521945 B2	19900511 <--
			US 1991-690485 B2	19910424 <--
			US 1991-805721 B2	19911121 <--
			US 1992-867301 A2	19920410 <--
			US 1994-209350 B2	19940107 <--
			US 1994-242960 A2	19940516 <--
			NZ 1996-325561 A1	19961118 <--
			US 1997-789734 A2	19970127 <--

AB Novel burst-free, sustained release biocompatible and biodegradable microcapsules which can be programmed to release their active core for variable durations ranging from 1-100 days in an aqueous physiol. environment. The microcapsules are comprised of a core of polypeptide or other biol. active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer having a molar composition of lactide/glycolide from 90/10 to 40/60, which may contain a pharmaceutically-acceptable adjuvant, as a blend of uncapped free carboxyl end group and end-capped forms ranging to ratios from 100/0 to 1/99.

IC ICM A61K009-14
ICS A61K039-40; A61K009-48; A61K009-26; A61K009-16
INCL 424489000; 424177000; 424179000; 424451000; 424470000; 424482000; 424490000
CC 63-5 (Pharmaceuticals)
Section cross-reference(s): 1, 15
IT Acinetobacter
Actinobacillus
Actinomyces
Actinomycetales
Aerobacter
Aerococcus
Aeromonas
Arbovirus

Arcanobacterium haemolyticum
Arenavirus
Bacilli
Bacteroides
Bordetella
Borrelia
Brucella
Calymmatobacterium
Campylobacter
Campylobacter fetus
Clostridium
Coronavirus
Corynebacterium
Cytomegalovirus
Cytophaga
Ebola virus
Enterobacter aerogenes
Enterobacteriaceae
Enterococcus
Enterovirus
Erysipelothrix
Escherichia coli
Filovirus
Flavobacterium
Fusobacterium
Gardnerella
Gemella
Gram-negative bacteria
Gram-positive bacteria
Haemophilus
Helicobacter
Hepatitis A virus
Hepatitis B virus
Hepatitis C virus
Human adenovirus
Human herpesvirus
Human herpesvirus 1
Human herpesvirus 2
Human herpesvirus 3
Human herpesvirus 4
Human herpesvirus 5
Human immunodeficiency virus
Human parainfluenza virus
Human poliovirus
Influenza virus
Klebsiella
Lactococcus
Legionella
Legionella pneumophila
Leptospira
Leuconostoc
Listeria
Measles virus
Micrococcus
Moraxella
Morganella morganii
Mumps virus
Mycobacterium
Mycoplasma
Neisseria

Neisseria meningitidis
Papillomavirus
Parasite
Pasteurella
Pediococcus
Peptococcus
Peptostreptococcus
Planococcus (bacterium)
Plesiomonas
Polyomavirus
Poxviridae
Propionibacterium
Proteus (bacterium)
Proteus vulgaris
Pseudomonas
Rabies virus
Reoviridae
Respiratory syncytial virus
Rhinovirus
Rhodococcus
Rotavirus
Rothia (bacterium)
Rubella virus
Salmonella typhi
Shigella boydii
Shigella dysenteriae
Shigella flexneri
Shigella sonnei
Spirillum
Staphylococcus
Staphylococcus aureus
Streptobacillus
Streptococcus
Streptococcus pyogenes
Treponema
Vibrio
Vibrio cholerae
Wolinella succinogenes
Yersinia
(infection by, treatment and prevention of; sustained-release biodegradable microcapsules for delivery of anti-infective agents in treatment and prevention of infections)

IT 56-75-7, Chloramphenicol 59-01-8, Kanamycin 59-87-0 61-33-6, biological studies 114-07-8, Erythromycin 288-32-4D, Imidazole, antibiotic derivs. 443-48-1 738-70-5, Trimethoprim 751-94-0 1397-89-3, Amphotericin B 1403-66-3, Gentamicin 1404-26-8, Polymyxin B 1404-90-6, Vancomycin 11111-12-9, Cephalosporin 13292-46-1, Rifampin 32986-56-4, Tobramycin 37517-28-5, Amikacin 61036-62-2, Teicoplanin 78110-38-0, Aztreonam 80738-43-8, Lincosamide 92309-29-0, Imipenem-cilastatin-mixture
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(delivery of; sustained-release biodegradable microcapsules for delivery of anti-infective agents in treatment and prevention of infections)

IT 1404-90-6, Vancomycin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(delivery of; sustained-release biodegradable microcapsules for delivery of anti-infective agents in treatment and prevention of infections)

RN 1404-90-6 CAPLUS

CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Bu-i

PAGE 2-A



REFERENCE COUNT: 68 THERE ARE 68 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:430954 CAPLUS Full-text
DOCUMENT NUMBER: 141:1204
TITLE: Antimicrobial activity of antibodies producing reactive oxygen species
INVENTOR(S): Wentworth, Paul; Lerner, Richard A.
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.; The Scripps Research Institute
SOURCE: PCT Int. Appl., 131 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004044191	A1	20040527	WO 2003-EP12709		20031113 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW					
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR					
CA 2505932	A1	20040527	CA 2003-2505932		20031113 <--
AU 2003288057	A1	20040603	AU 2003-288057		20031113 <--
EP 1563062	A1	20050817	EP 2003-779919		20031113 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003016245	A	20051004	BR 2003-16245		20031113 <--
CN 1738898	A	20060222	CN 2003-80108716		20031113 <--
JP 2006506419	T	20060223	JP 2004-551019		20031113 <--
US 2007009537	A1	20070111	US 2005-534575		20050511 <--
PRIORITY APPLN. INFO.:			US 2002-426242P	P	20021114 <--
			WO 2003-EP12709	W	20031113

AB The invention provides compns. having antibodies that can generate reactive oxygen species when exposed to singlet oxygen, as well as methods of using the compns., for example, to treat microbial infections. The invention provides methods for utilizing newly discovered abilities of antibodies to produce reactive oxygen species. Hydrogen proxyde production mediated by Igs was demonstrated. It was also demonstrated, that antibodies catalyze the oxidation of water. According to the invention, antibodies can kill microbes by converting singlet oxygen into reactive oxygen species. Reactive oxygen species generated by the antibodies of the invention include superoxide radicals, hydroxyl radicals, hydrogen peroxide, ozone and other reactive oxygen species. Thus, the invention is directed to an anti-microbial composition consisting essentially of a pharmaceutically acceptable carrier and an isolated antibody that can bind to a microbe, wherein the antibody can generate a reactive oxygen species when singlet oxygen is present. The anti-microbial composition can also contain a sensitizer mol. that can generate singlet oxygen. Examples of sensitizer mol. include a pterin, a flavin, a hematoporphyrin, a tetrakis (4-sulfonatophenyl) porphyrin, a bipyridyl ruthenium (II) complex, a rose Bengal dye, a quinone, a rhodamine dye, a

phthalocyanine, a hypocrellin, rubrocyanine, pinacyanol, allocyanine or a chlorin.

IC ICM C12N009-00
ICS A61P031-04; A61P031-12; C07K016-12; C07K016-08

CC 1-5 (Pharmacology)
Section cross-reference(s): 7, 15, 63

IT Adenoviridae
Aeromonas
Alphavirus
Antibacterial agents
Antimicrobial agents
Antiviral agents
Arenavirus
Bacillus (bacterium genus)
Bacteroides
Bunyavirus
Burkholderia cepacia
Campylobacter
Cholera
Clostridium
Coronavirus
DNA viruses
Diarrhea
Enterobacter
Enterococcus
Enterococcus faecalis
Enterococcus faecium
Enterovirus
Escherichia
Escherichia coli
Filovirus
Flavivirus
Food poisoning
Gastrospirillum
Gram-negative bacteria
Helicobacter
Helicobacter pylori
Hepadnaviridae
Hepatitis A virus
Hepatitis B virus
Hepatitis C virus
Herpesviridae
Human immunodeficiency virus
Influenza A virus
Influenza B virus
Klebsiella
Lyssavirus
Morbillivirus
Nairovirus
Orbivirus
Orthomyxovirus
Papovaviridae
Paramyxovirus
Parvovirus
Phlebovirus
Picornaviridae
Pneumonia
Pneumovirus
Poxviridae
Prion diseases

Pseudomonas
Pseudomonas aeruginosa
RNA viruses
Reoviridae
Retroviridae
Rhabdoviridae
Rhinovirus
Rotavirus
Rubivirus
Salmonella
Salmonella typhi
Salmonella typhimurium
Shigella
Shigella dysenteriae
Staphylococcus
Staphylococcus aureus
Ulcer
Vibrio
Vibrio cholerae
Viroid
Yersinia
(antimicrobial activity of antibodies producing reactive oxygen species)

IT 1404-90-6, Vancomycin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(bacteria with resistance to; antimicrobial activity of antibodies producing reactive oxygen species)

IT 1404-90-6, Vancomycin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(bacteria with resistance to; antimicrobial activity of antibodies producing reactive oxygen species)

RN 1404-90-6 CAPLUS
CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Bu-i

PAGE 2-A



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:182718 CAPLUS Full-text
DOCUMENT NUMBER: 140:241007
TITLE: Multifunctional context-activated protides and methods of use
INVENTOR(S): Yeaman, Michael R.; Yount, Nannette Y.; Edwards, John E., Jr.; Brass, Eric P.
PATENT ASSIGNEE(S): Harbor-UCLA Research and Education Institute, USA
SOURCE: PCT Int. Appl., 103 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004017985	A1	20040304	WO 2003-US26405	20030820 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2006074016	A1	20060406	US 2002-225562		20020820 <--
US 7067621	B2	20060627			
AU 2003274919	A1	20040311	AU 2003-274919		20030820 <--
US 2006135416	A1	20060622	US 2005-524952		20050218 <--
PRIORITY APPLN. INFO.:			US 2002-225562	A	20020820 <--
			WO 2003-US26405	W	20030820

AB This invention is directed to multifunctional, context-activated protides that have two or more effectors with individually distinct biol. functions and one or more corresponding activator sites that can each initiate or amplify the biol. function of one or more effectors upon context-activation. The context-activated protides of the invention are useful in the diagnosis, prophylaxis, and therapy of a broad range of pathol. conditions.

IC ICM A61K038-00

CC 63-5 (Pharmaceuticals)

IT Human immunodeficiency virus
(viral protein R of; multifunctional context-activated protides and methods of use)

IT 61-32-5, Methicillin 1404-90-6, Vancomycin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(-resistant Staphylococcus aureus; multifunctional context-activated protides and methods of use)

IT 1404-90-6, Vancomycin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(-resistant Staphylococcus aureus; multifunctional context-activated protides and methods of use)

RN 1404-90-6 CAPLUS

CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Bu-i

PAGE 2-A



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 5 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:80343 CAPLUS Full-text
DOCUMENT NUMBER: 140:122836
TITLE: Use of 2,3-alkylcarbonyloxybenzoic acids, derivatives and analogues therefrom in the treatment of tissue and cellular dysfunction, damage and injury in mammals
INVENTOR(S): Stec, Karen; Rubinstein, Israel; Eiznhamer, David; Xu, Ze-qu; Flavin, Michael
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 6 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004019022	A1	20040129	US 2003-622302	20030718 <--
WO 2004010989	A1	20040205	WO 2003-US23644	20030718 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,

PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003252178	A1	20040216	AU 2003-252178	20030718 <--
EP 1539132	A1	20050615	EP 2003-772019	20030718 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.:	US 2002-398523P	P	20020725 <--
	WO 2003-US23644	W	20030718

AB A method for the treatment of cellular and tissue damage is disclosed. The inventive method comprises the use of 2,3-alkylcarbonyloxybenzoic acid and salts thereof for the prevention and treatment of dysfunction, damage, and/or injuries to organs, tissues and/or cells in human or animal subjects caused by diseases, infections and conditions such as pneumonia, coronavirus, multiple transfusions, trauma, ischemic-reperfusion dysfunctions, stroke, drug overdose, and severe acute respiratory syndrome. The 2,3-alkylcarbonyloxybenzoic acid may be used alone or in combination with other therapeutic agents such as antibiotics. The acid may be administered in any practical delivery form, and in free acid or buffered form.

IC ICM A61K038-12
ICS A61K038-00; A61K038-16; A61K031-704; A61K031-60; A61K031-496
INCL 514159000; 514008000; 514192000; 514034000; 514252130; 514029000; 514002000; 514253080; 514312000
CC 1-12 (Pharmacology)
Section cross-reference(s): 2, 4, 10, 63
IT AIDS (disease)
Acinetobacter
Acne
Alcoholism
Alzheimer's disease
Anti-AIDS agents
Anti-Alzheimer's agents
Antibacterial agents
Antibiotics
Antibiotics
Antihypotensives
Antiparkinsonian agents
Antiviral agents
Arthritis
Asthma
Atherosclerosis
Brain, disease
Chlamydia pneumoniae
Cirrhosis
Coronavirus
Cystic fibrosis
Diabetes mellitus
Drug interactions
Emphysema
Encephalitis
Enterococcus
Escherichia coli
Haemophilus influenzae
Hemochromatosis
Hepatitis
Human
Human adenovirus

Human herpesvirus 4
Human immunodeficiency virus
Human immunodeficiency virus 1
Human metapneumovirus
Human parainfluenza virus
Immunomodulators
Injury
Klebsiella pneumoniae
Lung
Lupus erythematosus
Lyme disease
Meningitis
Multiple sclerosis
Mycobacterium
Mycobacterium avium
Mycobacterium tuberculosis
Mycoplasma pneumoniae
Mycosis
Neutrophil
Paramyxovirus
Parkinson's disease
Platelet aggregation inhibitors
Pneumonia
Poisoning, biological
Preeclampsia
Preeclampsia
Prion diseases
Pseudomonas aeruginosa
Psoriasis
Respiratory syncytial virus
Rheumatoid arthritis
Rhinovirus
Sarcoidosis
Sepsis
Staphylococcus aureus
Streptococcus
Streptococcus pneumoniae
Surgery
Thrombolytics
Thrombus
Transplant and Transplantation
β-Adrenoceptor agonists
(use of alkylcarbonyloxybenzoic acids, derivs. and analogs therefrom for treatment of tissue and cellular dysfunction, damage and injury in mammals)

IT 51-61-6, Dopamine, biological studies 52-67-5, Penicillamine 56-75-7, Chloramphenicol 58-32-2, Dipyridamole 64-86-8, Colchicine 65-85-0D, Benzoic acid, alkylcarbonyloxy derivs. and sodium salts 70-51-9, Desferrioxamine 486-79-3, 2,3-Diacetoxybenzoic acid 564-25-0, Doxycycline 1403-66-3, Gentamicin 1404-90-6, Vancomycin 1406-05-9, Penicillin 9002-01-1, Streptokinase 9039-53-6, Urokinase 9041-92-3, Prolastin 13292-46-1, Rifampin 18323-44-9, Clindamycin 36791-04-5, Ribavirin 64221-86-9, Imipenem 65277-42-1, Ketoconazole 81103-11-9, Clarithromycin 81669-57-0, Anistreplase 84625-61-6, Itraconazole 86386-73-4, Fluconazole 98530-76-8, Drotrecogin alfa (activated) 105857-23-6, Alteplase 113665-84-2, Clopidogrel 126602-89-9, Quinupristin/dalfopristin 133652-38-7, Reteplase 139639-23-9, Tissue plasminogen activator 165800-03-3, Linezolid 191588-94-0, Tenecteplase
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(use of alkylcarbonyloxybenzoic acids, derivs. and analogs therefrom for treatment of tissue and cellular dysfunction, damage and injury in mammals)

IT 1404-90-6, Vancomycin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of alkylcarbonyloxybenzoic acids, derivs. and analogs therefrom for treatment of tissue and cellular dysfunction, damage and injury in mammals)

RN 1404-90-6 CAPLUS
CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Bu-i



L46 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:41226 CAPLUS Full-text
DOCUMENT NUMBER: 140:105321
TITLE: Methods and compositions relating to isoleucine boroproline compounds
INVENTOR(S): Adams, Sharlene; Miller, Glenn T.; Jesson, Michael I.; Jones, Barry
PATENT ASSIGNEE(S): Point Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 152 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004658	A2	20040115	WO 2003-US21405	20030709 <--
WO 2004004658	A3	20050804		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2491466	A1	20040115	CA 2003-2491466	20030709 <--
AU 2003265264	A1	20040123	AU 2003-265264	20030709 <--
US 2004077601	A1	20040422	US 2003-616694	20030709 <--
US 2005084490	A1	20050421	US 2003-616409	20030709 <--
EP 1578434	A2	20050928	EP 2003-763380	20030709 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006507352	T	20060302	JP 2004-562634	20030709 <--
CN 1802090	A	20060712	CN 2003-821282	20030709 <--

CN 1826129	A	20060830	CN 2003-821281		20030709 <--
IN 2005KN00151	A	20050916	IN 2005-KN151		20050208 <--
PRIORITY APPLN. INFO.:			US 2002-394856P	P	20020709 <--
			US 2002-414978P	P	20021001 <--
			US 2003-466435P	P	20030428
			WO 2003-US21405	W	20030709

OTHER SOURCE(S): MARPAT 140:105321

AB A method for treating subjects with, inter alia, abnormal cell proliferation or infectious disease using agents of formula (I, AmNHCH(CH(CH3)CH2CH3)COA1R) (where Am and A1 are amino acids and R = organo boronates, organo phosphonates, fluoroalkyl ketones, alphaketos, N-peptiolyl-O-(acylhydroxylamines), azapeptides, azetidines, fluoroolefins dipeptide isosteres, peptidyl (α-aminoalkyl) phosphonate esters, aminoacyl pyrrolidine-2-nitriles and 4-cyanothiazolidides) is claimed. Methods for stimulating an immune response using the compds. of the invention are also claimed. Compns. containing Ile-boroPro compds. are also provided as are kits containing the compns. The invention embraces the use of these compds. alone or in combination with other therapeutic agents.

IC ICM A61K

CC 1-12 (Pharmacology)
Section cross-reference(s): 15

IT Actinomyces
Adenoviridae
Bacteroides
Borrelia
Campylobacter
Citrobacter
Clostridium difficile
Corynebacterium
Cytomegalovirus
Echinococcus
Enterobacter
Escherichia coli
Fasciola
Gardnerella
Haemophilus
Helicobacter pylori
Human herpesvirus 1
Human herpesvirus 2
Human herpesvirus 3
Human herpesvirus 4
Human immunodeficiency virus
Human papillomavirus
Hymenolepis
Klebsiella
Legionella
Listeria
Monkeypox virus
Necator americanus
Neisseria
Nocardia
Paragonimus
Pasteurella
Pneumocystis
Proteus (bacterium)
Pseudomonas
Respiratory syncytial virus
Rotavirus
Salmonella
Shigella

Spirillum
Spirochaeta
Streptobacillus
Streptococcus
Streptococcus pneumoniae
Taenia
Treponema
Trichomonas vaginalis
Trichuris trichiura
Trypanosoma brucei
Trypanosoma cruzi
(infection; therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)

IT 50-18-0, Cyclophosphamide 50-44-2 50-59-9, Cephaloridine 50-63-5, Chloroquine phosphate 50-65-7, Niclosamide 50-76-0, Dactinomycin 50-91-9, Floxuridine 51-21-8, Fluorouracil 52-68-6, Metrifonate 53-03-2, Prednisone 54-42-2, Idoxuridine 54-85-3, Isoniazid 55-86-7, Mechlorethamine hydrochloride 56-75-7, Chloramphenicol 57-62-5, Chlortetracycline 57-68-1, Sulfamethazine 57-92-1, Streptomycin, biological studies 58-71-9, Cephalothin sodium 59-05-2, Methotrexate 60-54-8, Tetracycline 61-32-5, Methicillin 63-45-6, Primaquine phosphate 64-72-2, Chlortetracycline hydrochloride 64-73-3, Demeclocycline hydrochloride 64-75-5, Tetracycline hydrochloride 66-79-5, Oxacillin 67-20-9, Nitrofurantoin 67-45-8, Furazolidone 68-35-9, Sulfadiazine 68-41-7, Cycloserine 69-05-6, Quinacrine hydrochloride 69-52-3, Ampicillin sodium 69-53-4, Ampicillin 69-57-8, Penicillin g sodium 69-74-9, Cytarabine hydrochloride 70-00-8, Trifluridine 70-10-0, Ticlatone 72-14-0, Sulfathiazole 74-55-5, Ethambutol 77-46-3, Acedapsone 79-57-2, Oxytetracycline 80-08-0, Dapsone 80-74-0, Sulfisoxazole acetyl 83-73-8, Iodoquinol 87-08-1, Penicillin v 88-04-0, Chloroxylenol 90-89-1, Diethylcarbamazine 97-18-7, Bithionol 98-96-4, Pyrazinamide 100-97-0, Methenamine, biological studies 102-76-1, Triacetin 106-48-9 110-85-0, Piperazine, biological studies 112-38-9, Undecylenic acid 113-98-4, Penicillin g potassium 114-07-8, Erythromycin 115-02-6, Azaserine 121-19-7, Roxarsone 121-81-3, Nitromide 122-16-7, Sulfanitran 124-07-2, Octanoic acid, biological studies 126-07-8, Griseofulvin 127-07-1, Hydroxyurea 127-33-3, Demeclocycline 127-56-0, Sulfacetamide sodium 127-69-5, Gantrisin 127-71-9, Sulfabenzamide 127-77-5, Sulfabenz 127-79-7, Sulfamerazine 128-12-1, Acetosulfone sodium 130-16-5, Cloxyquin 132-92-3, Methicillin sodium 132-98-9, Penicillin v potassium 133-10-8, p-Aminosalicylate sodium 133-11-9, Phenyl aminosalicylate 133-51-7, Meglumine antimoniate 134-36-1, Erythromycin propionate 137-26-8, Thiram 138-39-6, Mafenide 140-64-7, Pentamidine isethionate 143-67-9, Vinblastine sulfate 144-80-9, Sulfacetamide 144-82-1, Sulfamethizole 145-63-1, Suramin 147-52-4, Nafcillin 147-94-4, Cytarabine 148-79-8, Thiabendazole 148-82-3, Melphalan 152-47-6, Sulfalene 153-61-7, Cephalothin 154-21-2, Lincomycin 288-32-4, Imidazole, biological studies 288-32-4D, Imidazole, derivs. 305-03-3, Chlorambucil 343-55-5, Dicloxacillin sodium 366-70-1, Procarbazine hydrochloride 389-08-2, Nalidixic acid 443-48-1, Metronidazole 494-79-1, Melarsoprol 500-92-5, Proguanil 527-75-3, Berythromycin 528-96-1, Benzoylpas calcium 530-43-8, Chloramphenicol palmitate 536-33-4, Ethionamide 547-32-0, Sulfadiazine sodium 554-72-3, Tryparsamide 555-84-0, Nifuradene 557-08-4, Zinc undecyl enate 564-25-0, Doxycycline 575-54-2, Penicillins 587-23-5, Methenamine mandelate 599-79-1, Sulfasalazine 632-00-8, Sulfasomizole 642-78-4, Cloxacillin sodium 643-22-1, Erythromycin stearate 651-06-9, Sulfameter 665-66-7,

Amantadine hydrochloride 723-46-6, Sulfamethoxazole 729-99-7, Sulfamoxole 735-52-4, Cetophenicol 738-70-5, Trimethoprim 751-94-0, Fusidate sodium 751-97-3, Rolitetracycline 768-94-5, Amantadine 777-11-7, Haloprogin 801-52-5, Porfiromycin 804-63-7, Quinine sulfate 808-26-4, Sancycline 847-25-6, Racephenicol 852-19-7, Sulfazamet 859-18-7, Lincomycin hydrochloride 909-14-8 914-00-1, Methacycline 982-57-0, Chloramphenicol sodium succinate 983-85-7, Penamecillin 985-16-0, Nafcillin sodium 987-02-0, Demecycline 1018-71-9, Pyrrolnitrin 1070-11-7, Ethambutol hydrochloride 1173-88-2, Oxacillin sodium 1220-83-3, Sulfamonomethoxine 1264-62-6, Erythromycin ethyl succinate 1264-72-8, Colistin sulfate 1322-14-1, Calcium undecylenate 1336-20-5, Tetracycline phosphate complex 1392-21-8, Kitasamycin 1397-89-3, Amphotericin B 1400-61-9, Nystatin 1402-82-0, Amphomycin 1403-17-4, Candicidin 1403-66-3, Gentamicin 1403-71-0, Hamycin 1404-00-8, Mitomycin 1404-08-6, Neutramycin 1404-48-4, Relomycin 1404-59-7, Rutamycin 1404-88-2, Tyrothricin 1404-90-6, Vancomycin 1404-93-9, Vancomycin hydrochloride 1405-00-1, Viridofulvin 1405-10-3, Neomycin sulfate 1405-20-5, Polymyxin b sulfate 1405-37-4, Capreomycin sulfate 1405-41-0, Gentamicin sulfate 1405-52-3, Sulfomyxin 1405-87-4, Bacitracin 1405-89-6, Bacitracin zinc 1405-97-6, Gramicidin 1406-04-8, Neomycin undecyl enate 1406-11-7, Polymyxin 1432-75-3, Nitralamine hydrochloride 1476-53-5, Novobiocin sodium 1501-84-4, Rimantadine hydrochloride 1538-09-6 1617-53-4, Amentoflavone 1910-68-5, Methisazone 2013-58-3, Meclocycline 2022-85-7, Flucytosine 2030-63-9, Clofazimine 2058-46-0, Oxytetracycline hydrochloride 2068-78-2, Vincristine sulfate 2398-96-1, Tolnaftate 2447-57-6, Sulfadoxine 2750-76-7, Rifamide 2751-09-9, Troleandomycin 3056-17-5, Stavudine 3116-76-5, Dicloxacillin 3270-71-1, Nifuraldezone 3374-05-8, Nalidixate sodium 3424-98-4 3485-14-1, Cyclacillin 3511-16-8, Hetacillin 3521-62-8, Erythromycin estolate 3545-67-3, Chloroquine hydrochloride 3570-75-0, Nifurthiazole 3577-01-3, Cephaloglycin 3696-28-4, Dipyrithione 3736-81-0, Diloxanide furoate 3778-73-2, Ifosfamide 3795-88-8, Levofuraltadone 3810-74-0, Streptomycin sulfate 3847-29-8, Erythromycin lactobionate 3922-90-5, Oleandomycin 3963-95-9, Methacycline hydrochloride 4117-65-1, Aspartocin 4197-24-4, Carbol-fuchsin 4291-63-8, Cladribine 4299-60-9, Sulfisoxazole diolamine 4342-03-4, Dacarbazine 4375-07-9D, Epipodophyllotoxin, antibody conjugates 4428-95-9 4575-42-2, Coumermycin sodium 4697-36-3, Carbenicillin 4800-94-6, Carbenicillin disodium 4803-44-5, Levopropylcillin potassium 4803-45-6, Thiphencillin potassium 4914-30-1, Dehydroemetine 4936-47-4, Nifuratel 5036-03-3, Nifurdazil 5055-20-9, Nifurquinazol 5118-17-2, Furazolium chloride 5250-39-5, Floxacillin 5321-32-4, Hetacillin potassium 5355-16-8, Diaveridine 5490-27-7, Dihydrostreptomycin sulfate 5536-17-4, Vidarabine 5560-62-3, Biphenamine hydrochloride 5578-73-4, Sanguinarium chloride 5579-95-3, Nifurmerone 5585-59-1, Nitrocycline 5588-20-5, Chlordantoin 5667-71-0, Streptonicozid 5714-05-6, Quindecamine acetate 5714-73-8, Methenamine hippurate 5874-95-3, Amicycline 5928-84-7, Penicillin v benzathine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)

IT 1404-90-6, Vancomycin 1404-93-9, Vancomycin hydrochloride
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic methods and compns. relating to isoleucine boroproline

compds. alone or in combination with other drugs, antibodies, or antigens)

RN 1404-90-6 CAPLUS

CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Bu-i

PAGE 2-A



RN 1404-93-9 CAPLUS
CN Vancomycin, hydrochloride (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Bu-i

PAGE 2-A



PAGE 2-B

●x HCl

L46 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:656550 CAPLUS Full-text
DOCUMENT NUMBER: 139:185702
TITLE: Method for systemic drug delivery through the nail
INVENTOR(S): Bruno-Raimondi, Alfredo Emilio; Karabelas, Argeris Jerry
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003068197	A1	20030821	WO 2003-EP1345	20030211 <--
WO 2003068197	A8	20040930		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU,

LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR

AU 2003210243 A1 20030904 AU 2003-210243 20030211 <--
EP 1492512 A1 20050105 EP 2003-739473 20030211 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
JP 2005517471 T 20050616 JP 2003-567380 20030211 <--
PRIORITY APPLN. INFO.: GB 2002-3276 A 20020212 <--
WO 2003-EP1345 W 20030211

AB A method for systemically delivering a pharmaceutical composition to a human or animal comprises forming an orifice in a nail of a human or animal by means of a laser-based device and applying a pharmaceutical composition in the orifice, wherein the method provides a controlled release of the pharmaceutical composition The pharmaceutical composition may be in the form of a liquid, semisolid, solid, solution, gel, emulsion, or powder.

IC ICM A61K009-70
ICS A61B018-20

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 62

IT Encephalitis
Human immunodeficiency virus 1
(Japanese, vaccines against; method for systemic drug delivery through nails)

IT 50-02-2, Dexamethasone 50-06-6, Phenobarbital, biological studies 50-14-6, Ergocalciferol 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-28-2, Estradiol, biological studies 50-48-6, Amitriptyline 50-49-7, Imipramine 50-55-5, Reserpine 50-78-2, Acetylsalicylic acid 50-81-7, Ascorbic acid, biological studies 51-21-8, Fluorouracil 51-34-3, Scopolamine 51-43-4, Epinephrine 51-48-9, Levothyroxine, biological studies 51-61-6, Dopamine, biological studies 52-01-7, Spironolactone 52-53-9, Verapamil 52-86-8, Haloperidol 53-03-2, Prednisone 53-86-1, Indomethacin 54-11-5, Nicotine 54-31-9, Furosemide 55-56-1, Chlorohexidine 55-63-0, Nitroglycerine 56-40-6, Aminoacetic acid, biological studies 56-54-2, Quinidine 56-75-7, Chloramphenicol 56-85-9, Levoglutamide, biological studies 57-27-2, Morphine, biological studies 57-41-0, Phenytoin 57-63-6, Ethinylestradiol 57-83-0, Progesterone, biological studies 58-05-9, Folinic acid 58-08-2, Caffeine, biological studies 58-22-0, Testosterone 58-32-2, Dipyridamole 58-55-9, Theophylline, biological studies 58-73-1, Diphenhydramine 58-85-5, Biotin 58-93-5, Hydrochlorothiazide 59-05-2, Methotrexate 59-30-3, Folic acid, biological studies 59-42-7, Phenylephrine 59-43-8, Thiamine, biological studies 59-67-6, Nicotinic acid, biological studies 59-92-7, Levodopa, biological studies 60-54-8, Tetracycline 61-33-6, Penicillin G, biological studies 62-49-7, Choline 65-23-6, Pyridoxine 66-22-8, Uracil, biological studies 68-19-9, Cyanocobalamin 68-22-4, Norethisterone 68-26-8, Retinol 68-89-3, Dipyrone 69-53-4, Ampicillin 69-72-7, Salicylic acid, biological studies 72-69-5, Nortriptyline 76-22-2, Camphor 76-25-5, Triamcinolone acetonide 76-57-3, Codeine 77-36-1, Chlorthalidone 79-83-4, Pantothenic acid 81-13-0, Dexpanthenol 83-43-2, Methylprednisolone 83-88-5, Riboflavin, biological studies 87-08-1, Penicillin V 87-33-2, Isosorbide dinitrate 90-82-4, Pseudoephedrine 94-09-7, Benzocaine 94-24-6, Tetracaine 97-59-6, Allantoin 98-92-0, Nicotinamide 99-66-1, Valproic acid 103-90-2, Acetaminophen 113-15-5, Ergotamine 113-92-8 114-07-8, Erythromycin 125-28-0, Dihydrocodeine 125-29-1, Hydrocodone 125-71-3, Dextromethorphan 126-07-8, Griseofulvin 137-58-6, Lidocaine

146-17-8, Flavin mononucleotide 146-22-5, Nitrazepam 153-18-4, Rutoside 298-46-4, Carbamazepine 299-42-3, Ephedrine 302-79-4, Tretinoin 303-49-1, Clomipramine 315-30-0, Allopurinol 322-35-0, Benserazide 364-62-5, Metoclopramide 378-44-9, Betamethasone 396-01-0, Triamterene 437-38-7, Fentanyl 439-14-5, Diazepam 466-99-9, Hydromorphone 469-62-5, Dextropropoxyphene 511-12-6, Dihydroergotamine 514-65-8, Biperiden 520-85-4, Medroxyprogesterone 525-66-6, Propranolol 541-15-1, Levocarnitine 552-79-4, N-Methylephedrine 555-30-6, Methyldopa 564-25-0, Doxycycline 599-79-1, Sulfasalazine 603-00-9, Proxyphylline 616-91-1, Acetylcysteine 721-50-6, Prilocaine 723-46-6, Sulfamethoxazole 738-70-5, Trimethoprim 797-63-7, Levonorgestrel 846-49-1, Lorazepam 1197-18-8, Tranexamic acid 1400-61-9, Nystatin 1403-66-3, Gentamicin 1404-04-2, Neomycin 1404-26-8, Polymyxin B 1404-90-6, Vancomycin 1406-18-4, Vitamin E 1490-04-6, Menthol 1622-61-3, Clonazepam 1812-30-2, Bromazepam 1951-25-3, Amiodarone 2098-66-0, Cyproterone 2438-72-4, Bufexamac 2609-46-3, Amiloride 2955-38-6, Prazepam 3572-43-8, Bromhexine 3737-09-5, Disopyramide 3930-20-9, Sotalol 4205-90-7, Clonidine 4419-39-0, Beclomethasone 4618-18-2, Lactulose 4759-48-2, Isotretinoin 5104-49-4, Flurbiprofen 5786-21-0, Clozapine 6493-05-6, Pentoxifylline 6533-00-2, Norgestrel 6809-52-5, Teprenone 7085-55-4, Troxerutin 8049-47-6, Pancreatin 9001-62-1, Lipase 9002-72-6, Somatotropin 9004-10-8, Insulin, biological studies 9004-61-9, Hyaluronic acid 9005-49-6, Heparin, biological studies 10118-90-8, Minocycline 10238-21-8, Glibenclamide 10540-29-1, Tamoxifen 11032-41-0, Dihydroergotoxin 11041-12-6, Cholestyramine 11103-57-4, Vitamin A 13292-46-1, Rifampicin 13392-18-2, Fenoterol 14611-51-9, Selegiline 14838-15-4, Phenylpropanolamine 15307-86-5, Diclofenac 15663-27-1, Cisplatin 15676-16-1, Sulpiride 15686-71-2, Cefalexin 15687-27-1, Ibuprofen 16051-77-7, Isosorbide mononitrate 16110-51-3, Cromoglycic acid 16662-47-8, Gallopamil 17902-23-7, Tegafur 18559-94-9, Salbutamol 18683-91-5, Ambroxol 19216-56-9, Prazosin 20830-75-5, Digoxin 21829-25-4, Nifedipine 22071-15-4, Ketoprofen 22204-53-1, Naproxen 22916-47-8, Miconazole 23031-25-6, Terbutaline 23593-75-1, Clotrimazole 24356-60-3, Cefatrexyl 25614-03-3, Bromocriptine 25655-41-8, Povidoneiodine 25812-30-0, Gemfibrozil 25953-19-9, Cefazolin 26787-78-0, Amoxicillin 26839-75-8, Timolol 27848-84-6, Nicergoline 28860-95-9, Carbidopa 28981-97-7, Alprazolam 29094-61-9, Glipizide 29122-68-7, Atenolol 30516-87-1, Zidovudine 31329-57-4, Naftidrofuryl 33419-42-0, Etoposide 34580-13-7, Ketotifen 36322-90-4, Piroxicam 36505-84-7, Buspirone 36894-69-6, Labetalol 37517-28-5, Amikacin 37517-30-9, Acebutolol 38304-91-5, Minoxidil 38396-39-3, Bupivacaine 39562-70-4, Nitrendipine 41294-56-8, Alfacalcidol 41575-94-4, Carboplatin 41859-67-0, Bezafibrate 42399-41-7, Diltiazem 47931-85-1, Salcatonin 49562-28-9, Fenofibrate 50679-08-8, Terfenadine 51333-22-3, Budesonide 51384-51-1, Metoprolol 51481-61-9, Cimetidine 52468-60-7, Flunarizine 53179-11-6, Loperamide 53994-73-3, Cefaclor 54024-22-5, Desogestrel 54063-53-5, Propafenone 54182-58-0, Sucralfate 54910-89-3, Fluoxetine 55142-85-3, Ticlopidine 55268-75-2, Cefuroxime 55837-25-7, Buflomedil 55985-32-5, Nicardipine 56030-54-7 57808-66-9, Domperidone 58001-44-8, Clavulanic acid 59122-46-2, Misoprostol 59277-89-3, Acyclovir 59467-70-8, Midazolam 60166-93-0, Iopamidol 62571-86-2, Captopril 63527-52-6, Cefotaxime 63590-64-7, Terazosin 64221-86-9, Imipenem 65277-42-1, Ketoconazole 66085-59-4, Nimodipine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for systemic drug delivery through nails)

IT 1404-90-6, Vancomycin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for systemic drug delivery through nails)

RN 1404-90-6 CAPLUS
CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Bu-i

PAGE 2-A



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 8 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:261602 CAPLUS Full-text
DOCUMENT NUMBER: 138:265609
TITLE: Use of neuraminidase inhibitors to prevent flu-associated bacterial infections
INVENTOR(S): McCullers, Jonathan A.
PATENT ASSIGNEE(S): St. Jude Children's Research Hospital, USA
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003026567	A2	20030403	WO 2002-US29417		20020917 <--
WO 2003026567	A3	20040826			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2002325026	A1	20030407	AU 2002-325026		20020917 <--
US 2004248825	A1	20041209	US 2004-809127		20040325 <--
PRIORITY APPLN. INFO.:			US 2001-325615P	P	20010927 <--
			WO 2002-US29417	W	20020917 <--

AB The invention provides a novel use for neuraminidase inhibitors in chemoprophylactic and treatment methods for the prevention, attenuation, and treatment of bacterial infections that may occur in association with, or as a sequelae of, viral influenza. The prophylactic methods of the invention are particularly suitable for the prevention of secondary bacterial infections, such as, but not limited to, infections of the lower respiratory tract (e.g., pneumonia), middle ear infections (e.g., otitis media), and bacterial sinusitis. The treatment methods are suitable for use in protocols designed to attenuate or treat bacterial infections that occur concurrent with, or as a sequelae of, the flu.

IC ICM A61K
CC 1-5 (Pharmacology)
IT Drugs
Human immunodeficiency virus
(immunosuppression from; neuraminidase inhibitors to prevent flu-associated bacterial infections)
IT 66-79-5, Oxacillin 69-53-4, Ampicillin 147-52-4, Nafcillin 1404-90-6, Vancomycin 3116-76-5, Dicloxacillin 8064-90-2 18323-44-9, Clindamycin 26787-78-0, Amoxicillin 34787-01-4, Ticarcillin 38821-53-3, Cephradine 50370-12-2, Cefadroxil 55268-75-2, Cefuroxime 63527-52-6, Cefotaxime 72558-82-8, Ceftazidime 73384-59-5, Ceftriaxone 74469-00-4, Augmentin 76470-66-1, Loracarbef 76497-13-7, Unasyn 79198-29-1, Amoxicillin-clavulanic acid mixture 79350-37-1, Cefixime 80210-62-4, Cefpodoxime 83905-01-5, Azithromycin

85721-33-1, Ciprofloxacin 86482-18-0, Timentin 88040-23-7, Cefepime
91832-40-5, Cefdinir 94935-63-4, Ampicillin-sulbactam mixture
96036-03-2, Meropenem 100986-85-4, Levofloxacin 126602-89-9, Synercid
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neuraminidase inhibitors to prevent flu-associated bacterial infections, and use with antibiotics)

IT 1404-90-6, Vancomycin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neuraminidase inhibitors to prevent flu-associated bacterial infections, and use with antibiotics)

RN 1404-90-6 CAPLUS
CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Bu-i



L46 ANSWER 9 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:77550 CAPLUS Full-text
DOCUMENT NUMBER: 138:131149
TITLE: Treatment of neurological disease
INVENTOR(S): Hesson, David P.; Pelura, Timothy J.; Frazer, Glen D.
PATENT ASSIGNEE(S): Integra Lifesciences Corp., USA
SOURCE: U.S. Pat. Appl. Publ., 14 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003022879	A1	20030130	US 2002-90442	20020304 <--
US 6689756	B2	20040210		

PRIORITY APPLN. INFO.: US 2001-331359P P 20010302 <--

AB The invention discloses a method of treating an animal infection or neoplasm of cerebrospinal tissue characterized by a risk of death. The method comprises of : (a) injecting a physiol. acceptable fluid for cerebrospinal perfusion into a first catheter into the cerebrospinal pathway, which fluid for cerebrospinal perfusion has an therapeutically effective amount an agent, the agent selected for effectiveness against the infection as identified or diagnosed; (b) withdrawing fluid at a second catheter into the cerebrospinal pathway to create a flow and flow pathway between the first and second catheters; and (c) maintaining the flow for a period of time adapted to perfuse at least 1 CSF volume.

IC ICM A61K031-551
ICS A61K031-522; A61K031-43
INCL 514192000; 514220000; 514263360; 514263380
CC 1-11 (Pharmacology)
Section cross-reference(s): 63
IT Brain, disease
Human herpesvirus 3
Human immunodeficiency virus
Human immunodeficiency virus 1
(infection; treatment of neurol. disease)

IT 52-24-4, Thiotepa 54-42-2, Idoxuridine 54-85-3, Isoniazid 56-75-7, Chloramphenicol 58-14-0, Pyrimethamine 59-05-2, Methotrexate 60-54-8, Tetracycline 61-32-5, Methicillin 61-33-6, Penicillin G, biological studies 66-79-5, Oxacillin 68-35-9, Sulfadiazin 68-41-7, Cycloserine 69-53-4, Ampicillin 74-55-5, Ethambutol 98-96-4, Pyrazinamide 114-07-8, Erythromycin 147-52-4, Nafcillin 147-94-4, DepoCyte 148-79-8, Thiabendazole 443-48-1, Metronidazole 536-33-4 1397-89-3, Amphotericin B 1403-66-3, Gentamicin 1404-90-6, Vancomycin 1406-05-9, Penicillin 3116-76-5, Dicloxacillin 6998-60-3, Rifamycin 13292-46-1, Rifampin 26787-78-0, Amoxicillin 32986-56-4, Tobramycin 55268-74-1, Praziquantel 55268-75-2, Cefuroxime 58001-44-8 59277-89-3, Acyclovir 61477-96-1, Piperacillin 62893-19-0, Cefoperazone 68373-14-8, Sulbactam 72558-82-8, Ceftazidime 73384-59-5, Ceftriaxone 80738-43-8, Lincosamide 88859-04-5, Mafosfamide 89786-04-9, Tazobactam 123948-87-8, Topotecan 154598-52-4, Sustiva
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of neurol. disease)

IT 1404-90-6, Vancomycin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of neurol. disease)

RN 1404-90-6 CAPLUS

CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Bu-i

PAGE 2-A



L46 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:960674 CAPLUS Full-text
DOCUMENT NUMBER: 138:34097
TITLE: Nucleic acid sequence detection employing probes comprising non-nucleosidic coumarin derivatives as polynucleotide crosslinking agents
INVENTOR(S): Wood, Michael L.; Albagli, David; Van Atta, Reuel B.; Thien, Douglas Y.; Cheng, Peter C.; Huan, Bingfang
PATENT ASSIGNEE(S): Naxcor, USA
SOURCE: U.S., 24 pp., Cont.-in-part of U.S. 6,277,570.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6495676	B1	20021217	US 1999-390124	19990903 <--
US 5616464	A	19970401	US 1994-364339	19941227 <--
US 6005093	A	19991221	US 1995-401630	19950309 <--
US 5767259	A	19980616	US 1995-487034	19950607 <--
US 6004513	A	19991221	US 1995-577121	19951222 <--
US 6277570	B1	20010821	US 1998-149161	19980904 <--
US 2003124547	A1	20030703	US 2002-93626	20020308 <--
US 2003134274	A1	20030717	US 2002-272466	20021015 <--
US 6737239	B2	20040518		

PRIORITY APPLN. INFO.:

US 1993-46568	B2	19930413 <--
US 1994-364339	A2	19941227 <--
US 1995-401630	A2	19950309 <--
US 1995-487034	A2	19950607 <--
US 1995-577121	A2	19951222 <--
US 1998-149161	A2	19980904 <--
US 1999-390124	A2	19990903 <--

AB Methods and compns. are provided for detecting nucleic acid sequences. Probes comprising a crosslinking agent are combined with a sample which may comprise a target sequence which is complementary to the probe. Hybridization is allowed to occur between complementary sequences. The crosslinking agent is activated. Covalent bonds are formed between the probe and the target sequence if they are hybridized to one another. The crosslinked nucleic acids can then be detected to indicate the presence of the target sequence. Also provided are kits comprising reagents. The crosslinking moiety comprises a coumarin derivative linked to a (poly)hydroxy hydrocarbon backbone moiety other than ribose or deoxyribose, and is exemplified by the synthesis of 3-(7-coumarinylmethyl)glycerol and its incorporation at the 5'-terminus of probes.

IC ICM C07H021-00

INCL 536025300; 536025310; 536025370; 435006000

CC 3-1 (Biochemical Genetics)

IT Borrelia burgdorferi
Chlamydia
Cytomegalovirus
Dengue virus
Eastern equine encephalitis virus
Ebola virus
Haemophilus ducreyi
Helicobacter pylori
Hepatitis A virus
Hepatitis B virus
Hepatitis C virus
Hepatitis delta virus
Human T-lymphotropic virus 2
Human herpesvirus 4
Human immunodeficiency virus 1
Human immunodeficiency virus 2
Human papillomavirus
Lassa virus
Legionella
Listeria monocytogenes
Microorganism
Mycobacterium
Mycoplasma
Neisseria
Pneumocystis carinii
Respiratory syncytial virus
Salmonella
Treponema pallidum
Western equine encephalitis virus
(detection of target DNA in; nucleic acid sequence detection employing probes comprising non-nucleosidic coumarin derivs. as polynucleotide crosslinking agents)

IT 114-07-8, Erythromycin 1404-90-6, Vancomycin 13292-46-1, Rifampin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(detection of genes for resistance to; nucleic acid sequence detection employing probes comprising non-nucleosidic coumarin derivs. as polynucleotide crosslinking agents)

IT 1404-90-6, Vancomycin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(detection of genes for resistance to; nucleic acid sequence detection employing probes comprising non-nucleosidic coumarin derivs. as polynucleotide crosslinking agents)

RN 1404-90-6 CAPLUS

CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Bu-i

PAGE 2-A



REFERENCE COUNT: 80 THERE ARE 80 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 11 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:928122 CAPLUS Full-text
DOCUMENT NUMBER: 138:12504
TITLE: Method for assaying biomolecules and other constituents using indicator conjugates with synthetic nucleounits in lateral flow, liquid, and dry chemistry techniques
INVENTOR(S): Smith, Jack V.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 46 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002182600	A1	20021205	US 2001-829563	20010411 <--
PRIORITY APPLN. INFO.:			US 2001-829563	20010411 <--

AB The present invention is a method for the use of particles made up of nucleotides or fragments of base groups of DNA and RNA mols. herein referred to as synthetic nucleounits which can be used as recognition mols. with specificity and sensitivity significantly greater than that of antibodies which are used in clin. diagnostics, biotechnol., and research. The method for detecting an analyte using nucleounits targeted to the analyte comprises (1) identifying a nucleounit from a mixture of synthetic random sequences of nucleounit libraries, (2) conjugating the nucleounit to an indicator for the analyte, and (3) detecting the analyte using the nucleounit-indicator conjugate in a buffer. Step 1 is carried out by (a) contacting the analyte with the mixture of synthetic random sequences of nucleounit libraries such that some nucleounits bind the analyte, (b) removing the unbound nucleounits by partitioning, and (c) amplifying the remaining nucleounits by PCR to obtain an enriched solution of nucleounits with high affinity for the analyte. Thus, a method and lateral flow test strip for detection of cytomegalovirus (CMV) presence in a biol. sample such as serum or urine is described. The strip is prepared with three solns., one containing anti-CMV antibodies, one containing "nucleounit to CMV antibody conjugated to red microparticles" and "red microparticles", and another containing "nucleounit to colored particles". The "nucleounit" may be an oligonucleotide aptamer specific for anti-CMV antibodies.

IC ICM C12Q001-68
INCL 435006000
CC 9-16 (Biochemical Methods)
IT Angiogenesis
Blood
Blood analysis
Human herpesvirus 3
Human immunodeficiency virus
Leukocyte
Urine analysis
(method for assaying biomols. and other constituents using indicator conjugates with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)
IT 50-00-0, Formaldehyde, analysis 50-02-2, Dexamethasone 50-06-6, Phenobarbital, analysis 50-22-6, Corticosterone 50-23-7, Cortisol 50-27-1, Estriol 50-28-2, Estradiol, analysis 50-33-9, Phenylbutazone, analysis 50-47-5, Desipramine 50-48-6, Amitriptyline 50-49-7, Imipramine 50-52-2, Thioridazine 50-53-3, Chlorpromazine, analysis

50-56-6, Oxytocin, analysis 50-67-9, Serotonin, analysis 50-81-7, Ascorbic acid, analysis 50-99-7, Glucose, analysis 51-06-9, Procainamide 51-35-4, Hydroxyproline 51-48-9, Thyroxine, analysis 52-39-1, Aldosterone 52-90-4, Cysteine, analysis 53-02-1, Tetrahydrocortisol 53-16-7, Estrone, analysis 53-43-0, Dehydroepiandrosterone 54-16-0, 5-Hydroxyindoleacetic acid, analysis 54-36-4, Metyrapone 54-85-3, Isoniazid 55-10-7, Vanillylmandelic acid 56-40-6, Glycine, analysis 56-41-7, Alanine, analysis 56-54-2, Quinidine 56-73-5, Glucose-6-phosphate 56-75-7, Chloramphenicol 56-81-5, Glycerol, analysis 56-85-9, Glutamine, analysis 56-89-3, Cystine, analysis 57-00-1, Creatine 57-12-5, Cyanide, analysis 57-13-6, Urea, analysis 57-27-2, Morphine, analysis 57-41-0, Diphenylhydantoin 57-42-1, Meperidine 57-43-2, Amobarbital 57-48-7, Fructose, analysis 57-50-1, Sucrose, analysis 57-53-4, Meprobamate 57-83-0, Progesterone, analysis 57-88-5, Cholesterol, analysis 58-08-2, Caffeine, analysis 58-22-0, Testosterone 58-25-3, Chlordiazepoxide 58-55-9, Theophylline, analysis 58-86-6, Xylose, analysis 59-05-2, Methotrexate 59-23-4, Galactose, analysis 59-30-3, analysis 59-67-6, Niacin, analysis 60-18-4, Tyrosine, analysis 60-27-5, Creatinine 60-92-4, Cyclic AMP 61-90-5, Leucine, analysis 62-44-2, Phenacetin 63-05-8, Androstenedione 63-42-3, Lactose 63-68-3, Methionine, analysis 63-91-2, Phenylalanine, analysis 64-17-5, Ethanol, analysis 64-77-7, Tolbutamide 64-85-7, 11-Deoxycorticosterone 67-56-1, Methanol, analysis 68-60-0, Tetrahydrodeoxycortisol 68-96-2, 17-Hydroxyprogesterone 69-72-7D, Salicylic acid, derivs. 69-93-2, Uric acid, analysis 70-18-8, Glutathione, analysis 72-18-4, Valine, analysis 72-44-6, Methaqualone 72-69-5, Nortriptyline 73-32-5, Isoleucine, analysis 76-42-6, Oxycodone 76-57-3, Codeine 76-73-3, Secobarbital 76-74-4, Pentobarbital 76-75-5, Thiopental 76-99-3, Methadone 77-10-1, Phencyclidine 77-21-4, Glutethimide 77-41-8, Methsuximide 77-67-8, Ethosuximide 79-14-1, Glycolic acid, analysis 79-83-4, Pantothenic acid 80-92-2 81-25-4, Cholic acid 82-58-6, Lysergic acid 83-44-3, Deoxycholic acid 83-88-5, Riboflavin, analysis 86-34-0, Phensuximide 87-86-5, Pentachlorophenol 97-31-4, Normetanephrine 99-66-1, Valproic acid 103-90-2, Acetaminophen 107-21-1, Ethylene glycol, analysis 113-18-8, Ethchlorvynol 123-63-7, Paraldehyde 125-33-7, Primidone 125-64-4, Methyprylon 127-17-3, Pyruvic acid, analysis 137-58-6, Lidocaine 143-74-8, Phenolsulfonphthalein 145-13-1, Pregnenolone 152-58-9, 11-Deoxycortisol 298-46-4, Carbamazepine 299-42-3, Ephedrine 300-62-9, Amphetamine 302-04-5, Thiocyanate, analysis 302-17-0, Chloral hydrate 306-08-1, Homovanillic acid 359-83-1, Pentazocine 438-60-8, Protriptyline 439-14-5, Diazepam 451-13-8, Homogentisic acid 466-99-9, Hydromorphone 469-62-5, Propoxyphene 487-90-1, Porphobilinogen 521-18-6, Dihydrotestosterone 525-66-6, Propranolol 537-46-2, Methamphetamine 553-12-8, Protoporphyrin 555-30-6, Methyldopa 591-81-1, γ-Hydroxybutyric acid 604-75-1, Oxazepam 635-65-4, Bilirubin, analysis 651-48-9, Dehydroepiandrosterone sulfate 846-49-1, Lorazepam 1098-45-9, Pregnanetriol 1319-82-0, Aminocaproic acid 1330-20-7, Xylene, analysis 1393-25-5, Secretin 1403-66-3, Gentamicin 1404-90-6, Vancomycin 1622-61-3, Clonazepam 1668-19-5, Doxepin 3737-09-5, Disopyramide 4205-90-7, Clonidine 4429-04-3, Fructosamine 4685-14-7, Paraquat 4697-36-3, Carbenicillin 5001-33-2, Metanephrine 5817-39-0, Reverse triiodothyronine 6027-13-0, Homocysteine 6893-02-3, Triiodothyronine 7439-89-6, Iron, analysis 7439-92-1, Lead, analysis 7439-93-2, Lithium, analysis 7439-95-4, Magnesium, analysis 7439-97-6, Mercury, analysis 7439-98-7, Molybdenum, analysis 7440-02-0, Nickel, analysis 7440-28-0, Thallium, analysis 7440-47-3, Chromium, analysis 7440-57-5, Gold, analysis 7440-66-6, Zinc, analysis 7440-70-2, Calcium, analysis 7782-49-2,

Selenium, analysis 7783-06-4, Hydrogen sulfide, analysis 8063-07-8, Kanamycin 9000-86-6, Alanine aminotransferase 9000-92-4, Amylase 9000-94-6, Antithrombin 9001-08-5, Pseudocholinesterase 9001-10-9, Pepsinogen 9001-15-4, Creatine kinase 9001-58-5, Isocitrate dehydrogenase 9001-62-1, Lipase 9001-63-2, Lysozyme 9001-77-8, Acid phosphatase 9001-80-3, Phosphofructokinase 9001-91-6, Plasminogen 9002-60-2, Adrenocorticotropic hormone, analysis 9002-61-3, Chorionic gonadotropin 9002-64-6, Parathyroid hormone 9002-68-0, Follicle stimulating hormone 9002-71-5, Thyroid stimulating hormone 9002-72-6, Growth hormone 9002-76-0, Gastrin 9004-07-3, Chymotrypsin 9004-10-8, Insulin, analysis 9007-12-9, Calcitonin 9007-92-5, Glucagon, analysis 9014-48-6, Transketolase 9015-94-5, Renin, analysis 9024-52-6, Aldolase 9035-54-5, Placental lactogen 9035-68-1, Proinsulin 9035-81-8, Antitrypsin 11000-17-2, Antidiuretic hormone 11016-39-0, Properdin 12794-10-4D, Benzodiazepine, derivs. 14797-65-0, Nitrite, analysis 14838-15-4, Phenylpropanolamine 15687-27-1, Ibuprofen 17617-23-1, Flurazepam 20830-75-5, Digoxin 23887-31-2, Clorazepate 24305-27-9, Thyrotropin-releasing hormone 24959-67-9, Bromide, analysis 26316-36-9, Uroporphyrin 27121-71-7, Coproporphyrin 29679-58-1, Fenoprofen 32795-44-1, n-Acetylprocainamide 32986-56-4, Tobramycin 37221-79-7, Vasoactive intestinal polypeptide 37517-28-5, Amikacin 39335-01-8, Macroamylase 51481-61-9, Cimetidine 54143-55-4, Flecainide 56391-56-1, Netilmicin 59112-80-0, c-Peptide 59763-91-6, Pancreatic polypeptide 59865-13-3, Cyclosporine 67763-96-6, Somatomedin c 69776-17-6 85876-02-4, Glutamyltransferase 152923-57-4, Lutropin
RL: ANT (Analyte); ANST (Analytical study)
(method for assaying biomols. and other constituents using indicator conjugates with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)

IT 1404-90-6, Vancomycin
RL: ANT (Analyte); ANST (Analytical study)
(method for assaying biomols. and other constituents using indicator conjugates with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)

RN 1404-90-6 CAPLUS
CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Bu-i

PAGE 2-A



L46 ANSWER 12 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:717056 CAPLUS Full-text
DOCUMENT NUMBER: 137:226655
TITLE: Methods for treatment of neuro- and nephro- disorders and therapeutic toxicities using aminothiol compounds
INVENTOR(S): Stogniew, Martin; Alberts, David S.; Kaplan, Edward H.
PATENT ASSIGNEE(S): U.S. Bioscience, Inc., USA; Medimmune Oncology Inc.
SOURCE: U.S. Pat. Appl. Publ., 15 pp., Division of Ser. No. US 1999-429290, filed on 28 Oct 1999
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002132795	A1	20020919	US 2002-137686	20020503 <--
US 7105575	B2	20060912		
US 5994409	A	19991130	US 1997-987550	19971209 <--
EP 1537861	A2	20050608	EP 2005-3650	19981209 <--
EP 1537861	A3	20050615		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY

US 6586476	B1	20030701	US 1999-429290		19991028 <--
US 2006040903	A1	20060223	US 2005-258335		20051025 <--
JP 2006188532	A	20060720	JP 2006-64774		20060309 <--
US 2006270636	A1	20061130	US 2006-501949		20060809 <--
PRIORITY APPLN. INFO.:			US 1997-987550	A3	19971209 <--
			US 1999-429290	A3	19991028 <--
			EP 1998-962011	A3	19981209 <--
			JP 2000-523983	A3	19981209 <--
			US 2002-137686	A1	20020503 <--

OTHER SOURCE(S): MARPAT 137:226655

AB The present invention relates to new uses of S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate (amifostine) and other aminothiol compds. to treat and reverse toxicities caused by therapeutic agents, radiation treatment or diabetes. In particular, the invention provides a method for treating neurotoxicity and nephrotoxicity associated with the administration of chemotherapeutic agents. Cancer patients with neurotoxicities from chemotherapy treatment were treated with amifostine.

IC ICM A61K031-66
ICS A61K031-135; A61K031-16; A61K031-13

INCL 514114000; X51-466.5; X51-464.6; X51-462.5

CC 1-12 (Pharmacology)
Section cross-reference(s): 4

IT Anti-AIDS agents
Antibiotics
Antihypertensives
Antitumor agents
Antiviral agents
Chemotherapy
Diabetes mellitus
Drugs
Fungicides
Radiotherapy
(toxicity from; treatment of neuro- and nephro- disorders and therapeutic toxicities using aminothiol compds.)

IT AIDS (disease)
Hypertension
Neoplasm
(toxicity in treatment of; treatment of neuro- and nephro- disorders and therapeutic toxicities using aminothiol compds.)

IT 57-22-7, Vincristine 865-21-4, Vinblastine 1397-89-3, Amphotericin B 1403-66-3, Gentamicin 1404-90-6, Vancomycin 3056-17-5, Stavudine 7481-89-2, Zalcitabine 8063-07-8, Kanamycin 15663-27-1, Cisplatin 20830-81-3, Daunorubicin 23214-92-8, Doxorubicin 30516-87-1, 3'-Azido-3'-deoxythymidine 32986-56-4, Tobramicin 33069-62-4, Paclitaxel 33419-42-0, Etoposide 37517-28-5, Amikacin 41575-94-4, Carboplatin 69655-05-6, Didanosine 95058-81-4, Gemcitabine 114977-28-5, Docetaxel 125317-39-7, Navelbine 134678-17-4, Lamivudine
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(toxicity from; treatment of neuro- and nephro- disorders and therapeutic toxicities using aminothiol compds.)

IT 1404-90-6, Vancomycin
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(toxicity from; treatment of neuro- and nephro- disorders and therapeutic toxicities using aminothiol compds.)

RN 1404-90-6 CAPLUS
CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Bu-i

PAGE 2-A



REFERENCE COUNT: 74 THERE ARE 74 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:695717 CAPLUS Full-text
DOCUMENT NUMBER: 137:210971
TITLE: Treatment of neurological disease with therapeutic agent-containing cerebrospinal perfusion fluid
INVENTOR(S): Hesson, David P.; Pelura, Timothy J.; Frazer, Glenn D.
PATENT ASSIGNEE(S): Neuron Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002069893	A2	20020912	WO 2002-US6108	20020228 <--
WO 2002069893	A3	20050519		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002242293	A1	20020919	AU 2002-242293	20020228 <--
PRIORITY APPLN. INFO.:			US 2001-798774 A	20010302 <--
			WO 2002-US6108 W	20020228 <--

AB Provided is, among other things, a method of treating in an animal infection or neoplasm of cerebrospinal tissue characterized by a risk of death, the method comprising: (a) injecting a physiol. acceptable fluid for cerebrospinal perfusion into a first catheter into the cerebrospinal pathway, which fluid for cerebrospinal perfusion has a therapeutically effective amount of an agent, the agent selected for effectiveness against the infection as identified or diagnosed; (b) withdrawing fluid at a second catheter into the cerebrospinal pathway to create a flow and flow pathway between the first and second catheters; and (c) maintaining the flow for a period of time adapted to perfuse at least 1 CSF volume

IC ICM A61K
CC 1-11 (Pharmacology)
Section cross-reference(s): 63
IT Human immunodeficiency virus
Nervous system, disease
(infection; treatment of neurol. disease with therapeutic agent-containing cerebrospinal perfusion fluid)
IT Alkylating agents, biological
Animals
Anthelmintics
Anti-AIDS agents
Anti-infective agents
Antibacterial agents
Antimicrobial agents
Antitumor agents
Antiviral agents
Endotoxemia
Eubacteria
Flow
Fungi

Fungicides
Leukemia
Mycoplasma pneumoniae
Nervous system, disease
Nervous system, neoplasm
Neuroglia, neoplasm
Protozoacides
Tuberculostatics
Virus
(treatment of neurol. disease with therapeutic agent-containing cerebrospinal perfusion fluid)

IT 52-24-4, Thiotepa 54-42-2, Idoxuridine 54-85-3, Isoniazid 56-75-7, Chloramphenicol 58-14-0, Pyrimethamine 59-05-2, Methotrexate 60-54-8, Tetracycline 61-32-5, Methicillin 61-33-6, Penicillin G, biological studies 66-79-5, Oxacillin 68-35-9, Sulfadiazine 68-41-7, Cycloserine 69-53-4, Ampicillin 74-55-5, Ethambutol 98-96-4, Pyrazinamide 114-07-8, Erythromycin 147-52-4, Nafcillin 147-94-4, Cytarabine 443-48-1, Metronidazole 536-33-4, Ethionamide 1397-89-3, Amphotericin B 1403-66-3, Gentamicin 1404-90-6, Vancomycin 1406-05-9D, Penicillin, compds. 3116-76-5, Dicloxacillin 6998-60-3, Rifamycin 13292-46-1, Rifampin 26787-78-0, Amoxicillin 32986-56-4, Tobramycin 55268-74-1, Praziquantel 55268-75-2, Cefuroxime 59277-89-3, Acyclovir 61477-96-1, Piperacillin 62893-19-0, Cefoperazone 72558-82-8, Ceftazidime 73384-59-5, Ceftriaxone 79198-29-1 88859-04-5, Mafosfamide 94935-63-4, Ampicillin/sulbactam 123683-33-0 123948-87-8, Topotecan 154598-52-4, Efavirenz
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of neurol. disease with therapeutic agent-containing cerebrospinal perfusion fluid)

IT 1404-90-6, Vancomycin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of neurol. disease with therapeutic agent-containing cerebrospinal perfusion fluid)

RN 1404-90-6 CAPLUS
CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Bu-i

PAGE 2-A



L46 ANSWER 14 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:71906 CAPLUS Full-text
DOCUMENT NUMBER: 136:123678
TITLE: Enhancement of the action of anti-infective agents using an administration medium containing nitrous oxide
INVENTOR(S): Meyer, Petrus Johannes
PATENT ASSIGNEE(S): Pitmy International N.V., Neth. Antilles
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002005850	A2	20020124	WO 2001-ZA98	20010719 <--
WO 2002005850	A3	20030109		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,

RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2416512	A1	20020124	CA 2001-2416512	20010719 <--
ZA 2003000366	A	20040629	ZA 2003-366	20030114 <--
PRIORITY APPLN. INFO.:			ZA 2000-3644 A	20000719 <--
			WO 2001-ZA98 W	20010719 <--

AB The invention provides a method of enhancing the action of anti-infective agents, i.e., antimicrobial agents, anthelmintics, and anti-ectoparasitic agents, but excluding coal tar solution and H1-antagonist antihistamines, characterized in that the agent is formulated with an administration medium which comprises a solution of nitrous oxide gas in a pharmaceutically acceptable carrier solvent for the gas. The administration medium includes at least one fatty acid or ester or other suitable derivative thereof selected from the group consisting of oleic acid, linoleic acid, α-linolenic acid, γ-linolenic acid, arachidonic acid, eicosapentaenoic acid [C20: 5ω3], docosahexaenoic acid [C22: 6ω3], ricinoleic acid and derivs. thereof selected from the group consisting of the C1-6 alkyl esters, the glycerol-polyethylene glycol esters and the reaction product of hydrogenated natural oils composed largely of ricinoleic acid-based oils, such as castor oil with ethylene oxide. For example, an aqueous emulsion was prepared by mixing 30 g vitamin F Et ester with 10 g Cremophor RH40, 2.2 g Me paraben, 0.08 g Bu hydroxyanisole, and 0.23 g Bu hydroxytoluene. Into 942.5 g of the stock nitrous oxide aqueous solution, 2.5 g sodium Pr paraben and 2.5 g Germall 115 were added with stirring at room temperature The oily composition was then emulsified into the aqueous solution to obtain a nanolipid vesicle formulation. A non-aqueous solution of nitrous oxide in carrier formulation was also prepared Polyoxyl hydrogenated castor oil (1.15 kg) was mixed with 2.35 kg vitamin F Et ester, 150.0 g α-tocopherol, and 1.295 kg PEG 400 at 40°. The oily mixture was gassed with nitrous oxide for 3 h at 2 bar and then heated at 70°. To the heated gas-oil mixture, 50.0 g Me paraben and 5.0 g butylated hydroxytoluene were added and the mixture was allowed to cool down. When the mixture was cooled down to approx. 40°, 5.00 kg pyrazinamide (particle size <40 μm) was added while continuously mixing and the mixture was addnl. gassed with nitrous oxide at 20 kPa for 30 min. After the mixture was cooled down to reach room temperature, it was encapsulated in soft gel capsules. Encapsulation of pyrazinamide in lipid vesicles led to a 65-70% decrease in BCG (bacillus Calmette-Guerin) viability within a 2-h incubation with no moving BCG observed, while the incubation with free pyrazinamide resulted in the appearance of single live bacteria with a few granuloma-type clumps, which gradually secreted single live bacteria.

IC ICM A61K047-00

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1, 10, 15

IT Anthelmintics
Anti-AIDS agents
Anti-infective agents
Antibacterial agents
Antibacterial agents
Antibiotics
Antimalarials
Antimicrobial agents
Antiviral agents
Drug bioavailability
Encapsulation
Fungicides
Parasiticides

Tuberculostatics
(lipid vehicles containing nitrous oxide for enhancement of activity of anti-infective agents)

IT 50-59-9, Cephaloridine 54-42-2, Idoxuridine 54-85-3 56-75-7, Chloramphenicol 57-62-5, Chlortetracycline 57-67-0, Sulfaguanidine 57-68-1, Sulfadimidine 57-92-1, Streptomycin, biological studies 60-54-8, Tetracycline 61-32-5, Methicillin 61-33-6, Penicillin G, biological studies 61-72-3, Cloxacillin 64-75-5, Tetracycline Hydrochloride 65-85-0, Benzoic Acid, biological studies 66-79-5, Oxacillin 67-20-9, Nitrofurantoin 68-35-9, Sulfadiazine 68-41-7, Cycloserine 69-53-4, Ampicillin 69-72-7, Salicylic acid, biological studies 70-00-8, Trifluridine 74-55-5, Ethambutol 79-09-4, Propionic Acid, biological studies 79-57-2, Oxytetracycline 80-08-0, Dapsone 80-35-3, Sulfamethoxypyridazine 85-73-4, Phthalylsulfathiazole 87-08-1, Penicillin V 98-96-4, Pyrazinamide 98-97-5, Pyrazinoic acid 100-97-0, Methenamin, biological studies 112-38-9, Undecylenic Acid 114-07-8, Erythromycin 116-43-8, Succinylsulfathiazole 122-11-2, Sulfadimethoxine 124-07-2, Caprylic Acid, biological studies 126-07-8, Griseofulvin 127-33-3, Demeclocycline 127-56-0, Sulfacetamide sodium 127-69-5, Sulfafurazole 144-80-9, Sulfacetamide 144-83-2, Sulfapyridine 147-52-4, Nafcillin 152-47-6, Sulfametopyrazine 288-32-4D, Imidazole, derivs. 389-08-2, Nalidixic Acid 536-33-4, Ethionamide 564-25-0, Doxycycline 599-79-1, Sulfasalazine 651-06-9, Sulfamethoxydiazine 723-46-6, Sulfamethoxazole 768-94-5, Amantadine 777-11-7, Haloprogin 914-00-1, Methacycline 1066-17-7, Colistin 1397-89-3, Amphotericin B 1400-61-9, Nystatin 1403-66-3, Gentamicin 1404-04-2, Neomycin 1404-26-8, Polymyxin B 1404-90-6, Vancomycin 1405-20-5, Polymyxin B Sulfate 1405-41-0, Gentamicin Sulfate 1405-87-4, Bacitracin 1405-89-6, Bacitracin Zinc 1695-77-8, Spectinomycin 2022-85-7, Flucytosine 2030-63-9, Clofazimine 2398-96-1, Tolnaftate 2447-57-6, Sulfadoxine 3056-17-5, Stavudine 3116-76-5, Dicloxacillin 3511-16-8, Hetacillin 4299-60-9, Sulfisoxazole diolamine 4428-95-9, Foscarnet 4697-36-3, Carbenicillin 5250-39-5, Flucloxacillin 5536-17-4, Vidarabine 6489-97-0, Metampicillin 7481-89-2, Zalcitabine 7681-11-0, Potassium Iodide, biological studies 7681-93-8, Natamycin 8063-07-8, Kanamycin 8064-90-2, Co-Trimoxazole 10118-90-8, Minocycline 11003-38-6, Capreomycin 13009-99-9, Mafenide Acetate 13292-46-1, Rifampicin 13392-28-4, Rimantadine 13721-01-2D, derivs. 13838-08-9, Azidamphenicol 14698-29-4, Oxolinic Acid 15318-45-3, Thiamphenicol 15686-71-2, Cefalexin 18323-44-9, Clindamycin 19562-30-2, Piromidic Acid 20461-54-5, Iodide, biological studies 22199-08-2, Silver sulfadiazine 22832-87-7, Miconazole nitrate 22916-47-8, Miconazole 23593-75-1, Clotrimazole 25953-19-9, Cephazolin 26787-78-0, Amoxicillin 27025-49-6, Carfecillin 27220-47-9, Econazole 27726-31-4, Pivcephalexin 28088-64-4, Aminosalicylic acid 28657-80-9, Cinoxacin 29342-05-0, Ciclopirox 30516-87-1, Zidovudine 32886-97-8, Pivmecillinam 32986-56-4, Tobramycin 33817-20-8, Pivampicillin 34444-01-4, Cephamandole 34787-01-4, Ticarcillin 35531-88-5, Carindacillin 35607-66-0, Cefoxitin 36791-04-5, Ribavirin 37091-66-0, Azlocillin 37517-28-5, Amicacin 38821-53-3, Cephradine 39809-25-1, Penciclovir 40034-42-2, Acrosoxacin 41621-49-2, Ciclopirox olamine 47747-56-8, Talampicillin 49842-07-1, Tobramycin sulfate 50370-12-2, Cefadroxil 50972-17-3, Bacampicillin 51481-65-3, Mezlocillin 51627-14-6, Cefatrizine 51940-44-4, Pipemidic Acid 53994-73-3, Cefaclor 55268-75-2, Cefuroxim 56391-56-1, Netilmicin 58001-44-8, Clavulanic Acid 59277-89-3, Acyclovir 60925-61-3, Ceforanide 61036-62-2, Teicoplanin 61270-58-4, Cefonicid 61318-90-9, Sulconazole 61477-96-1, Piperacillin 61622-34-2, Cefotiam 62587-73-9, Cefsulodin 62893-19-0, Cefoperazone 63469-19-2, Apalcillin

63527-52-6, Cefotaxime 63744-80-9, Cephamycin 64211-45-6, Oxiconazole 64221-86-9, Imipenem 64544-07-6, Cefuroxime axetil 64872-76-0, Butoconazole 64952-97-2, Latamoxef 65085-01-0, Cefmenoxime 65243-33-6, Cefetamet Pivoxil 65277-42-1, Ketoconazole 65472-88-0, Naftifine 65899-73-2, Tioconazole 66148-78-5, Temocillin 67915-31-5, Terconazole 68373-14-8, Sulbactam 68401-81-0, Ceftizoxime 69655-05-6, Didanosine 69712-56-7, Cefotetan 69739-16-8, Cefodizime 70458-92-3, Pefloxacin 70458-96-7, Norfloxacin 70797-11-4, Cefpiramide 72558-82-8, Ceftazidime 72559-06-9, Rifabutin 73384-59-5, Ceftriaxone 74011-58-8, Enoxacin 76168-82-6, Ramoplanin 76470-66-1, Loracarbef 77181-69-2, Sorivudine 78110-38-0, Aztreonam 79350-37-1, Cefixime 79660-72-3, Fleroxacin 80214-83-1, Roxithromycin 81103-11-9, Clarithromycin 82410-32-0, Ganciclovir 82419-36-1, Ofloxacin 83905-01-5, Azithromycin 84625-61-6, Itraconazole 85721-33-1, Ciprofloxacin 86386-73-4, Fluconazole 86393-37-5, Amifloxacin 88040-23-7, Cefepime 89786-04-9, Tazobactam 91161-71-6, Terbinafine 91832-40-5, Cefdinir 92665-29-7, Cefprozil 93106-60-6, Enrofloxacin 96036-03-2, Meropenem 97519-39-6, Ceftibuten 98079-51-7, Lomefloxacin 100490-36-6, Tosufloxacin 100986-85-4, Levofloxacin 101363-10-4, Rufloxacin 104227-87-4, Famciclovir 110871-86-8, Sparfloxacin 124832-26-4, Valacyclovir 124858-35-1, Nadifloxacin 126602-89-9, RP 59500 134678-17-4, Lamivudine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lipid vehicles containing nitrous oxide for enhancement of activity of anti-infective agents)

IT 1404-90-6, Vancomycin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lipid vehicles containing nitrous oxide for enhancement of activity of anti-infective agents)

RN 1404-90-6 CAPLUS

CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Bu-i

PAGE 2-A



L46 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:10505 CAPLUS Full-text
DOCUMENT NUMBER: 136:79729
TITLE: Antimicrobial peptides and methods of use thereof
INVENTOR(S): Hancock, Robert E. W.; Zhang, Lijuan
PATENT ASSIGNEE(S): The University of British Columbia, Can.
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000687	A2	20020103	WO 2001-CA918	20010627 <--
WO 2002000687	A3	20020906		
WO 2002000687	A9	20030918		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,

IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6337317	B1	20020108	US 2000-604864	20000627 <--
CA 2412531	A1	20020103	CA 2001-2412531	20010627 <--
EP 1294745	A2	20030326	EP 2001-944839	20010627 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004507228	T	20040311	JP 2002-505809	20010627 <--
NZ 523183	A	20041224	NZ 2001-523183	20010627 <--
US 2002156017	A1	20021024	US 2002-42872	20020108 <--
US 6747007	B2	20040608		

PRIORITY APPLN. INFO.: US 2000-604864 A 20000627 <--
WO 2001-CA918 W 20010627 <--

OTHER SOURCE(S): MARPAT 136:79729

AB A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO:3), RRWCFRVCYKGFCRYKCR (SEQ ID NO:4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO:11) (I). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject. I provided protection against endotoxemia in mice.

IC ICM C07K007-00
CC 1-5 (Pharmacology)

IT Antibacterial agents
Antiviral agents
Candida albicans
Circular dichroism
Enterococcus faecalis
Escherichia coli
Fungicides
Gram-negative bacteria
Gram-positive bacteria
Hepatitis B virus
Hepatitis C virus
Herpesviridae
Human
Human herpesvirus
Human immunodeficiency virus 1
Influenza A virus
Pseudomonas aeruginosa
Salmonella minnesota
Salmonella typhimurium
Staphylococcus aureus
Staphylococcus epidermidis
Vesicular stomatitis virus
(antimicrobial peptides and methods of use thereof)

IT 56-75-7, Chloramphenicol 57-92-1, Streptomycin, biological studies 60-54-8, Tetracycline 61-32-5, Methicillin 61-33-6, Penicillin G, biological studies 61-72-3, Cloxacillin 66-79-5, Oxacillin 67-20-9, Nitrofurantoin 69-53-4, Ampicillin 87-08-1, Penicillin V 114-07-8, Erythromycin 147-52-4, Nafcillin 153-61-7, Cephalothin 389-08-2, Nalidixic acid 564-25-0, Doxycycline 643-22-1, Erythromycin stearate 723-46-6, Sulfamethoxazole 738-70-5, Trimethoprim 1264-62-6, Erythromycin ethylsuccinate 1403-66-3, Gentamicin 1404-90-6, Vancomycin 1406-05-9D, Penicillin, compds. 3116-76-5, Dicloxacillin 3521-62-8, Erythromycin estolate 3847-29-8, Erythromycin lactobionate 4697-36-3, Carbenicillin 8063-07-8, Kanamycin 9001-63-2, Lysozyme 10118-90-8, Minocycline 11111-12-9D, Cephalosporin, compds. 12650-69-0, Mupirocin 13292-46-1, Rifampin 18323-44-9, Clindamycin 23067-13-2, Erythromycin gluceptate 25953-19-9, Cefazolin 26787-78-0,

Amoxicillin 28657-80-9, Cinoxacin 32986-56-4, Tobramycin 34444-01-4, Cefamandole 34787-01-4, Ticarcillin 35607-66-0, Cefoxitin 37091-66-0, Azlocillin 37517-28-5, Amikacin 51481-65-3, Mezlocillin 53994-73-3, Cefaclor 55268-75-2, Cefuroxime 56391-56-1, Netilmicin 56796-20-4, Cefmetazole 61036-62-2, Teicoplanin 61270-58-4, Cefonicid 61477-96-1, Piperacillin 62587-73-9, Cefsulodin 62893-19-0, Cefoperazone 63527-52-6, Cefotaxime 64221-86-9, Imipenem 65052-63-3, Cefetamet 68401-81-0, Ceftizoxime 69712-56-7, Cefotetan 70458-96-7, Norfloxacin 72558-82-8, Ceftazidime 73384-59-5, Ceftriaxone 74011-58-8, Enoxacin 76470-66-1, Loracarbef 78110-38-0, Aztreonam 79350-37-1, Cefixime 79660-72-3, Fleroxacin 80210-62-4, Cefpodoxime 81103-11-9, Clarithromycin 82419-36-1, Ofloxacin 83200-96-8D, Carbapenem, compds. 83905-01-5, Azithromycin 85721-33-1, Ciprofloxacin 88040-23-7, Cefepime 92665-29-7, Cefprozil 98079-51-7, Lomefloxacin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptide in combination with; antimicrobial peptides and methods of use thereof)

IT 1404-90-6, Vancomycin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptide in combination with; antimicrobial peptides and methods of use thereof)

RN 1404-90-6 CAPLUS

CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Bu-i

PAGE 2-A



L46 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:635933 CAPLUS Full-text
DOCUMENT NUMBER: 135:215973
TITLE: Use of peptide conjugates for enhancing drug delivery across biological membranes and tissues
INVENTOR(S): Rothbard, Jonathan B.; Wender, Paul A.
PATENT ASSIGNEE(S): Cellgate, Inc., USA
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001062297	A1	20010830	WO 2001-US4459	20010209 <--
WO 2001062297	A9	20030109		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002009491	A1	20020124	US 2001-779693	20010207 <--
CA 2400099	A1	20010830	CA 2001-2400099	20010209 <--
EP 1263469	A1	20021211	EP 2001-909135	20010209 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003523982	T	20030812	JP 2001-561360	20010209 <--
MX 2002PA07820	A	20021023	MX 2002-PA7820	20020813 <--
PRIORITY APPLN. INFO.:			US 2000-182166P P	20000214 <--
			US 2001-779693 A	20010207 <--
			WO 2001-US4459 W	20010209 <--

AB This invention provides compns. and methods for enhancing delivery of drugs and other agents across a biol. barrier, including epithelial tissues such as the skin, gastrointestinal tract, pulmonary epithelium, and the like. The compns. and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compns. and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound across one or more layers of the tissue, compared to the non-conjugated compound The delivery-enhancing polymers include, for example, poly-arginine mols. that are preferably between about 6 and 50 residues in length. Taxol conjugates with a heptamer of arginine was soluble in water in contrast with taxol itself. The conjugate was equally potent when assayed for biol. activity using standard cytotoxicity assay.

IC ICM A61K047-42
ICS A61K047-48

CC 63-5 (Pharmaceuticals)
Section cross-reference(s): 1

IT AIDS (disease)
Alzheimer's disease
Analgesics
Antibacterial agents
Antiviral agents
Asthma
Biological transport
Blood-brain barrier
Cystic fibrosis
Epilepsy
Epithelium
Fungicides
Helicobacter pylori
Immunosuppressants
Infection
Ischemia
Membrane, biological
Multiple sclerosis
Neoplasm
Pain
Parkinson's disease
Permeation enhancers
Schizophrenia
Skin
(use of peptide conjugates for enhancing drug delivery across biol. membranes and tissues)

IT 50-18-0, Cyclophosphamide 50-36-2, Cocaine 50-44-2, 6-Mercaptopurine 50-76-0, Dactinomycin 51-05-8, Novocaine 51-21-8, 5-Fluorouracil 54-42-2, Idoxuridine 55-86-7, Mechlorethamine hydrochloride 59-05-2, Methotrexate 59-46-1, Procaine 60-54-8, Tetracycline 64-86-8, Colchicine 65-45-2, Salicylamide 66-79-5, Oxacillin 69-53-4, Ampicillin 70-00-8, Trifluridine 80-08-0, Dapsone 94-09-7, Benzocaine 94-24-6, Tetracaine 96-88-8, Mepivacaine 100-33-4, Pentamidine 114-07-8, Erythromycin 126-07-8, Griseofulvin 127-07-1, Hydroxyurea 137-58-6, Lidocaine 147-52-4, Nafcillin 147-94-4, Cytarabine 154-42-7, 6-Thioguanine 154-93-8, Carmustine 446-86-6, Azathioprine 499-67-2, Proparacaine 599-79-1, Sulfasalazine 671-16-9, Procarbazine 721-50-6, Prilocaine 865-21-4, Vinblastine 1400-61-9, Nystatin 1403-66-3, Gentamycin 1404-00-8, Mitomycin 1404-90-6, Vancomycin 1406-05-9, Penicillin 3056-17-5, Stavudine 4342-03-4, Dacarbazine 4428-95-9, Foscarnet 7481-89-2, Zalcitabine 9004-10-8, Insulin, biological studies 9007-12-9, Calcitonin 10118-90-8, Minocycline 11000-17-2, Vasopressin

11056-06-7, Bleomycin 11111-12-9, Cephalosporin 12633-72-6, Amphotericin 13292-46-1, Rifampin 13392-28-4, Rimantadine 15663-27-1, Cisplatin 16110-51-3, Cromolyn 20830-81-3, Daunorubicin 21679-14-1, Fludarabine 22916-47-8, Miconazole 23214-92-8, Doxorubicin 23593-75-1, Clotrimazole 26787-78-0, Amoxycillin 27220-47-9, Econazole 29342-05-0, Ciclopirox 29767-20-2, Teniposide 30516-87-1, Zidovudine 33419-42-0, Etoposide 36637-18-0, Etidocaine 36791-04-5, Ribavirin 38396-39-3, Bupivacaine 53910-25-1, Pentostatin 58822-25-6, Leucine enkephalin 59277-89-3, Acyclovir 63527-52-6, Cefotaxime 65271-80-9, Mitoxantrone 65277-42-1, Ketoconazole 65472-88-0, Naftifine 69049-73-6, Nedocromil 69655-05-6, Didanosine 73384-59-5, Ceftriaxone 77181-69-2, Sorivudine 79217-60-0, Cyclosporin 82410-32-0, Ganciclovir 84057-95-4, Ropivacaine 84625-61-6, Itraconazole 85721-33-1, Ciprofloxacin 86386-73-4, Fluconazole 91161-71-6, Terbinafine 104227-87-4, Famciclovir 104987-11-3, Tacrolimus 113852-37-2, Cidofovir 124832-26-4, Valacyclovir 357417-87-9

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of peptide conjugates for enhancing drug delivery across biol. membranes and tissues)

IT 1404-90-6, Vancomycin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of peptide conjugates for enhancing drug delivery across biol. membranes and tissues)

RN 1404-90-6 CAPLUS

CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Bu-i

PAGE 2-A



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:614284 CAPLUS Full-text
DOCUMENT NUMBER: 135:191244
TITLE: Nucleic acid sequence detection employing probes comprising non-nucleosidic coumarin derivatives as polynucleotide-crosslinking agents
INVENTOR(S): Wood, Michael L.; Albagli, David; Van Atta, Reuel B.; Cheng, Peter C.; Huan, Bingfang; Thien, Douglas Y.
PATENT ASSIGNEE(S): Naxcor, USA
SOURCE: U.S., 24 pp., Cont.-in-part of U.S. 6,005,093.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6277570	B1	20010821	US 1998-149161	19980904 <--
US 5616464	A	19970401	US 1994-364339	19941227 <--
US 6005093	A	19991221	US 1995-401630	19950309 <--
US 5767259	A	19980616	US 1995-487034	19950607 <--
US 6004513	A	19991221	US 1995-577121	19951222 <--
US 6495676	B1	20021217	US 1999-390124	19990903 <--
US 2003124547	A1	20030703	US 2002-93626	20020308 <--
US 2003134274	A1	20030717	US 2002-272466	20021015 <--
US 6737239	B2	20040518		

PRIORITY APPLN. INFO.:

US 1993-46568	B2	19930413 <--
US 1994-364339	A2	19941227 <--
US 1995-401630	A2	19950309 <--
US 1995-487034	A2	19950607 <--
US 1995-577121	A2	19951222 <--
US 1998-149161	A2	19980904 <--

US 1999-390124 A2 19990903 <--

AB Methods and compns. are provided for detecting nucleic acid sequences. Probes comprising a crosslinking agent are combined with a sample which may comprise a target sequence which is complementary to the probe. Hybridization is allowed to occur between complementary sequences. The crosslinking agent is activated. Covalent bonds are formed between the probe and the target sequence if they are hybridized to one another. The crosslinked nucleic acids can then be detected to indicate the presence of the target sequence. Also provided are kits comprising reagents.

IC ICM C12Q001-68
ICS C07H021-00

INCL 435006000

CC 3-1 (Biochemical Genetics)

IT Antibiotic resistance
Blood
Borrelia burgdorferi
Crosslinking agents
Cytomegalovirus
Dengue virus
Eastern equine encephalitis virus
Ebola virus
Enterobacteriaceae
Fluorescent substances
Haemophilus ducreyi
Helicobacter pylori
Human T-lymphotropic virus 2
Human herpesvirus 4
Human immunodeficiency virus 1
Human immunodeficiency virus 2
Human papillomavirus
Labels
Lassa virus
Microorganism
Neisseria gonorrhoeae
Nucleic acid hybridization
Pneumocystis carinii
Radioactive substances
Respiratory syncytial virus
Salmonella
Test kits
Treponema pallidum
Western equine encephalitis virus
(nucleic acid sequence detection employing probes comprising non-nucleosidic coumarin derivs. as polynucleotide-crosslinking agents)

IT 114-07-8, Erythromycin 1404-90-6, Vancomycin 13292-46-1, Rifampin
RL: BSU (Biological study, unclassified); BIOL (Biological study) (resistance gene; nucleic acid sequence detection employing probes comprising non-nucleosidic coumarin derivs. as polynucleotide-crosslinking agents)

IT 1404-90-6, Vancomycin
RL: BSU (Biological study, unclassified); BIOL (Biological study) (resistance gene; nucleic acid sequence detection employing probes comprising non-nucleosidic coumarin derivs. as polynucleotide-crosslinking agents)

RN 1404-90-6 CAPLUS
CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Bu-i

PAGE 2-A



REFERENCE COUNT: 79 THERE ARE 79 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 18 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:525934 CAPLUS Full-text
DOCUMENT NUMBER: 135:97511
TITLE: Reduction in bacterial colonization by administering bacteriophage compositions
INVENTOR(S): Morris, J. Glenn; Alavidze, Zemphira; Sulakvelidze, Alexander; Pasternack, Gary R.; Brown, Torrey C.
PATENT ASSIGNEE(S): Intralytix, Inc., USA
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001051066	A2	20010719	WO 2001-US809	20010111 <--
WO 2001051066	A3	20020110		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2430498	A1	20010719	CA 2001-2430498	20010111 <--
US 2002015720	A1	20020207	US 2001-757704	20010111 <--
US 6703040	B2	20040309		
EP 1250143	A2	20021023	EP 2001-922226	20010111 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004029250	A1	20040212	US 2001-757687	20010111 <--
US 6699701	B2	20040302		
EP 1421855	A2	20040526	EP 2003-79196	20010111 <--
EP 1421855	A3	20040714		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
US 2005175991	A1	20050811	US 2003-655217	20030905 <--
US 2004247569	A1	20041209	US 2003-724900	20031202 <--
US 2004191224	A1	20040930	US 2003-733064	20031211 <--
US 2004208853	A1	20041021	US 2003-732954	20031211 <--
US 2005244383	A1	20051103	US 2005-173082	20050701 <--
AU 2006245214	A1	20061221	AU 2006-245214	20061128 <--

PRIORITY APPLN. INFO.:

US 2000-175377P	P	20000111 <--
US 2000-175415P	P	20000111 <--
US 2000-175416P	P	20000111 <--
US 2000-205240P	P	20000519 <--
AU 2001-230889	A	20010111 <--
AU 2001-30889	A3	20010111 <--
EP 2001-903016	A3	20010111 <--
US 2001-757685	B1	20010111 <--
US 2001-757686	B1	20010111 <--
US 2001-757687	A3	20010111 <--
WO 2001-US809	W	20010111 <--
US 2003-733064	A1	20031211

AB The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or

more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacterial subject to infection by said bacteriophage. For example, vancomycin-resistant Enterococcus (VRE) phage were isolated from raw sewage. A broth culture which produced the maximum yield of bacteriophage was grown in a petri dish, the top layer with the phage was scraped, mixed with a broth to obtain a suspension and the bacteriophage were isolated and purified by ion exchange chromatog. A mouse model was used to demonstrate efficacy of lytic bacteriophage in reducing VRE gastrointestinal colonization. The colonization was reduced by at least 3 logs.

IC ICM A61K035-00
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1, 62
IT AIDS (disease)
Antibacterial agents
Antiulcer agents
Bactericide resistance
Bacteriophage
Carcinoma
Cystic fibrosis
Dentifrices
Electric apparatus
Escherichia coli
Haemophilus
Klebsiella
Leukemia
Lymphoma
Multidrug resistance
Neisseria
Pathogenic bacteria
Proteus (bacterium)
Respirators
Sarcoma
Sepsis
Streptococcus pneumoniae
Telephones
Wound
Wound healing promoters
(bacteriophage compns. for reduction of bacterial colonization in immunocompromised patients and in medical facility)
IT 61-32-5, Methicillin 1404-90-6, Vancomycin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(resistance; bacteriophage compns. for reduction of bacterial colonization in immunocompromised patients and in medical facility)
IT 1404-90-6, Vancomycin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(resistance; bacteriophage compns. for reduction of bacterial colonization in immunocompromised patients and in medical facility)
RN 1404-90-6 CAPLUS
CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Bu-i

PAGE 2-A



L46 ANSWER 19 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:137250 CAPLUS Full-text
DOCUMENT NUMBER: 134:188181

TITLE: Cathelicidin-derived peptides with broad spectrum antimicrobial activity

INVENTOR(S): Tack, Brian E.; McCray, Paul; Welsh, Michael; Travis, Sue M.; Lehrer, Robert

PATENT ASSIGNEE(S): University of Iowa Research Foundation, USA; The Regents of the University of California

SOURCE: PCT Int. Appl., 137 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001012668	A1	20010222	WO 2000-US22781	20000818 <--
WO 2001012668	A9	20020718		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 7071293	B1	20060704	US 2000-642744	20000818 <--

PRIORITY APPLN. INFO.: US 1999-149886P P 19990818 <--

AB The invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Antimicrobial truncated peptides are disclosed which are based on SMAP 29 and RCAP 18, but which contain a lesser number of amino acid residues yet still retain bactericidal activity. In addition, synthetic peptides based upon the SMAP 29 protein are disclosed which have fewer amino acid residues and include substitutions yet retain substantial activity. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention, or by combining the peptides with other antimicrobial agents or antibiotics.

IC ICM C07K014-47
ICS C07K007-08; A61K038-17; A61P031-04

CC 1-5 (Pharmacology)

IT Alcaligenes
Alcaligenes xylosoxidans
Anti-AIDS agents
Antibacterial agents
Antimicrobial agents
Antiviral agents
Burkholderia cepacia
Drug delivery systems
Drug resistance
Enterococcus faecalis
Enterococcus faecium
Equine infectious anemia virus
Escherichia coli
Human herpesvirus
Human immunodeficiency virus
Listeria monocytogenes
Mannheimia haemolytica
Neisseria gonorrhoeae
Pseudomonas aeruginosa
Staphylococcus aureus

Staphylococcus epidermidis
Stenotrophomonas maltophilia
Xanthomonas
(cathelicidin-derived peptides with broad spectrum antimicrobial activity)

IT 61-32-5, Methicillin 1404-90-6, Vancomycin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(resistance to; cathelicidin-derived peptides with broad spectrum antimicrobial activity)

IT 1404-90-6, Vancomycin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(resistance to; cathelicidin-derived peptides with broad spectrum antimicrobial activity)

RN 1404-90-6 CAPLUS
CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Bu-i

PAGE 2-A



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:725476 CAPLUS Full-text
DOCUMENT NUMBER: 133:291106
TITLE: Immunomodulating polymers
INVENTOR(S): Tzianabos, Arthur O.; Kasper, Dennis L.; Onderdonk, Andrew B.; Wang, Ying
PATENT ASSIGNEE(S): Brigham and Women's Hospital, Inc., USA
SOURCE: PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000059515	A2	20001012	WO 2000-US8586	20000331 <--
WO 2000059515	A3	20010111		
WO 2000059515	A9	20020829		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2366895	A1	20001012	CA 2000-2366895	20000331 <--
AU 200040563	A	20001023	AU 2000-40563	20000331 <--
AU 781950	B2	20050623		
BR 2000009531	A	20011226	BR 2000-9531	20000331 <--
EP 1169045	A2	20020109	EP 2000-919958	20000331 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002541113	T	20021203	JP 2000-609078	20000331 <--
EP 1459757	A1	20040922	EP 2004-14020	20000331 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY

US 7083777	B1	20060801	US 2000-540024		20000331 <--
MX 2001PA09930	A	20030714	MX 2001-PA9930		20011001 <--
US 2004209818	A1	20041021	US 2004-848779		20040519 <--
US 7026285	B2	20060411			
AU 2005201963	A1	20050602	AU 2005-201963		20050510 <--
US 2006153832	A1	20060713	US 2006-385111		20060321 <--
PRIORITY APPLN. INFO.:			US 1999-127584P	P	19990402 <--
			US 1999-162457P	P	19991029 <--
			AU 2000-40563	A3	20000331 <--
			EP 2000-919958	A3	20000331 <--
			US 2000-540024	A3	20000331 <--
			WO 2000-US8586	W	20000331 <--

AB Methods and products for inducing IL-2 secretion, inducing IL-10 secretion, activating T cells, suppressing IgG antibody response to specific antigen, promoting allograft survival, reducing postoperative surgical adhesion formation, and protecting against abscess formation associated with surgery, trauma or diseases that predispose the host to abscess formation are provided. The methods of the invention are accomplished using an immunomodulator which is a polymer having at least two repeating charge motifs separated by at least a certain min. distance.

IC ICM A61K031-7088
ICS A61K038-00; A61K038-20; A61K039-395; A61P037-02

CC 1-7 (Pharmacology)
Section cross-reference(s): 63

IT AIDS (disease)
Abscess
Antibacterial agents
Immunomodulators
Immunostimulants
Immunosuppressants
Infection
Melanoma
Molecular weight distribution
Oxidizing agents
Repeat motifs (protein)
Surgery
Zwitterions
(immunomodulating polymers)

IT 56-75-7, Chloramphenicol 61-32-5, Methicillin 61-33-6, Penicillin g, biological studies 61-72-3, Cloxacillin 66-79-5, Oxacillin 69-53-4, Ampicillin 87-08-1, Penicillin v 114-07-8, Erythromycin 147-52-4, Nafcillin 154-21-2, Lincomycin 443-48-1, Metronidazole 1404-04-2, Neomycin 1404-90-6, Vancomycin 3116-76-5, Dicloxacillin 3485-14-1, Cyclacillin 3511-16-8, Hetacillin 4697-36-3, Carbenicillin 5250-39-5, Flucloxacillin 8064-90-2 13292-46-1, Rifampin 15686-71-2, Cephalexin 18323-44-9, Clindamycin 20556-18-7 25953-19-9, Cefazolin 26774-90-3, Epicillin 26787-78-0, Amoxicillin 32887-01-7, Amdinocillin 33817-20-8, Pivampicillin 34444-01-4, Cefamandole 34787-01-4, Ticarcillin 35607-66-0, Cefoxitin 37091-66-0, Azlocillin 38821-53-3, Cephradine 50370-12-2, Cefadroxil 50972-17-3, Bacampicillin 51481-65-3, Mezlocillin 53994-73-3, Cefaclor 56979-41-0 56979-46-5 58001-44-8 61270-58-4, Cefonicid 61477-96-1, Piperacillin 62893-19-0, Cefoperazone 63527-52-6, Cefotaxime 64221-86-9, Imipenem 64544-07-6, Cefuroxime axetil 64952-97-2, Moxalactam 65085-01-0, Cefmenoxime 68373-14-8, Sulbactam 68401-81-0, Ceftizoxime 69712-56-7, Cefotetan 72558-82-8, Ceftazidime 73384-59-5, Ceftriaxone 84290-27-7, Tucaresol 86482-18-0, Timentin 266997-84-6 266998-00-9 266998-03-2

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(immunomodulating polymers)

IT 1404-90-6, Vancomycin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(immunomodulating polymers)

RN 1404-90-6 CAPLUS

CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Bu-i



L46 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:390368 CAPLUS Full-text
DOCUMENT NUMBER: 131:39760
TITLE: Methods for treatment of neuro- and nephro-disorders and therapeutic toxicities using amifostine and other aminothiol compounds
INVENTOR(S): Stogniew, Martin; Alberts, David S.; Kaplan, Edward H.
PATENT ASSIGNEE(S): U.S. Bioscience, Inc., USA; The Arizona Board of Regents
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9929312	A1	19990617	WO 1998-US26096	19981209 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 5994409	A	19991130	US 1997-987550	19971209 <--
CA 2313089	A1	19990617	CA 1998-2313089	19981209 <--
AU 9917184	A	19990628	AU 1999-17184	19981209 <--
AU 739068	B2	20011004		
EP 1039887	A1	20001004	EP 1998-962011	19981209 <--
EP 1039887	B1	20060524		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
JP 2001525359	T	20011211	JP 2000-523983	19981209 <--
BR 9813524	A	20020219	BR 1998-13524	19981209 <--
EP 1537861	A2	20050608	EP 2005-3650	19981209 <--

EP 1537861	A3	20050615			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY					
AT 326956	T	20060615	AT 1998-962011		19981209 <--
PT 1039887	T	20061031	PT 1998-962011		19981209 <--
ES 2260857	T3	20061101	ES 1998-962011		19981209 <--
MX 2000PA05668	A	20010219	MX 2000-PA5668		20000608 <--
JP 2006188532	A	20060720	JP 2006-64774		20060309 <--
PRIORITY APPLN. INFO.:			US 1997-987550	A	19971209 <--
			EP 1998-962011	A3	19981209 <--
			JP 2000-523983	A3	19981209 <--
			WO 1998-US26096	W	19981209 <--

OTHER SOURCE(S): MARPAT 131:39760

AB S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate (amifostine) and other aminothiol compds. are used to treat and reverse toxicities caused by therapeutic agents, radiation treatment or diabetes. A method is provided for treating neurotoxicity and nephrotoxicity associated with the administration of chemotherapeutic agents.

IC ICM A61K031-095
ICS A61K031-16

CC 1-12 (Pharmacology)
Section cross-reference(s): 63

IT Alopecia
Anti-AIDS agents
Antibiotics
Antidiabetic agents
Antihypertensives
Antitumor agents
Antiviral agents
Diabetes mellitus
Fungicides
Kidney, disease
Neoplasm
Nervous system agents
Radioprotectants
Radiotherapy
X-ray
(amifostine and other aminothiols for treatment of neuro- and nephro-disorders and therapeutic toxicities)

IT 57-22-7, Vincristine 865-21-4, Vinblastine 1397-89-3, Amphotericin B 1403-66-3, Gentamicin 1404-90-6, Vancomycin 3056-17-5, d4T 7481-89-2, DdC 8063-07-8, Kanamycin 15663-27-1, Cisplatin 20830-81-3, Daunorubicin 23214-92-8, Doxorubicin 30516-87-1, AZT 32986-56-4, Tobramicin 33069-62-4, Paclitaxel 33419-42-0, Etoposide 37517-28-5, Amikacin 41575-94-4, Carboplatin 69655-05-6, DdI 95058-81-4, Gemcitabine 114977-28-5, Docetaxel 125317-39-7, Navelbine 134678-17-4, 3TC
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amifostine and other aminothiols for treatment of neuro- and nephro-disorders and therapeutic toxicities)

IT 1404-90-6, Vancomycin
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amifostine and other aminothiols for treatment of neuro- and nephro-disorders and therapeutic toxicities)

RN 1404-90-6 CAPLUS
CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Bu-i

PAGE 2-A



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:689249 CAPLUS Full-text
DOCUMENT NUMBER: 129:270605
TITLE: Medicament based on singlet oxygen-producing agent
INVENTOR(S): Stief, Thomas W.
PATENT ASSIGNEE(S): Germany
SOURCE: Ger. Offen., 6 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19712565	A1	19981001	DE 1997-19712565	19970325 <--
PRIORITY APPLN. INFO.:			DE 1997-19712565	19970325 <--

AB Substances which can give rise to singlet O and/or photons without excitation by irradiation are useful for treatment of diseases susceptible to singlet O or phototherapy, and can be used as anti-infective (especially antiviral) agents, immunostimulants, antithrombotics, and/or cytostatic agents. Viruses with a high concentration of cholesterol in the envelope, e.g. HIV, are especially susceptible to these agents. The agents may therefore be used for treating blood or blood products to inactivate viruses. Singlet O-generating substances can be stabilized by use as prodrugs or by addition of stabilizers such as taurine, carbonate salts, or mono- or oligosaccharides. Thus, N-chlorotaurine showed antithrombotic activity, as shown by dose-dependent prolongation of the thrombin, prothrombin, and activated partial thromboplastin times of citrated human plasma in vitro on addition of 2.5 or 3.3 mM N-chlorotaurine. N-chlorotaurine at 1 mM caused >1000-fold inactivation of HIV in whole blood within 15 min.

IC ICM A61K041-00
ICS A61K033-02
CC 1-5 (Pharmacology)
IT Anti-infective agents
Anticoagulants
Antioxidants
Antiviral agents
Blood
Blood plasma
Blood products
Cytotoxic agents
Disinfectants
Fibrinolytics
Hepatitis B virus
Hepatitis C virus
Human herpesvirus
Human immunodeficiency virus
Immunostimulants
Luminescent substances
Oxidizing agents
Photoconductors
Stabilizing agents
(medicament based on singlet oxygen-producing agent)
IT 107-35-7, Taurine 127-52-6, Chloramine B 127-65-1, Chloramine T
1404-90-6, Vancomycin 7681-52-9, Sodium hypochlorite
7790-92-3D, Hypochlorous acid, salts 23155-02-4, Phosphomycin
51036-13-6, N-Chlorotaurine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicament based on singlet oxygen-producing agent)

IT 1404-90-6, Vancomycin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicament based on singlet oxygen-producing agent)

RN 1404-90-6 CAPLUS
CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Bu-i



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 23 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:618371 CAPLUS Full-text
DOCUMENT NUMBER: 129:255004
TITLE: Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations, and histidine compositions therefor
INVENTOR(S): Thomas, Peter G.
PATENT ASSIGNEE(S): Cytos Pharmaceuticals LLC, USA
SOURCE: U.S., 10 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5811446	A	19980922	US 1997-839805	19970418 <--
WO 9847366	A1	19981029	WO 1998-US7319	19980417 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9873583	A	19981113	AU 1998-73583	19980417 <--
PRIORITY APPLN. INFO.:			US 1997-839805 A	19970418 <--
			WO 1998-US7319 W	19980417 <--

AB Methods are provided for protecting the eye from degenerative eye conditions by administering prophylactic histidine compns. Also provided are for treating ocular inflammation resulting from various causative agents, by administering therapeutic histidine compns. Further provided are histidine compns. for carrying out the methods.

IC ICM A01N043-50

ICS C07D233-60
INCL 514399000
CC 1-12 (Pharmacology)
Section cross-reference(s): 62, 63
IT Adenoviridae
Arbovirus
Bacteria (Eubacteria)
Borrelia burgdorferi
Corynebacterium diphtheriae
Cytomegalovirus
DNA viruses
Fungi
Haemophilus
Human enterovirus 70
Human herpesvirus 1
Human herpesvirus 2
Human herpesvirus 3
Human herpesvirus 4
Human immunodeficiency virus
Human poliovirus
Influenza virus
Measles virus
Moraxella
Mumps virus
Neisseria gonorrhoeae
Neisseria meningitidis
Papillomavirus
Parasite
Pseudomonas
RNA viruses
Rabies virus
Rhinovirus
Serratia marcescens
Staphylococcus
Staphylococcus aureus
Staphylococcus epidermidis
Streptococcus
(infection, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT 50-02-2, Dexamethasone 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-81-7, Ascorbic acid, biological studies 51-55-8, Atropine, biological studies 51-83-2, Carbachol 53-03-2, Prednisone 53-86-1, Indomethacin 54-42-2, Idoxuridine 56-75-7, Chloramphenicol 57-47-6, Physostigmine 59-02-9, α-Tocopherol 59-42-7, Phenylephrine 59-66-5, Acetazolamide 69-53-4, Ampicillin 70-00-8, Trifluridine 70-18-8, Glutathione, biological studies 92-13-7, Pilocarpine 114-07-8, Erythromycin 127-40-2, Lutein 144-68-3, Zeaxanthin 378-44-9, Betamethasone 426-13-1, Fluorometholone 472-61-7, Astaxanthin 514-78-3, Canthaxanthin 616-91-1, Acetyl cysteine 738-70-5, Trimethoprim 768-94-5, Amantadine 1403-66-3, Gentamycin 1404-90-6, Vancomycin 1405-87-4, Bacitracin 1406-05-9, Penicillin 1406-11-7, Polymyxin 1695-77-8, Spectinomycin 4697-36-3, Carbenicillin 5104-49-4, Flurbiprofen 5536-17-4, Vidarabine 7235-40-7, β-Carotene 7761-88-8, Silver nitrate, biological studies 7783-00-8, Selenious acid 9054-89-1, Superoxide dismutase 11111-12-9, Cephalosporin 13292-46-1, Rifampin 13392-28-4, Rimantadine 13410-01-0, Sodium selenate 15307-86-5, Diclofenac 18323-44-9, Clindamycin 22071-15-4, Ketoprofen 25953-19-9, Cefazolin 26787-78-0, Amoxicillin 26921-17-5, Timolol maleate 30516-87-1, Azidothymidine 32986-56-4, Tobramycin 34787-01-4, Ticarcillin 51481-65-3, Mezlocillin

56272-24-3, Histidine hydrochloride 59277-89-3, Acyclovir 68767-14-6, Loxoprofen 70458-96-7, Norfloxacin 74103-06-3, Ketorolac 82410-32-0, Ganciclovir 82419-36-1, Ofloxacin 82768-44-3 85721-33-1, Ciprofloxacin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(histidine compns. and methods for ocular degenerative diseases and inflammations)

IT 1404-90-6, Vancomycin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(histidine compns. and methods for ocular degenerative diseases and inflammations)

RN 1404-90-6 CAPLUS
CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Bu-i

PAGE 2-A



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:527193 CAPLUS Full-text
DOCUMENT NUMBER: 129:166193
TITLE: Therapeutic treatment and prevention of infections with a bioactive material encapsulated within a biodegradable-biocompatible polymeric matrix
INVENTOR(S): Setterstrom, Jean A.; Van Hamont, John E.; Reid, Robert H.; Jacob, Elliot; Jeyanthi, Ramasubbu; Boedeker, Edgar C.; McQueen, Charles E.; Tice, Thomas R.; Roberts, F. Donald; Friden, Phil
PATENT ASSIGNEE(S): United States Dept. of the Army, USA; Van Hamont, John E.; et al.
SOURCE: PCT Int. Appl., 363 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 17
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9832427	A1	19980730	WO 1998-US1556	19980127 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6309669	B1	20011030	US 1997-789734	19970127 <--
AU 9863175	A	19980818	AU 1998-63175	19980127 <--
PRIORITY APPLN. INFO.:			US 1997-789734 A	19970127 <--
			US 1984-590308 B1	19840316 <--
			US 1992-867301 A2	19920410 <--
			US 1995-446148 A2	19950522 <--

US 1995-446149 B2 19950522 <--
US 1996-590973 B2 19960124 <--
WO 1998-US1556 W 19980127 <--

AB Novel burst-free, sustained release biocompatible and biodegradable microcapsules are disclosed which can be programmed to release their active core for variable durations ranging from 1-100 days in an aqueous physiol. environment. The microcapsules are comprised of a core of polypeptide or other biol. active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer, which may contain a pharmaceutically acceptable adjuvant, as a blend of upcapped free carboxyl end group and end-capped forms ranging in ratios from 100/0 to 1/99.

IC ICM A61K009-52
ICS A61K047-30
CC 63-5 (Pharmaceuticals)
Section cross-reference(s): 1, 2, 15

IT AIDS (disease)
Acinetobacter
Actinomycetales
Adenoviridae
Adrenoceptor agonists
Aerococcus
Aeromonas
Allergy inhibitors
Alzheimer's disease
Analgesics
Anesthetics
Angiogenesis
Angiogenesis inhibitors
Anthelmintics
Anti-infective agents
Anti-inflammatory agents
Antiarrhythmics
Antiarthritics
Antibacterial agents
Antibiotics
Anticholesteremic agents
Anticoagulants
Anticonvulsants
Antidepressants
Antidiabetic agents
Antidiarrheals
Antiemetics
Antihistamines
Antihypertensives
Antimalarials
Antimigraine agents
Antiparkinsonian agents
Antipyretics
Antirheumatic agents
Antiserums
Antitumor agents
Antitussives
Antiulcer agents
Antiviral agents
Appetite depressants
Arbovirus
Arcanobacterium haemolyticum
Arenavirus
Asthma
Bacillus (bacterium genus)

Biocompatibility
Blood substitutes
Bordetella
Borrelia
Bronchodilators
Brucella
Cachexia
Calymmatobacterium
Campylobacter
Cardiopulmonary bypass
Cardiotonics
Cardiovascular agents
Cholinergic agonists
Clostridium
Contraceptives
Coronavirus
Corynebacterium
Cryptosporidium parvum
Cystic fibrosis
Cytomegalovirus
Cytotoxic agents
Decongestants
Diagnosis
Diarrhea
Dissolution rate
Diuretics
Drug bioavailability
Drug dependence
Ebola virus
Echinococcus
Electrolytes, biological
Emulsifying agents
Enterobacteriaceae
Enterococcus
Enterovirus
Epitopes
Erysipelothrix
Expectorants
Filovirus
Flavobacterium
Freeze drying
Fungicides
Gardnerella
Gram-negative bacteria
Gram-positive bacteria (Firmicutes)
Haemophilus
Haemophilus ducreyi
Helicobacter
Hepatitis A virus
Hepatitis B virus
Hepatitis C virus
Human herpesvirus 3
Human herpesvirus 4
Human immunodeficiency virus
Human immunodeficiency virus 1
Human parainfluenza virus
Human poliovirus
Hypercholesterolemia
Hypnotics and Sedatives
Immunization

Immunomodulators
Immunostimulants
Infection
Influenza virus
Kidney, disease
Lactococcus
Legionella
Leptospira
Leuconostoc
Listeria
Measles virus
Melanoma
Micrococcus
Molluscum contagiosum virus
Moraxella
Multiple sclerosis
Mumps virus
Muscle relaxants
Narcotics
Neisseria
Nervous system agents
Nutrients
Opioid antagonists
Osteoarthritis
Osteomyelitis
Osteoporosis
Ovary, neoplasm
Pancreas, neoplasm
Papillomavirus
Parasiticides
Parkinson's disease
Pediococcus
Planococcus (bacterium)
Plesiomonas
Pneumonia
Poxviridae
Pseudomonas
Psoriasis
Psychotropics
Rabies virus
Reoviridae
Respiratory syncytial virus
Rheumatoid arthritis
Rhinovirus
Rhodococcus
Rotavirus
Rothia (bacterium)
Rubella virus
Salmonella typhi
Sexually transmitted diseases
Shigella boydii
Shigella dysenteriae
Shigella flexneri
Shigella sonnei
Spirillum
Staphylococcus
Streptobacillus
Streptococcus
Thrombosis
Tranquilizers

Treponema
Vaccines
Vasodilators
Vibrio
Vibrio cholerae
Wolinella succinogenes
Yersinia
(prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT 50-06-6, Phenobarbital, biological studies 50-12-4, Mephenytoin 50-18-0, Cyclophosphamide 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-28-2, 17β-Estradiol, biological studies 50-33-9, Phenylbutazone, biological studies 50-52-2, Thioridazine 50-55-5, Reserpine 50-78-2, Aspirin 51-55-8, Atropine, biological studies 52-24-4, Thiotepa 52-76-6, Lynestrenol 53-03-2, Prednisone 53-16-7, Estrone, biological studies 53-86-1, Indomethacin 54-11-5, Nicotine 55-48-1, Atropine sulfate 55-63-0, Nitroglycerin 55-86-7, Nitrogen mustard 56-53-1, Diethyl stilbestrol 56-75-7, Chloramphenicol 57-27-2, Morphine, biological studies 57-33-0, Sodium pentobarbital 57-42-1, Meperidine 57-53-4, Meprobamate 57-63-6, Ethinyl estradiol 57-85-2, Testosterone propionate 57-92-1, Streptomycin a, biological studies 58-08-2, Caffeine, biological studies 58-14-0, Pyrimethamine 58-22-0 58-25-3, Chlordiazepoxide 58-39-9, Perphenazine 58-73-1, Diphenhydramine 59-01-8, Kanamycin a 59-05-2, Methotrexate 59-92-7, L-Dopa, biological studies 61-33-6, Penicillin g, biological studies 67-20-9, Nitrofurantoin 68-22-4, Norethisterone 68-23-5, Norethynodrel 69-09-0, Chlorpromazine hydrochloride 69-53-4, Ampicillin 69-72-7D, Salicylic acid, derivs. 71-58-9, Medroxyprogesterone acetate 72-33-3, Mestranol 76-57-3, Codeine 79-57-2, Oxytetracycline 79-64-1, Dimethisterone 91-81-6, Tripelennamine 103-90-2, Acetaminophen 113-15-5, Ergotamine 114-07-8, Erythromycin 114-49-8, Hyoscine hydrobromide 121-54-0 122-09-8, Phentermine 125-29-1, Dihydrocodeinone 125-71-3, Dextromethorphan 127-48-0, Trimethadione 128-62-1, Noscapine 145-94-8, Chlorindanol 148-82-3, Melphalan 155-41-9, Methscopolamine bromide 288-32-4D, Imidazole, derivs. 297-76-7, Ethynodiol diacetate 302-22-7, Chlormadinone acetate 305-03-3, Chlorambucil 309-43-3, Sodium secobarbital 315-30-0, Allopurinol 434-03-7, Ethisterone 439-14-5, Diazepam 443-48-1, Metronidazole 469-62-5 471-34-1, Calcium carbonate, biological studies 497-19-8, Sodium carbonate, biological studies 523-87-5, Dimenhydrinate 546-93-0, Magnesium carbonate 578-66-5D, 8-Aminoquinoline, derivs. 578-68-7D, 4-Aminoquinoline, derivs. 595-33-5, Megestrol acetate 738-70-5, Trimethoprim 846-50-4, Temazepam 1397-89-3, Amphotericin b 1397-94-0, Antimycin a 1403-66-3, Gentamicin 1404-26-8, Polymyxin b 1404-90-6, Vancomycin 1406-05-9D, Penicillin, derivs. 4696-76-8, Kanamycin b 5588-33-0, Mesoridazine 5633-18-1, Melengestrol 5786-21-0, Clozapine 5800-19-1, Metiapine 6533-00-2, Norgestrel 7447-40-7, Potassium chloride (KCl), biological studies 8063-07-8, Kanamycin 9000-83-3, Atpase 9000-92-4, Amylase 9001-62-1, Lipase 9001-63-2, Muramidase 9001-67-6, Neuraminidase 9001-78-9, Alkaline phosphatase 9001-99-4, Ribonuclease 9002-02-2, Succinic acid dehydrogenase 9002-07-7, Trypsin 9004-07-3, Chymotrypsin 9004-10-8, Insulin, biological studies 9025-82-5, Phosphodiesterase 9029-12-3, Glutamic acid dehydrogenase 9035-74-9, Glycogen phosphorylase 9046-27-9, γ-Glutamyltranspeptidase 9079-67-8 10118-90-8, Minocycline 11111-12-9, Cephalosporins 13292-46-1, Rifampin 14271-04-6 21645-51-2, Aluminum hydroxide, biological studies 22232-71-9, Mazindol 24730-10-7, Dihydroergocristine methanesulfonate 25447-66-9 26780-50-7, Poly(lactide co-glycolide) 26787-78-0, Amoxicillin 30516-87-1, Azt 32986-56-4, Tobramycin 35189-28-7,

Norgestimate 37205-61-1, Proteinase inhibitor 37517-28-5, Amikacin 53678-77-6D, Muramyl dipeptide, derivs. 53994-73-3, Cefaclor 55268-75-2, Cefuroxime 61036-62-2, Teicoplanin 64221-86-9, Imipenem 80738-43-8, Lincosamide 81103-11-9, Clarithromycin 82419-36-1, Ofloxacin 85721-33-1, Ciprofloxacin
RL: BPR (Biological process); BSU (Biological study, unclassified); DEV (Device component use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT 1404-90-6, Vancomycin
RL: BPR (Biological process); BSU (Biological study, unclassified); DEV (Device component use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

RN 1404-90-6 CAPLUS
CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Bu-i



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:31330 CAPLUS Full-text
DOCUMENT NUMBER: 128:97702
TITLE: TNF-derived peptides having neutrophil and/or monocyte/macrophage stimulatory activity for prevention and treatment of infection
INVENTOR(S): Rathjen, Deborah Ann; Sleigh, Joy Merilyn; Mack, Philip On-Lok; Widmer, Fred
PATENT ASSIGNEE(S): Peptech Ltd., Australia; Rathjen, Deborah Ann; Sleigh, Joy Merilyn; Mack, Philip On-Lok; Widmer, Fred
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9748725	A1	19971224	WO 1997-AU395		19970620 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
AU 9730842	A	19980107	AU 1997-30842		19970620 <--
ZA 9705500	A	19981221	ZA 1997-5500		19970620 <--
PRIORITY APPLN. INFO.:			AU 1996-610	A	19960621 <--
			AU 1996-2165	A	19960906 <--
			AU 1996-3309	A	19961029 <--
			WO 1997-AU395	W	19970620 <--

OTHER SOURCE(S): MARPAT 128:97702

AB Peptides of 8 to 15 amino acids in length are described which possess neutrophil and/or monocyte/macrophage stimulatory activity. The peptides may be used in methods of treatment of various diseases and conditions in which enhancement of neutrophil and/or monocyte/macrophage function is desirable. The peptides are X1-X2-X3-X4-Ser-Thr-X5-Val-X6-Ile-Thr-X7-X8- X9-X10 [X1 = absent, Cys, R1; X2 = absent, Ala, Arg, Glu, Gly; X3 = absent, Ala, Arg, Asn, Cys, Glu, Gly, His, Ile, Leu, Lys, Met, Pro, Ser, Trp, γ-Abu, βAla, Dbu, Sar, Suc, N-Me-Ala; X4 = absent, Ala, Arg, Asn, Glu, His, Leu, Lys, Met, Pro, Ser, Trp, βAla, Nip; X5 = Ala, His; X6 = Ala, Gly, Ile, Leu, Phe, Pro, Ser, Thr, Trp, Val, D-Ala, D-Ile, D-Pro, D-Ser, D-Thr, D-Val, βAla; X7 = His or Ala; X8 = absent, Ile, Leu, Thr, D-Ile; X9 = absent, Ile, D-Ile, Aib; X10 = absent, Cys, R2; R1 = H, RCO (R = C1-20 straight-chain, branched, or cyclic alkyl (optionally substituted and with optional double bonds)), glycosyl, nucleosyl, lipoyl, or R1 is absent when adjacent amino acid is unsubstituted desamino derivative; R2 = NR12R13 (R12, R13 = H, optionally substituted straight-chain, branched, or cyclic alkyl, aralkyl, or aryl), N-glycosyl, etc.]. The peptides are derived from a a portion of the TNF sequence. The peptides may be used in combination therapy with other agents.

IC ICM C07K007-06
ICS C07K007-08; C07K007-10; A61K037-02

CC 1-5 (Pharmacology)
Section cross-reference(s): 15

IT AIDS (disease)
Cystic fibrosis
Diabetes mellitus
Leukemia
Lymphoma
Neoplasm
Paroxysmal nocturnal hemoglobinuria
Tuberculosis
(infection treatment in; TNF-derived peptides having neutrophil and/or monocyte/macrophage stimulatory activity for prevention and treatment of infection, and combinations with other agents)

IT 50-18-0, Cyclophosphamide 50-24-8 50-44-2, Mercaptopurine 50-76-0, Dactinomycin 50-91-9, Floxuridine 51-21-8, Fluorouracil 51-75-2, Mechlorethamine 54-85-3, Isoniazid 55-98-1, Busulfan 60-54-8, Tetracycline 66-79-5, Oxacillin 69-53-4, Ampicillin 69-74-9, Cytarabine hydrochloride 74-55-5, Ethambutol 98-96-4, Pyrazinamide 114-07-8, Erythromycin 125-84-8, Aminoglutethimide 127-07-1, Hydroxyurea 147-52-4, Nafcillin 148-82-3, Melphalan 154-93-8, Carmustine 305-03-3, Chlorambucil 320-67-2, Azacitidine 366-70-1, Procarbazine hydrochloride 443-48-1, Metronidazole 564-25-0, Doxycycline 645-05-6, Hexamethylmelamine 1397-89-3, Amphotericin B 1403-66-3, Gentamycin 1404-00-8, Mitomycin 1404-90-6, Vancomycin 1406-05-9, Penicillin 2022-85-7, Flucytosine 3778-73-2, Ifosfamide 4342-03-4, Dacarbazine 11111-12-9, Cephalosporin 13010-47-4, Lomustine 13292-46-1, Rifampin 14769-73-4, Levamisole 15663-27-1, Cisplatin 18323-44-9, Clindamycin 18378-89-7, Plicamycin 21679-14-1, Fludarabine 23214-92-8, Doxorubicin 32986-56-4, Tobramycin 33419-42-0, Etoposide 34787-01-4, Ticarcillin 35607-66-0, Cefoxitin 37517-28-5, Amikacin 41575-94-4, Carboplatin 51264-14-3, Amsacrine 53910-25-1, Deoxycoformycin 56391-56-1, Netilmicin 59277-89-3, Acyclovir 59865-13-3, Cyclosporin A 64221-86-9, Imipenem 65271-80-9, Mitoxantrone 65277-42-1, Ketoconazole 72559-06-9, Rifabutin 78110-38-0, Aztreonam 81103-11-9, Clarithromycin 82410-32-0, Ganciclovir 83869-56-1, Granulocyte-macrophage colony-stimulating factor 83905-01-5, Azithromycin 143011-72-7, Granulocyte colony-stimulating factor
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TNF-derived peptides having neutrophil and/or monocyte/macrophage stimulatory activity for prevention and treatment of infection, and combinations with other agents)

IT 1404-90-6, Vancomycin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TNF-derived peptides having neutrophil and/or monocyte/macrophage stimulatory activity for prevention and treatment of infection, and combinations with other agents)

RN 1404-90-6 CAPLUS
CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Bu-i



L46 ANSWER 26 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:281150 CAPLUS Full-text
DOCUMENT NUMBER: 126:260137
TITLE: Targeting of proteins to the cell wall of gram-positive bacteria
INVENTOR(S): Schneewind, Olaf; Baba, Tadashi
PATENT ASSIGNEE(S): Regents of the University of California, USA
SOURCE: PCT Int. Appl., 123 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9708553	A1	19970306	WO 1996-US14154		19960822 <--
W: AU, BR, CA, IL, JP					
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
AU 9669133	A	19970319	AU 1996-69133		19960822 <--
PRIORITY APPLN. INFO.:			US 1995-2615P	P	19950822 <--
			WO 1996-US14154	W	19960822 <--

OTHER SOURCE(S): MARPAT 126:260137

AB A method of stable noncovalent display of proteins, peptides, or compds. covalently linked to proteins or peptides on the surface of gram-pos. bacteria provides advantages over phage display. One embodiment of the present invention comprises a method for noncovalent protein targeting, comprising the steps of: (1) cloning a nucleic acid segment encoding a chimeric protein into a gram-pos. bacterium to generate a cloned chimeric protein including therein a carboxyl-terminal cell-wall targeting signal; (2) growing the bacterium into which the nucleic acid segment has been cloned to express the chimeric protein to generate a chimeric protein including therein a carboxyl-terminal cell-wall targeting signal; and (3) binding the expressed chimeric protein noncovalently and stably to the cell-wall via the carboxyl-terminal cell-wall targeting signal so that the chimeric protein is displayed on the surface on the gram-pos. bacterium in such a way that the protein is accessible to a ligand. Alternatively, the chimeric protein can be produced by expression in another expression system and contacted with the gram-pos. bacterium. Described are

methods for producing vaccines as well as for using antibiotic-protein conjugates to treat infections.

IC ICM G01N033-53
ICS G01N033-569; G01N033-536; G01N033-543; G01N033-566; G01N033-549; G01N033-531; C12N001-20; C12N015-00; C12N015-63; C12N001-14; C12N015-09; C12N015-70; C12N015-74; A61K038-00; C07K002-00; C07K004-00; C07K005-00; C07K007-00; C07K016-00

CC 3-2 (Biochemical Genetics)
Section cross-reference(s): 63

IT Cell wall
Genetic vectors
Gram-positive bacteria (Firmicutes)
Human immunodeficiency virus
Infection
Microorganism
Molecular cloning
PCR (polymerase chain reaction)
Reverse transcription
Staphylococcus
Staphylococcus aureus
Staphylococcus simulans
Vaccines
Virus
(proteins targeting to cell wall of gram-pos. bacteria)

IT 56-75-7D, Chloramphenicol, protein conjugates 57-92-1D, Streptomycin, protein conjugates, biological studies 69-53-4D, Ampicillin, protein conjugates 1403-66-3D, Gentamicin, protein conjugates 1404-04-2D, Neomycin, protein conjugates 1404-90-6D, Vancomycin, protein conjugates 1406-05-9D, Penicillin, protein conjugates 8063-07-8D, Kanamycin, protein conjugates 11111-12-9D, Cephalosporin, protein conjugates 13292-46-1D, Rifampin, protein conjugates 18323-44-9D, Clindamycin, protein conjugates 32986-56-4D, Tobramycin, protein conjugates 37517-28-5D, Amikacin, protein conjugates 70458-96-7D, Norfloxacin, protein conjugates 84420-34-8D, Paromomycin, protein conjugates 85721-33-1D, Ciprofloxacin, protein conjugates
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(proteins targeting to cell wall of gram-pos. bacteria)

IT 1404-90-6D, Vancomycin, protein conjugates
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(proteins targeting to cell wall of gram-pos. bacteria)

RN 1404-90-6 CAPLUS
CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Bu-i

PAGE 2-A



L46 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1992:439893 CAPLUS Full-text
DOCUMENT NUMBER: 117:39893

TITLE: Therapy of Rhodococcus equi disseminated infections in nude mice

AUTHOR(S): Nordmann, Patrice; Kerestedjian, Jean Jacques; Ronco, Esthel

CORPORATE SOURCE: Serv. Microbiol., Hop. Raymond Poincare, Garches, 92380, Fr.

SOURCE: Antimicrobial Agents and Chemotherapy (1992), 36(6), 1244-8
CODEN: AMACCQ; ISSN: 0066-4804

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Rhodococcus equi is a facultative, intracellular, gram-pos. coccobacillus increasingly reported as an opportunistic pathogen in human immunodeficiency virus-pos. patients. However, the optimal drug regimen for treating R. equi pulmonary or systemic infections is not yet known. Therefore, a model of i.v. infected nude mice with disseminated infection was created to study the efficacy of antibiotics alone or in combination as determined by the reduction of bacterial CFU per g in the lungs and spleen after 4 and 11 days of treatment. The studied antibiotics possessing low MICs against R. equi strains were amikacin, ciprofloxacin, erythromycin, imipenem, minocycline, rifampin, and vancomycin. Vancomycin, imipenem, and rifampin were the most effective agents in monotherapy. On the other hand, amikacin, ciprofloxacin, erythromycin, and minocycline alone were not active in this model. The most active drug combinations were those including vancomycin. No antibiotic-resistant mutants were selected in vivo with treatment involving any drugs used alone or in combination. Although the treatment recommended until now for R. equi infections is rifampin plus erythromycin, this study suggests that antibiotic combinations which include vancomycin may be the most effective in vivo.

CC 1-5 (Pharmacology)

IT Acquired immune deficiency syndrome
(Rhodococcus equi infection in, antibiotics treatment of)

IT 114-07-8, Erythromycin 1404-90-6, Vancomycin 10118-90-8, Minocycline 13292-46-1, Rifampin 37517-28-5, Amikacin 64221-86-9, Imipenem 85721-33-1, Ciprofloxacin
RL: BIOL (Biological study)
(Rhodococcus equi infection treatment by)

IT 1404-90-6, Vancomycin
RL: BIOL (Biological study)
(Rhodococcus equi infection treatment by)

RN 1404-90-6 CAPLUS

CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Bu-i

PAGE 2-A



L46 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1987:594823 CAPLUS Full-text
DOCUMENT NUMBER: 107:194823

TITLE: Broth microdilution testing of susceptibilities to 30 antimicrobial agents of Mycobacterium avium strains from patients with acquired immune deficiency syndrome

AUTHOR(S): Yajko, David M.; Nassos, Patricia S.; Hadley, W. Keith
CORPORATE SOURCE: Dep. Lab. Med., Univ. California, San Francisco, CA, 94110, USA

SOURCE: Antimicrobial Agents and Chemotherapy (1987), 31(10), 1579-84
CODEN: AMACCQ; ISSN: 0066-4804
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A total of 31 strains of M. avium complex isolated from patients with acquired immune deficiency syndrome were tested for susceptibility to 30 antimicrobial agents by using microdilution trays containing dried antimicrobial agents. MICs were determined over a period of 7 days of growth in a broth medium (7HSF) that is equivalent to 7H11 agar. MICs obtained by this method showed good agreement with MICs determined by the agar dilution method. Strains could be divided into two groups by their antimicrobial susceptibility patterns. All group 1 strains (8 of the 31 strains tested) were at least moderately susceptible to inhibition by a variety of β-lactam antimicrobial agents, including amoxicillin-clavulanic acid and cefmenoxime. Group 2 strains (23 of 31) were susceptible only to amikacin (22 of 23 strains). All 31 strains were resistant to oxacillin, clindamycin, erythromycin, tetracycline, chloramphenicol, vancomycin, nitrofurantoin, and aztreonam at the highest concentration of antimicrobial agent present in the microdilution trays. The addition of Tween 80 to 7HSF broth increasedd the susceptibility of M. avium complex to many of the antimicrobial agents tested. Killing of M. avium complex (i.e., ≤1% survival after 7 days) was found to vary for different strains and antimicrobial agents. Killing of some strains by amoxicillin- clavulanic acid, carbenicillin, azlocillin, cefmenoxime, cefotaxime, amikacin, and ampicillin occurred at concns. of antimicrobial agent that are achievable in serum. Further studies are needed to determine whether any of these antimicrobial agents has activity against M. avium complex cells that have been ingested by macrophages.

CC 10-5 (Microbial Biochemistry)

IT Immunodeficiency
(acquired immune deficiency syndrome, Mycobacterium avium from humans with, antibiotic susceptibility of)

IT 56-75-7, Chloramphenicol 60-54-8, Tetracycline 61-33-6, biological studies 66-79-5, Oxacillin 67-20-9, Nitrofurantoin 69-53-4, Ampicillin 114-07-8, Erythromycin 153-61-7, Cephalothin 1403-66-3, Gentamicin 1404-90-6, Vancomycin 4697-36-3, Carbenicillin 8064-90-2 18323-44-9, Clindamycin 26787-78-0, Amoxicillin 34787-01-4, Ticarcillin 37091-66-0, Azlocillin 37517-28-5, Amikacin 51481-65-3, Mezlocillin 55268-75-2, Cefuroxime 56391-56-1, Netilmicin 61270-58-4, Cefonicid 61477-96-1, Piperacillin 62893-19-0, Cefoperazone 63527-52-6, Cefotaxime 64221-86-9, Imipenem 64952-97-2, Moxalactam 65085-01-0, Cefmenoxime 68401-81-0, Ceftizoxime 73384-59-5, Ceftriaxone 78110-38-0, Aztreonam
RL: BIOL (Biological study)
(Mycobacterium avium susceptibility to)

IT 1404-90-6, Vancomycin
RL: BIOL (Biological study)
(Mycobacterium avium susceptibility to)

RN 1404-90-6 CAPLUS

CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Bu-i

PAGE 2-A



SPECIES SEARCH

```
=> fil reg;d stat que l39; fil capl; s l39
FILE 'REGISTRY' ENTERED AT 13:10:29 ON 12 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   11 SEP 2007  HIGHEST RN 946658-01-1
DICTIONARY FILE UPDATES:  11 SEP 2007  HIGHEST RN 946658-01-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

L4                STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

Uploading L4.str
```



```
chain nodes :
31  32  40  45  46  47
ring nodes :
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23
```

24 25 26 27 28 29 30 33 36 37 38 39 41 42 43 44
ring/chain nodes :
34 35
chain bonds :
10-46 19-31 21-32 25-47 38-40 41-45
ring/chain bonds :
11-34 15-34 18-35 24-26 28-36
ring bonds :
1-2 1-6 2-3 2-44 3-4 4-5 5-6 5-33 7-8 7-12 7-39 8-9 9-10 9-33 10-11
11-12 13-14 13-18 14-15 15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23
23-24 25-26 25-30 26-27 27-28 28-29 29-30 36-37 36-41 37-38 38-39 41-42
42-43 43-44
exact/norm bonds :
2-44 5-33 7-39 9-33 10-46 11-34 15-34 18-35 19-31 21-32 24-26 25-47 28-
36 36-37 36-41 37-38 38-39 38-40 41-42 41-45 42-43 43-44
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-
15 15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23 23-24 25-26 25-30
26-27 27-28 28-29 29-30

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:Atom 30:Atom 31:CLASS 32:CLASS 33:Atom 34:CLASS 35:CLASS 36:Atom 37:Atom
38:Atom 39:Atom 40:CLASS 41:Atom 42:Atom 43:Atom 44:Atom 45:CLASS 46:CLASS
47:CLASS

L8 7166 SEA FILE=REGISTRY SSS FUL L4
L32 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

Uploading L32.str



chain nodes :
31 32 40 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 65
66 67 68 69 71 72 73 74 75 76 77

ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 33 36 37 38 39 41 42 43 44 62 63 64
ring/chain nodes :
34 35
chain bonds :
6-71 10-46 16-48 19-31 20-59 21-32 25-47 35-49 38-40 39-53 41-45 44-58
49-50 49-72 50-51 50-52 53-54 54-55 54-57 55-56 59-60 60-61 62-68 64-65
65-66 65-67 66-69 72-73 73-74 73-77 74-75 75-76
ring/chain bonds :
11-34 15-34 18-35
ring bonds :
1-2 1-6 2-3 2-44 3-4 4-5 5-6 5-33 7-8 7-12 7-39 8-9 9-10 9-33 10-11
11-12 13-14 13-18 14-15 15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23
23-24 23-64 24-26 25-26 25-30 26-27 27-28 28-29 28-36 29-30 36-37 36-41
37-38 38-39 41-42 42-43 43-44 43-62 62-63 63-64
exact/norm bonds :
2-44 5-33 7-39 9-33 10-46 11-34 15-34 18-35 19-31 21-32 23-64 24-26 25-
47 28-36 36-37 36-41 37-38 38-39 38-40 39-53 41-42 41-45 42-43 43-44
43-62 44-58 49-72 53-54 54-55 54-57 55-56 59-60 62-63 62-68 63-64 65-66
65-67 66-69 72-73 73-74 73-77 74-75
exact bonds :
6-71 16-48 20-59 35-49 49-50 60-61 64-65 75-76
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-
15 15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23 23-24 25-26 25-30
26-27 27-28 28-29 29-30 50-51 50-52

Connectivity :
56:1 E exact RC ring/chain 69:1 E exact RC ring/chain
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:Atom 30:Atom 31:CLASS 32:CLASS 33:Atom 34:CLASS 35:CLASS 36:Atom 37:Atom
38:Atom 39:Atom 40:CLASS 41:Atom 42:Atom 43:Atom 44:Atom 45:CLASS 46:CLASS
47:CLASS 48:CLASS 49:CLASS 50:CLASS 51:CLASS 52:CLASS 53:CLASS 54:CLASS
55:CLASS 56:CLASS 57:CLASS 58:CLASS 59:CLASS 60:CLASS 61:Atom 62:Atom
63:Atom 64:Atom 65:CLASS 66:CLASS 67:CLASS 68:CLASS 69:CLASS 71:CLASS
72:CLASS 73:CLASS 74:CLASS 75:CLASS 76:Atom 77:CLASS
Generic attributes :
61:
Saturation : Saturated
Number of Carbon Atoms : 7 or more
Type of Ring System : Polycyclic
76:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

L33 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

Uploading L33.str



chain nodes :
31 32 40 45 46 47 48 52 55 56 57 58 59 63 64 65 66 67 69 73 74
89 90 91 92 93 94 95 96
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 33 34 35 36 37 38 39 41 42 43 44 49 50 51
53 54 60 61 62 70 71 72 75 76 77 78 79 80 81 82 83 84 85 86 87
88
chain bonds :
6-69 10-46 16-48 19-31 20-57 21-32 25-47 35-74 38-40 41-45 44-56 50-52
54-55 57-58 58-59 59-92 60-66 62-63 63-64 63-65 64-67 67-96 71-73 72-90
77-89 82-91 92-93 92-94 92-95
ring bonds :
1-2 1-6 2-3 2-44 3-4 4-5 5-6 5-33 7-8 7-12 7-39 8-9 9-10 9-33 10-11
11-12 11-34 13-14 13-18 14-15 15-16 15-34 16-17 17-18 18-35 19-20 19-24
20-21 21-22 22-23 23-24 23-62 24-26 25-26 25-30 26-27 27-28 28-29 28-36
29-30 35-49 36-37 36-41 37-38 38-39 39-53 41-42 42-43 43-44 43-60 49-50
49-70 50-51 51-75 53-54 54-75 60-61 61-62 70-71 71-72 72-85 75-79 76-77
76-81 77-78 78-79 79-80 80-81 81-88 82-83 82-87 83-84 83-88 84-85 85-86
86-87
exact/norm bonds :
2-44 5-33 7-39 9-33 10-46 11-34 15-34 18-35 19-31 20-57 21-32 23-62 24-
26 25-47 28-36 35-49 36-37 36-41 37-38 38-39 38-40 39-53 41-42 41-45
42-43 43-44 43-60 44-56 49-50 49-70 50-51 50-52 51-75 53-54 54-55 54-75
57-58 58-59 59-92 60-61 60-66 61-62 63-64 63-65 64-67 67-96 70-71 71-72
71-73 72-85 72-90 75-79 77-89 81-88 82-91 83-88 92-93 92-94 92-95
exact bonds :
6-69 16-48 35-74 62-63
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-
15 15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23 23-24 25-26 25-30
26-27 27-28 28-29 29-30 76-77 76-81 77-78 78-79 79-80 80-81 82-83 82-87
83-84 84-85 85-86 86-87

Connectivity :
57:2 E exact RC ring/chain 59:2 E exact RC ring/chain 67:2 E exact RC ring/chain
93:1 E exact RC ring/chain 94:1 E exact RC ring/chain 95:1 E exact RC ring/chain
Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:Atom 30:Atom 31:CLASS 32:CLASS 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom
38:Atom 39:Atom 40:CLASS 41:Atom 42:Atom 43:Atom 44:Atom 45:CLASS 46:CLASS
47:CLASS 48:CLASS 49:Atom 50:Atom 51:Atom 52:CLASS 53:Atom 54:Atom 55:CLASS
56:CLASS 57:CLASS 58:CLASS 59:CLASS 60:Atom 61:Atom 62:Atom 63:CLASS
64:CLASS 65:CLASS 66:CLASS 67:CLASS 69:CLASS 70:Atom 71:Atom 72:Atom
73:CLASS 74:CLASS 75:Atom 76:Atom 77:Atom 78:Atom 79:Atom 80:Atom 81:Atom
82:Atom 83:Atom 84:Atom 85:Atom 86:Atom 87:Atom 88:Atom 89:CLASS 90:CLASS
91:CLASS 92:CLASS 93:CLASS 94:CLASS 95:CLASS 96:CLASS

L34 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

Uploading L34.str



chain nodes :
31 32 40 45 46 47 48 52 55 56 60 61 62 63 64 66 67 68 69 70 71
73 74 75 77 78 79 80 81 82
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 33 34 35 36 37 38 39 41 42 43 44 49 50 51
53 54 57 58 59 72
chain bonds :
6-66 10-46 16-48 19-31 20-82 21-32 25-47 35-71 38-40 41-45 44-56 49-67
50-52 54-55 57-63 59-60 60-61 60-62 61-64 64-74 67-68 68-69 68-70 69-73
69-77 72-78 73-75 78-79 79-80 79-81
ring bonds :
1-2 1-6 2-3 2-44 3-4 4-5 5-6 5-33 7-8 7-12 7-39 8-9 9-10 9-33 10-11
11-12 11-34 13-14 13-18 14-15 15-16 15-34 16-17 17-18 18-35 19-20 19-24
20-21 21-22 22-23 23-24 23-59 24-26 25-26 25-30 26-27 27-28 28-29 28-36
29-30 35-49 36-37 36-41 37-38 38-39 39-53 41-42 42-43 43-44 43-57 49-50
50-51 51-72 53-54 54-72 57-58 58-59
exact/norm bonds :
2-44 5-33 7-39 9-33 10-46 11-34 15-34 18-35 19-31 21-32 23-59 24-26 25-
47 28-36 35-49 35-71 36-37 36-41 37-38 38-39 38-40 39-53 41-42 41-45
42-43 43-44 43-57 44-56 49-50 49-67 50-51 50-52 51-72 53-54 54-55 54-72
57-58 57-63 58-59 60-61 60-62 61-64 64-74 67-68 68-70 69-73 69-77 72-78

73-75 78-79 79-80 79-81
exact bonds :
6-66 16-48 20-82 59-60 68-69
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-15 15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23 23-24 25-26 25-30 26-27 27-28 28-29 29-30

Connectivity :
64:2 E exact RC ring/chain 75:1 E exact RC ring/chain 77:1 E exact RC ring/chain 78:2 E exact RC ring/chain
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:CLASS 32:CLASS 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom 38:Atom 39:Atom 40:CLASS 41:Atom 42:Atom 43:Atom 44:Atom 45:CLASS 46:CLASS 47:CLASS 48:CLASS 49:Atom 50:Atom 51:Atom 52:CLASS 53:Atom 54:Atom 55:CLASS 56:CLASS 57:Atom 58:Atom 59:Atom 60:CLASS 61:CLASS 62:CLASS 63:CLASS 64:CLASS 66:CLASS 67:Atom 68:Atom 69:Atom 70:CLASS 71:CLASS 72:Atom 73:CLASS 74:CLASS 75:CLASS 77:CLASS 78:CLASS 79:CLASS 80:CLASS 81:CLASS 82:CLASS
Generic attributes :
74:
Saturation : Saturated
Number of Carbon Atoms : 7 or more
Type of Ring System : Polycyclic

L39 3 SEA FILE=REGISTRY SUB=L8 SSS FUL (L32 OR L33 OR L34)

100.0% PROCESSED 2277 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.01

FILE 'CAPLUS' ENTERED AT 13:10:29 ON 12 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 12 Sep 2007 VOL 147 ISS 12
FILE LAST UPDATED: 11 Sep 2007 (20070911/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

L47 4 L39

=> d scan ti

L47 4 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
TI Glycopeptide antibiotic derivatives, their preparation and their use as antiviral agents

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4

L47 4 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
TI Structure-Activity Relationship Studies of a Series of Antiviral and Antibacterial Aglycon Derivatives of the Glycopeptide Antibiotics Vancomycin, Eremomycin, and Dechloroeremomycin

L47 4 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
TI Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics

L47 4 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
TI Antiretroviral Activity of Semisynthetic Derivatives of Glycopeptide Antibiotics

ALL ANSWERS HAVE BEEN SCANNED

ALL OF THESE REFERENCES WERE DISPLAYED IN FULL AS PART OF THE INVENTORS SEARCH

SEARCH HISTORY

=> d stat que l39;d his nofile
L4 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

Uploading L4.str



chain nodes :
31 32 40 45 46 47
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 33 36 37 38 39 41 42 43 44
ring/chain nodes :
34 35
chain bonds :
10-46 19-31 21-32 25-47 38-40 41-45
ring/chain bonds :
11-34 15-34 18-35 24-26 28-36
ring bonds :
1-2 1-6 2-3 2-44 3-4 4-5 5-6 5-33 7-8 7-12 7-39 8-9 9-10 9-33 10-11
11-12 13-14 13-18 14-15 15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23
23-24 25-26 25-30 26-27 27-28 28-29 29-30 36-37 36-41 37-38 38-39 41-42
42-43 43-44
exact/norm bonds :
2-44 5-33 7-39 9-33 10-46 11-34 15-34 18-35 19-31 21-32 24-26 25-47 28-
36 36-37 36-41 37-38 38-39 38-40 41-42 41-45 42-43 43-44
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-
15 15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23 23-24 25-26 25-30
26-27 27-28 28-29 29-30

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:Atom 30:Atom 31:CLASS 32:CLASS 33:Atom 34:CLASS 35:CLASS 36:Atom 37:Atom

38:Atom 39:Atom 40:CLASS 41:Atom 42:Atom 43:Atom 44:Atom 45:CLASS 46:CLASS
47:CLASS

L8 7166 SEA FILE=REGISTRY SSS FUL L4
L32 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

Uploading L32.str



chain nodes :
31 32 40 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 65
66 67 68 69 71 72 73 74 75 76 77
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 33 36 37 38 39 41 42 43 44 62 63 64
ring/chain nodes :
34 35
chain bonds :
6-71 10-46 16-48 19-31 20-59 21-32 25-47 35-49 38-40 39-53 41-45 44-58
49-50 49-72 50-51 50-52 53-54 54-55 54-57 55-56 59-60 60-61 62-68 64-65
65-66 65-67 66-69 72-73 73-74 73-77 74-75 75-76
ring/chain bonds :
11-34 15-34 18-35
ring bonds :
1-2 1-6 2-3 2-44 3-4 4-5 5-6 5-33 7-8 7-12 7-39 8-9 9-10 9-33 10-11
11-12 13-14 13-18 14-15 15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23
23-24 23-64 24-26 25-26 25-30 26-27 27-28 28-29 28-36 29-30 36-37 36-41
37-38 38-39 41-42 42-43 43-44 43-62 62-63 63-64
exact/norm bonds :
2-44 5-33 7-39 9-33 10-46 11-34 15-34 18-35 19-31 21-32 23-64 24-26 25-
47 28-36 36-37 36-41 37-38 38-39 38-40 39-53 41-42 41-45 42-43 43-44
43-62 44-58 49-72 53-54 54-55 54-57 55-56 59-60 62-63 62-68 63-64 65-66
65-67 66-69 72-73 73-74 73-77 74-75
exact bonds :
6-71 16-48 20-59 35-49 49-50 60-61 64-65 75-76
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-
15 15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23 23-24 25-26 25-30

26-27 27-28 28-29 29-30 50-51 50-52

Connectivity :
56:1 E exact RC ring/chain 69:1 E exact RC ring/chain
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:Atom 30:Atom 31:CLASS 32:CLASS 33:Atom 34:CLASS 35:CLASS 36:Atom 37:Atom
38:Atom 39:Atom 40:CLASS 41:Atom 42:Atom 43:Atom 44:Atom 45:CLASS 46:CLASS
47:CLASS 48:CLASS 49:CLASS 50:CLASS 51:CLASS 52:CLASS 53:CLASS 54:CLASS
55:CLASS 56:CLASS 57:CLASS 58:CLASS 59:CLASS 60:CLASS 61:Atom 62:Atom
63:Atom 64:Atom 65:CLASS 66:CLASS 67:CLASS 68:CLASS 69:CLASS 71:CLASS
72:CLASS 73:CLASS 74:CLASS 75:CLASS 76:Atom 77:CLASS
Generic attributes :
61:
Saturation : Saturated
Number of Carbon Atoms : 7 or more
Type of Ring System : Polycyclic
76:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

L33 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

Uploading L33.str



chain nodes :
31 32 40 45 46 47 48 52 55 56 57 58 59 63 64 65 66 67 69 73 74
89 90 91 92 93 94 95 96
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

24 25 26 27 28 29 30 33 34 35 36 37 38 39 41 42 43 44 49 50 51
53 54 60 61 62 70 71 72 75 76 77 78 79 80 81 82 83 84 85 86 87
88
chain bonds :
6-69 10-46 16-48 19-31 20-57 21-32 25-47 35-74 38-40 41-45 44-56 50-52
54-55 57-58 58-59 59-92 60-66 62-63 63-64 63-65 64-67 67-96 71-73 72-90
77-89 82-91 92-93 92-94 92-95
ring bonds :
1-2 1-6 2-3 2-44 3-4 4-5 5-6 5-33 7-8 7-12 7-39 8-9 9-10 9-33 10-11
11-12 11-34 13-14 13-18 14-15 15-16 15-34 16-17 17-18 18-35 19-20 19-24
20-21 21-22 22-23 23-24 23-62 24-26 25-26 25-30 26-27 27-28 28-29 28-36
29-30 35-49 36-37 36-41 37-38 38-39 39-53 41-42 42-43 43-44 43-60 49-50
49-70 50-51 51-75 53-54 54-75 60-61 61-62 70-71 71-72 72-85 75-79 76-77
76-81 77-78 78-79 79-80 80-81 81-88 82-83 82-87 83-84 83-88 84-85 85-86
86-87
exact/norm bonds :
2-44 5-33 7-39 9-33 10-46 11-34 15-34 18-35 19-31 20-57 21-32 23-62 24-
26 25-47 28-36 35-49 36-37 36-41 37-38 38-39 38-40 39-53 41-42 41-45
42-43 43-44 43-60 44-56 49-50 49-70 50-51 50-52 51-75 53-54 54-55 54-75
57-58 58-59 59-92 60-61 60-66 61-62 63-64 63-65 64-67 67-96 70-71 71-72
71-73 72-85 72-90 75-79 77-89 81-88 82-91 83-88 92-93 92-94 92-95
exact bonds :
6-69 16-48 35-74 62-63
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-
15 15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23 23-24 25-26 25-30
26-27 27-28 28-29 29-30 76-77 76-81 77-78 78-79 79-80 80-81 82-83 82-87
83-84 84-85 85-86 86-87

Connectivity :
57:2 E exact RC ring/chain 59:2 E exact RC ring/chain 67:2 E exact RC ring/chain
93:1 E exact RC ring/chain 94:1 E exact RC ring/chain 95:1 E exact RC ring/chain
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:Atom 30:Atom 31:CLASS 32:CLASS 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom
38:Atom 39:Atom 40:CLASS 41:Atom 42:Atom 43:Atom 44:Atom 45:CLASS 46:CLASS
47:CLASS 48:CLASS 49:Atom 50:Atom 51:Atom 52:CLASS 53:Atom 54:Atom 55:CLASS
56:CLASS 57:CLASS 58:CLASS 59:CLASS 60:Atom 61:Atom 62:Atom 63:CLASS
64:CLASS 65:CLASS 66:CLASS 67:CLASS 69:CLASS 70:Atom 71:Atom 72:Atom
73:CLASS 74:CLASS 75:Atom 76:Atom 77:Atom 78:Atom 79:Atom 80:Atom 81:Atom
82:Atom 83:Atom 84:Atom 85:Atom 86:Atom 87:Atom 88:Atom 89:CLASS 90:CLASS
91:CLASS 92:CLASS 93:CLASS 94:CLASS 95:CLASS 96:CLASS

L34 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

Uploading L34.str



chain nodes :
31 32 40 45 46 47 48 52 55 56 60 61 62 63 64 66 67 68 69 70 71
73 74 75 77 78 79 80 81 82
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 33 34 35 36 37 38 39 41 42 43 44 49 50 51
53 54 57 58 59 72
chain bonds :
6-66 10-46 16-48 19-31 20-82 21-32 25-47 35-71 38-40 41-45 44-56 49-67
50-52 54-55 57-63 59-60 60-61 60-62 61-64 64-74 67-68 68-69 68-70 69-73
69-77 72-78 73-75 78-79 79-80 79-81
ring bonds :
1-2 1-6 2-3 2-44 3-4 4-5 5-6 5-33 7-8 7-12 7-39 8-9 9-10 9-33 10-11
11-12 11-34 13-14 13-18 14-15 15-16 15-34 16-17 17-18 18-35 19-20 19-24
20-21 21-22 22-23 23-24 23-59 24-26 25-26 25-30 26-27 27-28 28-29 28-36
29-30 35-49 36-37 36-41 37-38 38-39 39-53 41-42 42-43 43-44 43-57 49-50
50-51 51-72 53-54 54-72 57-58 58-59
exact/norm bonds :
2-44 5-33 7-39 9-33 10-46 11-34 15-34 18-35 19-31 21-32 23-59 24-26 25-
47 28-36 35-49 35-71 36-37 36-41 37-38 38-39 38-40 39-53 41-42 41-45
42-43 43-44 43-57 44-56 49-50 49-67 50-51 50-52 51-72 53-54 54-55 54-72
57-58 57-63 58-59 60-61 60-62 61-64 64-74 67-68 68-70 69-73 69-77 72-78
73-75 78-79 79-80 79-81
exact bonds :
6-66 16-48 20-82 59-60 68-69
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-
15 15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23 23-24 25-26 25-30
26-27 27-28 28-29 29-30

Connectivity :
64:2 E exact RC ring/chain 75:1 E exact RC ring/chain 77:1 E exact RC ring/chain
78:2 E exact RC ring/chain
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:Atom 30:Atom 31:CLASS 32:CLASS 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom
38:Atom 39:Atom 40:CLASS 41:Atom 42:Atom 43:Atom 44:Atom 45:CLASS 46:CLASS
47:CLASS 48:CLASS 49:Atom 50:Atom 51:Atom 52:CLASS 53:Atom 54:Atom 55:CLASS
56:CLASS 57:Atom 58:Atom 59:Atom 60:CLASS 61:CLASS 62:CLASS 63:CLASS
64:CLASS 66:CLASS 67:Atom 68:Atom 69:Atom 70:CLASS 71:CLASS 72:Atom
73:CLASS 74:CLASS 75:CLASS 77:CLASS 78:CLASS 79:CLASS 80:CLASS 81:CLASS

82:CLASS
Generic attributes :
74:
Saturation : Saturated
Number of Carbon Atoms : 7 or more
Type of Ring System : Polycyclic

L39 3 SEA FILE=REGISTRY SUB=L8 SSS FUL (L32 OR L33 OR L34)

100.0% PROCESSED 2277 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.01

(FILE 'HOME' ENTERED AT 11:21:28 ON 12 SEP 2007)

FILE 'REGISTRY' ENTERED AT 11:21:35 ON 12 SEP 2007

FILE 'CAPLUS' ENTERED AT 11:21:38 ON 12 SEP 2007
E US2005-525784/APPS
L1 1 SEA ABB=ON US2005-525784/AP
D SCAN
SEL RN

FILE 'REGISTRY' ENTERED AT 11:22:26 ON 12 SEP 2007
L2 176 SEA ABB=ON (110865-90-2/BI OR 112848-47-2/BI OR 118395-73-6/BI OR 118693-63-3/BI OR 1404-55-3/BI OR 1404-90-6/BI OR 61036-62-2/BI OR 103-72-0/BI OR 104581-72-8/BI OR 104581-77-3/BI OR 111465-73-7/BI OR 114894-40-5/BI OR 116528-12-2/BI OR 119789-44-5/BI OR 121844-63-1/BI OR 122172-99-0/BI OR 123631-08-3/BI OR 133376-45-1/BI OR 135157-94-7/BI OR 137709-99-0/BI OR 137710-10-2/BI OR 164515-56-4/BI OR 164515-57-5/BI OR 171099-12-0/BI OR 174421-39-7/BI OR 185461-61-4/BI OR 185461-67-0/BI OR 193685-70-0/BI OR 193685-71-1/BI OR 193685-72-2/BI OR 193742-05-1/BI OR 204332-65-0/BI OR 204332-66-1/BI OR 204332-67-2/BI OR 204332-68-3/BI OR 204332-74-1/BI OR 204332-77-4/BI OR 204332-79-6/BI OR 204332-82-1/BI OR 204332-84-3/BI OR 204332-85-4/BI OR 204332-88-7/BI OR 270927-20-3/BI OR 300582-65-4/BI OR 354123-19-6/BI OR 410077-91-7/BI OR 410077-94-0/BI OR 508241-91-6/BI OR 508241-92-7/BI OR 508241-93-8/BI OR 562105-14-0/BI OR 562105-16-2/BI OR 562105-17-3/BI OR 562105-18-4/BI OR 562105-19-5/BI OR 562105-20-8/BI OR 562105-21-9/BI OR 562105-22-0/BI OR 562105-23-1/BI OR 562105-24-2/BI OR 562105-27-5/BI OR 562105-28-6/BI OR 562105-29-7/BI OR 562105-30-0/BI OR 562105-31-1/BI OR 562105-32-2/BI OR 562105-33-3/BI OR 562105-34-4/BI OR 562105-35-5/BI OR 562105-36-6/BI OR 562105-38-8/BI OR 562105-40-2/BI OR 562105-41-3/BI OR 562105-42-4/BI OR 562105-43-5/BI OR 562105-44-6/BI OR 562105-45-7/BI OR 562105-46-8/BI OR 562105-47-9/BI OR 562105-48-0/BI OR 668993-07-5/BI OR 668993-09-7/BI OR 668993-11-1/BI OR 668993-13-3/BI OR 668993-14-4/BI OR 668993-15-5/BI OR 668993-16-6/BI OR 668993-17-7/BI OR 668993-18-8/BI OR 668993-19-9/BI OR 668993-20-2/BI OR 668993-21-3/BI OR 668993-22-4/BI OR 668993-23-5/BI OR 668993-25-7/BI OR 668993-26-8/BI OR 668993-27-9/BI OR 668993-28-0/BI OR 668993-29-1/BI OR 668993-30-4/BI OR 668993-31-5/BI OR 668993-32-6/BI OR 668993-33-7/BI OR 668993-34-8/BI OR 668993-35-9/BI OR 668993-36-0/BI OR 668993-37-1/BI OR 668993-38-2/BI OR

```
                668993-39-3/BI OR 668993-40-6/BI OR 668993-41-7/BI OR 668993-42
                -8/BI OR 668993-43-9/BI
                E RISTOMYCIN/CN
L3            1 SEA ABB=ON  "RISTOMYCIN A"/CN
                D SCAN
L4              STRUCTURE UPLOADED
L5           50 SEA SSS SAM L4
L6            0 SEA ABB=ON  L5 AND L2
L7         7940 SEA SSS FUL L4 EXTEND
L8         7166 SEA SSS FUL L4
                SAVE TEMP L8 MOH784FULL/A

     FILE 'CAPLUS' ENTERED AT 11:49:45 ON 12 SEP 2007
L9         8578 SEA ABB=ON  L8
L10           1 SEA ABB=ON  L1 AND L9
                D SCAN
                E "AIDS (DISEASE)"+ALL/CT
                E ANTI-AIDS AGENTS+ALL/CT
                E ANTIVIRAL AGENTS+ALL/CT
                E HUMAN IMMUNODEF/CT
                E E7+ALL
L11       40388 SEA ABB=ON  HUMAN IMMUNODEFICIENCY VIRUS+NT/CT
L12       49201 SEA ABB=ON  ANTIVIRAL AGENTS+OLD/CT
L13       20238 SEA ABB=ON  ANTI-AIDS AGENTS/CT
                E "AIDS (DISEASE)"+OLD/CT
L14       21658 SEA ABB=ON  "AIDS (DISEASE)"+OLD/CT
L15         167 SEA ABB=ON  L9 AND (L11 OR L12 OR L13 OR L14)
L16        5597 SEA ABB=ON  L9 AND (PY<2003 OR AY<2003 OR PRY<2003)
L17          93 SEA ABB=ON  L16 AND (L11 OR L12 OR L13 OR L14)
L18          29 SEA ABB=ON  L16 AND (L11 OR L13 OR L14)
L19         979 SEA ABB=ON  BALZARINI J?/AU
L20         481 SEA ABB=ON  PREOBRAZHENSKAYA M?/AU
L21        2099 SEA ABB=ON  DECLERCQ E?/AU OR DE CLERCQ E?/AU
L22          35 SEA ABB=ON  (L19 AND L20 AND L21) OR ((L19 OR L20 OR L21) AND
                L9) OR (L1 AND L9)
L23          30 SEA ABB=ON  ((L19 OR L20 OR L21) AND L9) OR (L1 AND L9)
L24         783 SEA ABB=ON  (L19 AND (L20 OR L21)) OR (L20 AND L21)
L25           4 SEA ABB=ON  (L24 AND L9) OR (L1 AND L9)
                SAVE TEMP L25 MOH784CAAU/A
                SAVE TEMP L18 MOH784AIDS/A

     FILE 'REGISTRY' ENTERED AT 12:17:13 ON 12 SEP 2007
                E ADAMANTYL
L26        4158 SEA ABB=ON  ADAMANTYL
L27           0 SEA ABB=ON  L2 AND L26
L28         170 SEA ABB=ON  L2 AND CL/ELS
L29         173 SEA ABB=ON  L8 AND L2

     FILE 'ZCAPLUS' ENTERED AT 12:19:12 ON 12 SEP 2007
L30        7763 SEA ABB=ON  L29

     FILE 'REGISTRY' ENTERED AT 12:19:19 ON 12 SEP 2007
L31          21 SEA ABB=ON  L29 AND TRICYCLO
L32             STRUCTURE UPLOADED
L33             STRUCTURE UPLOADED
L34             STRUCTURE UPLOADED
L35           0 SEA SUB=L8 SSS SAM (L32 OR L33 OR L34)

     FILE 'LREGISTRY' ENTERED AT 13:00:03 ON 12 SEP 2007
                E 2/CL
```

```
     FILE 'REGISTRY' ENTERED AT 13:00:31 ON 12 SEP 2007
L36     1445013 SEA ABB=ON  2/CL
L37        5076 SEA ABB=ON  L36 AND L8
L38        2277 SEA SUB=L8 SSS FUL (L32 OR L33 OR L34) EXTEND
L39           3 SEA SUB=L8 SSS FUL (L32 OR L33 OR L34)
                SAVE TEMP L39 MOH784SUB1/A

     FILE 'ZCAPLUS' ENTERED AT 13:01:05 ON 12 SEP 2007
L40           4 SEA ABB=ON  L39
                D SCAN TI

     FILE 'CAPLUS' ENTERED AT 13:01:27 ON 12 SEP 2007
L41           4 SEA ABB=ON  L39
L42           4 SEA ABB=ON  L25 AND L41

     FILE 'CAPLUS' ENTERED AT 13:06:28 ON 12 SEP 2007
                D QUE NOS L25
L43           4 SEA ABB=ON  (L19 OR L20 OR L21) AND (L11 OR L12 OR L13 OR L14)
                AND L9
L44           4 SEA ABB=ON  (L25 OR L43)
                D QUE NOS L43
L45           4 SEA ABB=ON  (L25 OR L43)
                D IBIB ABS HITIND HITSTR L45 1-4
                SEL HIT RN L45 1-4

     FILE 'REGISTRY' ENTERED AT 13:09:22 ON 12 SEP 2007
                D STAT QUE L8

     FILE 'CAPLUS' ENTERED AT 13:09:22 ON 12 SEP 2007
                D QUE NOS L18
L46          28 SEA ABB=ON  L18 NOT L45
                D IBIB ABS HITIND HITSTR L46 1-28

     FILE 'REGISTRY' ENTERED AT 13:10:29 ON 12 SEP 2007
                D STAT QUE L39

     FILE 'CAPLUS' ENTERED AT 13:10:29 ON 12 SEP 2007
L47           4 SEA ABB=ON  L39
                D SCAN TI
                D STAT QUE L39
                D SAVED
                D QUE NOS L47

     FILE 'STNGUIDE' ENTERED AT 13:24:13 ON 12 SEP 2007

     FILE 'CAPLUS' ENTERED AT 13:40:46 ON 12 SEP 2007
                D QUE NOS L47
L48           4 SEA ABB=ON  (L19 OR L20 OR L21) AND L47
                D QUE NOS L48
                D IBIB ABS HITSTR L48 1-4
```

Mohamed, Abdel

From: O'Bryen, Barbara
Sent: Wednesday, September 12, 2007 1:57 PM
To: SCORE Support
Cc: Mohamed, Abdel
Subject: 10525784-ssr

20070912-1052578
4-str.zip

Ex Mohamed,
This search will become available on SCORE within the next few days. I'm sending you this advance copy because it is near the end of the fiscal year.

pp. 1-10 are the inventor search
pp. 11-106 are the search of the broad structures of claim 23 + AIDS/HIV
pp.106-113 are the species search
pp. 114-121 are the search history

Please let me know if you have any questions.

Barb
x22518